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Abstract 
 
 
Photodynamic Detection (PDD) is a diagnostic technique involving administration of a 
photosensitizer to the targeted cells that can be stimulated by short wavelength light which 
then leads to emission of light at a different wavelength (lower energy). The light emitted by 
the cells can be detected and analysed (by a spectroscope). All cells have the innate ability 
(due to endogenous fluorophores) to fluoresce, termed autofluorescence. Any cellular, 
metabolic or structural changes can alter the fluorescence intensity peaks. In this study 5-
aminolevulinic acid (5-ALA) photosensitizer prodrug was used, which is metabolised in 
highly active cells to protoporphyrin IX (PpIX). Excitation of a cell at 405nm wavelength 
(light) leads to emission of autofluorescence at 500nm and PpIX at 635nm. 
The purpose of this investigation was to evaluate the use of compact fluorescence 
spectroscopy together with the photosensitizer prodrug 5-ALA, in assessing clinically 
suspicious oral lesions. To that end the followings were assessed: 
• The fluorescence intensity ratio (FIR) or Red/Green ratio at 635/500nm 
measurements of normal anatomical sites at ten oral anatomical sites to map and 
create baseline readings for normal oral mucosal site fluorescence. 
• The effect of participants’ characteristics on the normal oral mucosal site FIR 
measurements. 
• The use the fluorescence intensity ratio (FIR) measurements to determine any 
differences between the lesion and the normal oral readings and whether the 
FIR from clinically suspicious oral lesions is associated with the 
histopathology grade. In addition to the sensitivity and specificity of the 
technique in assessing clinically suspicious (premalignant) oral lesions for 
potential malignant change. 
 
Prior to the trial commencing, approval were obtained from the Research Ethics Committee 
(REC), local NHS Research and Development (R&D), and Medicine Healthcare product 
Regulatory Agency (MHRA) and the University of Dundee Research Innovation Services 
(RIS). 
A total of thirty five participants with clinically suspicious oral lesions were recruited in 
Dundee (Dundee Dental Hospital) and Glasgow (Southern General Hospital). A 
Photodynamic Detection method using compact fluorescence spectroscopy and 5-ALA 
mouth rinse was applied. FIR measurements from ten normal anatomical sites were obtained 
in every patient to study the variation at different normal oral sites and the effect of the 
xix 
participant’s characteristics on these readings. In addition, two FIR measurements were 
obtained from each lesion and a further one taken from normal looking mucosa well beyond 
the lesion boundary (i.e. more than 5mm away) prior to biopsy. The readings were compared 
to study the reliability, reproducibility and efficacy of the photodynamic method in detecting 
mucosal abnormality. 
A total of 292 spectral readings obtained from normal mucosa were used to study the FIR 
measurements at normal oral anatomical sites. The results showed that the oral regions could 
be grouped into two broad categories with similar readings, the palatal and tongue readings 
in one group and buccal, ventral tongue, floor of the mouth, gingiva and lip mucosa on the 
other (essentially keratinized and non keratinized groups).  
The same set of readings were further analysed to study the effect of individual 
characteristics (age, gender, presence of oral prosthesis, metabolic diseases, smoking and 
alcohol consumptions) on the FIR measurements. There was no significant difference 
between FIR measurements within each of the groups studied, although at times sample sizes 
were very small. 
A total of 134 spectral readings obtained from 47 lesions that were biopsied from 35 patients 
recruited to the trial were used for the next part of the study. There were 91 spectra obtained 
from the lesions and 43 spectra obtained from the normal sites (more than 5mm away from 
the borders of the lesion) for comparison. There was a significant difference between the 
lesion and normal site readings. The FIR readings for the dysplastic lesions were 
significantly different when compared with the normal and benign hyperkeratoses. However 
there was no significant difference between dysplastic and inflammatory lesions (lichen 
planus, lichenoid lesions and candidal leukoplakia) on the one hand and inflammatory 
lesions and hyperkeratotic lesion on the other. Further analysis showed the sensitivity in 
detecting all the clinically suspicious oral lesions from the normal sites was 59.5% and 
specificity was 73.8%. The sensitivity in detecting dysplasia from normal sites was 100% 
and specificity 100%. 
Photodynamic Detection was able to detect a difference between the oral lesions from 
normal mucosa (but so is the naked eye!). However there was variation in the sensitivity and 
specificity in detecting a range of different pathological conditions.  The technique was 
highly sensitive in detecting dysplasia from normal mucosa but unfortunately the technique 
is not able to discriminate reliably between dysplasia and inflammatory lesions whose 
clinical appearance can be very similar. In conclusion, the photodynamic detection method 
used in this study would not appear to offer a reliable screening tool for the early detection of 
oral dysplasia/cancer. The need to consider adjunctive tests that discriminate inflammation 
from dysplasia is required. 
xx 
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1.1 INTRODUCTION 
 
Suspicious oral lesions are lesions that clinically often look red, white or red and 
white in color and histologically may have a tendency to undergo malignant change. 
One of the greatest challenges the oral clinician faces is deciding whether the 
suspicious oral lesion is a potential cancer. Dysplastic and neoplastic lesions of the 
oral mucosa as well as hyperkeratotic and inflammatory lesions share many of the 
same clinical signs and symptoms. 
 
      Oral cancer is a worldwide problem with an estimated 405,000 new cases each 
year. In the European Union countries in particular, it has been estimated that 66,650 
new oral cancer cases are diagnosed each year (IARC, 2004). In Scotland, the 
incidence rates of oral cancer are significantly higher than in other parts of the UK 
due to the higher rates of tobacco and alcohol consumption (Statistical Information 
Team, 2004; ISD 2010). The incidence of the disease is increasing in the developed 
and poor countries as well. WHO and many other health organizations and 
institutions around the world are therefore, concerned about detection and control of 
the disease. Cancer is also of great concern to the health science strategists, 
economist and politicians. It is well recognized that early detection and treatment of 
oral cancer improve the standard of life and the survival rates of the patients. 
       
Surgical biopsy with histopathological diagnosis is still considered the “gold 
standard” in assessing pathological changes in tissue; however one of the most 
challenging aspects in early detection of oral cancer is in determining the optimal i.e. 
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the most dysplastic or cancerous location for biopsy in high risk patients. Patients at 
this stage usually require continuous monitoring which can be difficult in some 
instances (medically compromised patients), since this might involve multiple 
surgical biopsies. In addition it is time consuming, uncomfortable, and costly. 
Therefore, screening a large population at risk of developing the disease is not a 
feasible procedure. Several new alternative methods have been described to increase 
the visibility of mucosal lesions, such as photographs, application of iodine dye or 
toluidine blue.  
 
In the last decade there has been increased interest in "optical biopsy" systems 
using tissue spectroscopy to establish pathological diagnosis. Fluorescence 
diagnostics has attracted increased interest both at a research level, and in 
the clinics. Several point-monitoring and imaging systems have been 
developed, and some have also turned into commercial products. Some of 
these systems rely on tissue autofluorescence, while others are combined 
with the administration of fluorescent tumor markers (photosensitizers). The 
intent of these systems is to provide a non invasive method of diagnosis, reduced 
health care cost, less time consuming, and in many cases, eliminating the need for 
surgical biopsy. In addition to that, the immediacy of diagnostic information can 
speed up the treatment and reduce the emotional trauma to the patient waiting for the 
diagnosis and formulating a treatment plan. The technique can also be used to guide 
the delivery of photodynamic therapy specifically to the detected abnormal area. The 
principal of this technique depends on the use of the spectrum of light and the wave 
lengths delivered to, and emitted from the tissue. The use of autofluorescence 
spectroscopy in vivo was first described in the mid 80’s to differentiate between 
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normal and malignant tissues. Since then several investigators have reported their 
findings with this technique and published in scientific journals. The concept is based 
upon the property that when cells interact with light they become excited and re-emit 
light at different wavelengths i.e. with varying colors (fluorescence) and this can be 
detected by sensitive spectrometers. All tissues fluoresce, due to the presence of inter 
and intra cellular fluorescent substances (fluorophores). These fluorescent spectra 
reflect architectural and biochemical changes occurring within the tissue. The 
resultant spectra not only detect the fluorescence but also are sensitive to cellular 
components that absorb light e.g. hemoglobin. The fluorescence can either occur as 
auto-fluorescence induced by light or from the application of photosensitizers e.g. 
Photofrin, 5- aminolevulinic acid and Foscan.  
 
Photodynamic Detection (PDD) is a relatively recent diagnostic technique 
(medical technology) which involves administration of a light activating chemical 
(photosensitizer) to the targeted cells that is stimulated, usually by short wavelength 
light, then the emitted light is collected (at a different wavelength) and analysed by 
the spectroscope. 
 
The principal of 5-ALA induced PpIX is that in excess it results in accumulation 
of intracellular porphyrins (especially of PpIX) which increases tissue fluorescence. 
Subsequent irradiation of the lesion with visible light, matching the main absorption 
peak of PpIX (405nm), causes cellular excitation then leads to red fluorescence 
emission from PpIX, peaking at 635nm. Spectroscopy can detect different 
fluorophores which provide characteristic spectra intensities. The difference in the 
overall fluorescence i.e. the ratio of the peaks of autofluorescence (green at 500nm) 
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and PpIX fluorescence (red at 635nm) i.e. between endogenous natural fluorphores 
and PpIX in normal and lesions under investigation (potential 
premalignant/malignant tissue) theoretically makes fluorescence spectroscopy more 
applicable to the discrimination between malignant and non malignant tissue. These 
fluorescence intensity ratio measurements are governed by many conditions which 
this thesis attempts to address. 
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1.2 REVIEW OF LITERATURE 
 
      In physics, the term light sometimes refers to electromagnetic radiation of any 
wavelength, whether the light is visible or not. 
 1.2.1 The Electromagnetic Spectrum 
     It is defined as the range of all possible frequencies of electromagnetic radiation. 
The "electromagnetic spectrum" of an object is the characteristic distribution of 
electromagnetic radiation emitted or absorbed by that particular object. The 
electromagnetic spectrum involve frequencies that extend from that of below modern 
radio frequencies down through to gamma radiation at the short-wavelength end, 
covering wavelengths from thousands of kilometers down to a fraction of the size of 
an atom. 
The radio waves have a much longer wavelength than light waves with wavelengths 
ranging from hundreds of meters to about one millimeter. 
Microwaves  are electromagnetic waves with wavelengths ranging from as long as 
one meter down to as short as one millimeter, or equivalently, with frequencies 
between 300MHz (0.3 GHz) and 300 GHz. These have such a short wavelength that 
they are very easily absorbed by water. This is why they are used in microwave 
ovens. 
The infrared part of the electromagnetic spectrum covers the range from roughly 
300 GHz (1 mm) to 400 THz (750 nm). These radio/light waves have a very short 
wavelength; however their wavelength is longer than visible light. 
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The Visible Spectrum is the portion of the electromagnetic spectrum that is visible to 
(can be detected by) the human eye. Electromagnetic radiation in this range of 
wavelengths is called visible light or simply light. A typical human eye will respond 
to wavelengths from about 380 to 750 nm. Red, Orange, Yellow, Green, Blue, 
Indigo, and Violet, are the colours of the visible spectrum. 
Ultra Violet is radiation whose wavelength is shorter than the violet end of the 
visible spectrum, and longer than that of an x-ray. These waves have very high 
energy and very short wave lengths; shorter than visible light. 
X-Rays is the radiations have so much energy and such a short wavelength that they 
can go through the objects. The hard X-rays have shorter wavelengths than soft X-
rays. 
Gamma Rays are electromagnetic radiation of high energy and typically have 
frequencies above 1019 Hz. They have energies above 100 keV and wavelength less 
than 10 picometer. Gamma radioactive decay photons commonly have energies of a 
few hundred KeV, and are almost always less than 10 MeV in energy (Halliday, 
2008; Young and Freedman 2008). 
  
  1.2.1.1 The Spectrum of Light  
 
     The visible light spectrum is the section of the electromagnetic radiation spectrum 
that is visible to the human eye. It ranges in wavelength from approximately 400 nm 
(4 x 10-7 m) to 700 nm (7 x 10-7 m). It is also known as the optical spectrum of light.  
The wavelength (which is related to frequency and energy) of the light determines 
the perceived colour. The ranges of these different colours are listed in the table 
below. The boundries are approximate as they blend into each other. The edges of 
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the visible light spectrum blend into the ultraviolet and infrared levels of radiation 
(Halliday, 2008). 
 
  1.2.1.2 The Visible Light Spectrum 
 
     Ordinary white light is a superimposition of waves with wavelengths extending 
throughout the visible spectrum. Dispersion of light can be achieved by a prism, and 
the band of colours is called a spectrum (Young and Freedman 2008). 
  The colors and wavelengths of the visible light can be tabulated as follows;  
 
Colour Violet Blue Cyan Green Yellow Orange Red 
Wavelength 380-435 435-500 500-520 520-565 565-590 590-625 625-740 
                           
Table 1.2.1. The colors and the wavelengths of the visible 
light spectrum. 
 
Gama Ray X Ray UV/V
Visible
Light
Infra 
Red
Radio
400nm 700nm
Microwave
Short Wavelength (High Energy)                                                                                               Long Wavelength (Low Energy)
 
Figure 1.2.1. The electromagnetic spectrum.  
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  1.2.1.3 Methods of Light Production 
         Light is produced by one of two methods;  
1. Incandescence is the emission of light from "hot" matter. 
2. Luminescence is the emission of light when bound electrons fall 
to lower energy levels.  
Fluorescence is a type of luminescence which occurs when a substance absorbs 
radiation and begins to re-emit the radiation. This phenomenon occurs almost 
instantly and the fluorescent luminescence stops after the energy source is removed, 
that means it comes to an end as quickly as it begins. Usually, the wavelength of the 
re-emitted radiation is longer than the wavelength of the radiation of the substance 
absorbed.  
     The most direct way of detecting whether an atom has been exited to an upper 
state is to detect the fluorescence light released when the atom decays. The atom can 
return to the state from which it was excited via an electric dipole transition with 
increasing excitation energy (Svanberg, 1991). 
 
 1.2.2 The Light Interaction with Tissue 
 
     It is well known that light is essential for all forms of living activities. 
The light surrounding us is mainly originating from the sun. Within the 
biosphere, light participates in many processes. In plants, the absorption of 
the solar radiation by chlorophyll is a requirement for photosynthesis 
(Nedbal, 2007). Also in our bodies many photochemical and 
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photobiological reactions take place. The most obvious is the reaction with 
the photoreceptors in the eyes, enabling our visual perception (Collin et al, 
2009). In the skin we can see the result of the interaction between light and 
tissue, as e.g. for this, is a tan following sun exposure. This is part of the 
protection against light that also might be harmful. The optical properties of 
the skin restrict the penetration depth, preventing most parts of the body 
from being exposed to light. Moreover, the optical properties determine the 
appearance of the tissue, as they are responsible for the colour and intensity 
of the reflected and diffusely scattered light (Gilchrest 1989; Juzenien et al, 
2009). 
 
      The beneficial properties of light for medical treatment have been 
known for a long time. The ancient cultures in, for example, China, India, 
Egypt, and Greece have been using sun-light to treat various diseases. The 
introduction of light into the modern western medicine is recently 
introduced (Ackroyd et al, 2001). At the beginning of the last century, light 
was used in the treatment of small-pox and skin tuberculosis (lupus Vulgaris). 
Experiments with illumination of fluorescent drugs were also performed for 
the treatment of for example skin cancer, and ultraviolet (UV) radiation was 
found to be beneficial for patients suffering from psoriasis. A thorough 
review of the history of the therapeutic use of light in medicine was 
published (Daniell and Hill, 1991; Ackroyd et al, 2001). Light was also 
introduced for diagnostic purposes. The isolation of porphyrine and the 
phototoxic effect on the tumour cells led to the development of 
Photodetection (PDD) or photodiagnosis method (Ackroyd et al, 2001). 
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 1.2.3 Photodynamic 
      Photodynamic is defined as the study of the activating effects of light on living 
organisms. 
 
  1.2.3.1 Photodynamic Technology in Healthcare 
 
     The Photodynamic method refers to the ability of certain compounds 
(photosensitizers) to destroy or inhibit the growth of living cells when exposed to 
light. The photosensitizer is not consumed during the process and may therefore be 
regarded as a catalyst, or energy transfer agent, where its primary purpose is to 
capture and channel the energy of light into the biological processes leading to cell 
death. This light-activated process can be used to destroy any type of living cell 
selectively, by appropriate targeting of the light, and thus photodynamic technology 
has numerous applications in healthcare, ranging from the treatment of medical 
conditions such as cancer, skin diseases and infected wounds to general sterilization 
of the environment and infection control. The correct choice of photosensitizer is 
critical for truly effective and beneficial photodynamic therapy, as it has to be readily 
deliverable to the relevant cells, either by systemic administration or topical 
application. As a result, few photosensitizers have to date achieved clinical success 
(Photopharmica, 2009). 
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  1.2.3.2 Overview of the History of the Use of Photodynamics 
             in Medicine 
 
     Sun exposure was used to treat diseases such as vitiligo, rickets, psoriasis, 
and skin cancer (Spikes 1985; Epstein 1990). It was not until early last century 
following the scientific discoveries by early pioneers such as Finsen, Raab and Von 
Tappeiner, utilizing phototherapy reappeared. The combination of light exposure and 
drug administration to the organ led to the emergence of photo-chemotherapy as a 
therapeutic or treatment method. The discovery of porphyrins, their tumour-
localizing properties and phototoxic effects on tumour tissue led to the development 
of modern photodynamic detection (PDD) and photodynamic therapy (PDT) 
(Ackroyd et al, 2001). 
 
     Fluorescence diagnostics is considered a natural counterpart to 
photodynamic therapy, since the photosensitizers are highly fluorescent. As 
a result of the growing interest of fluorescence for tissue investigations, the 
phenomenon of fluorescence was discovered in the mid 19th century. 
However utilization of this property was not started until the beginning of 
the 20th century at which the potential of fluorescence for medical 
applications was being investigated. It has been reported that the 
photosensitizing property of haematoporphyrin was discovered by Hausmann 
in his report on destruction of red blood cells. In this experiment, He had 
noticed the symptom of photosensitisation as a side effect of the use of 
photosensitizer on the mice. Few years later and after injecting himself with 
the haematoporphyrin, Meyer-Betz noticed severe pain and swelling of the 
light exposed areas a few minutes after irradiation and remained 
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photosensitive for more than two months. He reported his finding which 
proved the photosensitizing properties of the agent (Meyer-Betz, 1913; 
Cripps, 1986; Ackroyd et al, 2001; Pushpan et al, 2002; Szeimies, 2005). 
 
     Moan  and Peng (2003) mentioned in their review that there were two major 
advances in PDT in the period between the two world wars; The first 
finding was that Policard observed spontaneous fluorescence in 
experimental tumours illuminated with a Wood's lamp, and concluded that 
porphyrins selectively accumulate in tumours (Policard, 1924). The second 
finding was the report on photodynamic action involving haematoporphyrin 
on tumours published by Auler and Banzer in 1942. They investigated the 
selective uptake in animal tumours, and initiated some studies on humans, 
that were interrupted by the Second World War. This work, however, 
stimulated further studies on accumulation and retention of porphyrins. 
Figge et al, (1948) investigated the selective retention in vivo, and suggested the 
use of haematoporphyrin for cancer diagnosis. Further studies confirmed the tumour 
localizing properties of haematoporphyrin in a variety of tumours (Rasmussen-
Taxdal et al, 1955; Moan and Peng (2003). 
 
      The next major step within clinical PDT was the introduction of 
aminolevulinic acid (ALA). Kennedy et al, reported on the first clinical use 
of topical ALA in the treatment of skin malignancies in 1990 and 1992 
(Kennedy, 1992). Since then, ALA-PDT has been used in a large number of 
clinical specialities at various places. A review of the clinical research using 
this treatment modality was published and updated in the following articles 
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(Peng, 1997; McCaughan, 1999; Calzavara-Pinton et al, 2007). ALA can be used for 
both diagnosis (PDD) and therapy (PDT) of cancer, as will be discussed later. 
 
  1.2.3.3 Photodynamic Methods: 
    1.2.3.3.1 Photodynamic Therapy (PDT)  
     This method is also called photoradiation therapy, phototherapy, or 
photochemotherapy. Photodynamic therapy is now an established modality for the 
treatment of solid tumours and other accessible lesions (Pervaiz and Olivo, 2006). 
The basic principle of photodynamic method relies on a chemical reaction 
which involves liberation of singlet oxygen facilitated by light irradiation. 
This type of reaction is taken advantage of in photodynamic therapy (PDT). 
PDT is a modality for local treatment that has mostly been applied to 
malignant tumours. The technique relies on the coexistence of three 
components; a photosensitizer, oxygen, and light. A photosensitizer is the 
exogenous fluorophore or chromophore that is administered to the body, 
and that accumulates to a higher degree in diseased tissue. After a certain 
time, depending on the photosensitizing agent being used, the area is 
irradiated with non-ionizing radiation, usually light in the red wavelength 
region. A cytotoxic reaction is photo-chemically induced in the presence of 
oxygen and photosensitizer, leading to local cell destruction (McCaughan, 
1999; Calzavara- Pinton et al, 2007). 
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   1.2.3.3.2 Photodynamic Detection (PDD) 
 
     Photodynamic Detection (PDD) could be defined as a medical technology 
(diagnostic technique) involving administration of light activating chemical 
(photosensitizer) to the targeting cells that is stimulated usually by short wavelength 
light then collected (different wavelength with less energy) and analysed by the 
spectroscope. 
 
      Fluorescence diagnostics is considered as a natural counterpart to 
photodynamic therapy, since the photosensitizers used in the treatment are 
highly fluorescent, low energy or long wavelength (Red) light is required 
for PDT and short wavelength (Blue) light for PDD as shown in Figure 
1.2.2. The mechanisms of the two methods are shown in Figure 1.2.3. 
 
Photodynamic Methods
Administered Photosensitiser
to Dysplastic Lesion
Administered Photosensitiser
to Dysplastic Lesion
Fluorescence 
Blue Light (405nm)
Fluorescence 
Red Light (635nm)
Analysis by Spectroscope
Photodynamic Detection
PDD
Cell Death
Photodynamic Therapy
PDT
J.A  
Figure 1.2.2. The steps of the two photodynamic methods (PDD & PDT) using 
ALA. 
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     Optical spectroscopy techniques have in recent years been investigated 
in the search for novel, minimally or non-invasive methods for tissue 
characterization and for measurements of various parameters in the tissue. 
The techniques developed for tissue characterization are frequently called 
"optical biopsy". The methods of detecting the suspicious oral lesion using 
optical biopsy are shown in Figure 1.2.4. 
 
 
Figure 1.2.3. Light and wavelengths in PDD & PDT. Light of an appropriate 
wavelength (at the absorption maximum) is absorbed by protoporphyrin IX, which 
undergoes a transition from ground state (low energy) to the excited state. In 
photodynamic therapy, the activated photosensitizer interacts with oxygen to produce 
singlet oxygen that causes a toxic effect in tumour cells or microorganisms. In 
photodynamic diagnosis, the illumination of protoporphyrine IX (irradiated at short 
wavelength) leads to the emission of red fluorescence, while in PDT, the illumination of 
protoporphyrine IX with longer wavelength (low energy) lead to toxic effects 
(Konopka, 2007). 
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     To simplify the mechanism of photodynamic detection (PDD) and 
differentiate the procedure from the Photodynamic therapy (PDT), the 
author has drawn a series of diagrams explaining the mechanism of each 
technique in a step by step, and how do the cells react in response to each 
technique. The steps of the two techniques are shown in the following 
figures (Figures 1.2.5 A-E and 1.2.6 A-D).  
 
 
 
Figure 1.2.4. The methods of photodiagnosis. Optical biopsy (spectroscopy), or 
photodiagnosis, utilizes the fact that neoplasms cause molecular and structural changes in 
tissue. These changes are seen as the differences in the autofluorescence intensity between 
benign and premalignant/malignant tissue. In photodynamic detection, tissue fluorescence is 
induced by illumination of the administered photosensitizer with short wavelengths light. 
(Konopka, 2007). 
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Figure 1.2.5. The mechanism of Photodynamic Detection (PDD).  
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A- Topical application of the photosensitizer. 
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B- Application of the systemic photosensitizer. 
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C-Guiding the spectroscopic probe to the epithelium 
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D-Excitation of fluorophores (porphyrin) and activation of PpIX in normal  
and dysplastic cells using short wavelength (405nm) light.  
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E- Emission of green (500nm) light from the normal cell and red (635nm) light from 
dysplastic cell collected by the probe and analysed by the computer. The ALA 
autofluorescence emitter at 500nm. In the dysplastic cell, ALA converts to PpIX 
and emits red light at 635nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E 
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Figure 1.2.6. The mechanism of photodynamic therapy (PDT).  
 
 
Normal Cell                   Dysplastic Cell             Bacterial Cells
Photosensitizer
 
 
A- Application of the topical photosensitizer. 
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B- Guiding the light source to the lesion. 
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C- Exposure of the lesion to a long wavelength (635nm) light for few minutes, excitation of 
fluorophore (porphyrin) and activation of PpIX. 
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D- Death of the exposed dysplastic and bacterial cells with no effect on the normal cells. 
 
D 
C 
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  1.2.3.4 Theory of Fluorescence Detection 
 
     Every cell of the tissues contains molecules, which have a characteristic feature to 
become fluorescent when excited by ultraviolet or in a violet range radiation of 
suitable wavelength. This fluorescence emission, arising from endogenous 
fluorophores, is an intrinsic property of cells and is called autofluorescence. The 
autofluorescence should be distinguished from fluorescent signals obtained by 
adding exogenous markers (photosensitizer compounds). The majority of cell 
autofluorescence originates from molecules inside the mitochondria and lysosomes. 
Together with aromatic amino acids and lipo-pigments, the most important 
endogenous fluorophores are pyridinic (NADPH) and flavin coenzymes. The 
extracellular matrix in the tissues often contributes to the auto-fluorescence emission 
more than the cellular component, because collagen and elastin that is present among 
the endogenous fluorophores have a relatively high fluorescence emission. Changes 
occurring inside the cell and tissue state during physiological or pathological 
processes result in alteration of the amount and distribution of endogenous 
fluorophores, chemical and physical properties of their microenvironment. Therefore, 
analytical techniques based on autofluorescence monitoring can be utilized in order 
to obtain information about morphological and physiological state of cells and 
tissues. In addition, auto-fluorescence analysis can be performed in real time because 
it does not require any treatment of fixing or staining of the specimens. 
Autofluorescence may actually illuminate the structures of interest in the tissues or 
serve as a useful diagnostic indicator (Monici, 2005). 
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 1.2.4 Autofluorescence and Fluorophore 
   1.2.4.1 Mechanism of Autofluorescence 
 
     It is known that autofluorescence is the natural fluorescence of the tissue itself 
(auto). It is the fluorescence of tissues to which no chemical substances have been 
applied.  
 
      The term fluorescence in general is referred to the process by which excitation 
with light evokes the emission of light of a different wavelength (usually lower in 
energy i.e. red-shifted light). Fluorescence is the light emission resulted from a 
process that occurs in certain molecules called fluorophores and the process 
responsible for the fluorescence of fluorophores is illustrated by the electronic-state 
diagram (Jablonski diagram) as shown in Figure 1.2.7. 
 
 
Figure 1.2.7. Jablonski diagram. 
 
     The mechanism is explained as follows;  
1- A photon of energy hex (h=Planck’s constant, ex =excitation wavelength) is 
supplied by an external source of energy such as a lamp or a laser and absorbed by 
the fluorophore, creating an excited electronic singlet state (S1'). 
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2- The excited state exists for a short time (picoseconds) during which the energy of 
S1' is partially dissipated, yielding a relaxed singlet excited state (S1) and from 
which fluorescence emission originates. 
3- A photon of energy hem, the emission wavelength, is emitted. The fluorophore 
returns to its ground state S0. Due to energy dissipation during the excited-state 
lifetime, the energy of this photon is lower and therefore the wavelength is longer 
than the excitation photon hex. 
 
     The difference in energy or wavelength leads to the difference in wavelength 
between excitation and emission light. It allows one to easily separate the emitted 
fluorescence light from the excitation light. Continuous excitation of the fluorophore 
causes continuous emission of fluorescent light, unless the fluorophore can be 
destroyed by excitation or in other word called photobleaching (Elumalai et al, 
2002). 
   
  1.2.4.2 Fluorophores 
 
     Fluorophores (chromophores) are active structures present inside the tissue 
molecule which causes the molecule to be fluorescence. The fluorophore which is 
present inside the molecule absorbs energy at certain wavelength and re-emits energy 
at a different wavelength. The amount of energy and wavelength emitted depend on 
both the chemical environment of the fluorophore and the fluorephore itself. Many 
types of tissue fluorophors have been identified. They have the characteristic that 
they can absorb light over specific wavelength bands between 250 and 500 nm and 
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fluorescence emission spectra within the range 300–700 nm as shown in Figure 
1.2.8. 
 
 
       Figure 1.2.8. Normalised fluorescence emission spectra from the  
       endogenous tissue fluorophors (Stringer et al, 2008). 
 
     The autofluorescence studies involve contributions from a number of fluorophors. 
The recorded spectrum is generally broad and lacking in specific features, therefore 
discrimination between diseased and healthy tissue could be achieved by identifying 
the differences either in emission intensity or spectral distribution, or a combination 
of these findings. 
 
     Collagen, elastin, the reduced nicotinamide adenine dinucleotide (NADH) 
coenzyme, flavins, pyroxidine, tryptophan, tyrosine, and lipopigments, as well as 
porphyrins are tissue endogenous fluorophores. They can be obtained from patients 
and in vitro tissue by morphological and functional fluorescence imaging (Richards-
Kortum and Sevick-Muraca, 1996; Konig, 2000). For example, the development 
                                                                            - 26 -                           1.2 Review of literature 
from normal bronchial epithelium to invasive cancer, as illustrated in figure 1.2.9, is 
characterised by a progressive decrease in the overall fluorescence intensity and the 
intensity emission towards the end of the red spectrum. The explanation of this 
finding, is due to an increase in epithelial thickness (which attenuates the green light 
reaching the bronchial surface more than it does the red light) and an increase in 
blood vessel development in pre-malignant and malignant tissues (Harries et al 1995; 
Stringer et al, 2008). 
 
 
Figure 1.2.9. Fluorescence emission spectra from normal bronchial and 
tumour tissues (Stringer et al, 2008). 
 
 
   1.2.4.2.1 Elastin 
 
     Elastin is a protein, which is the major part of elastic fibres. These elastic fibres 
gives flexibility character to tissues such as the skin, lung and blood vessels (Barry et 
al 1992; Fendel and B. Schrader 1998). 
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   1.2.4.2.2 Collagen 
 
     Collagen is a strongly fluorescent protein that forms the major component of the 
connective tissue. There are several different types of collagen which their 
absorption and emission characteristics of light are slightly different (Eyre et al 
1984). 
 
   1.2.4.2.3 NADH/NAD+ 
 
     Nicotinamide adenine dinucleotid (NADH) is the reduced coenzyme form of 
vitamin B3, while NAD+ is the oxidized form. NAD+ and NADH are converted into 
each other in numerous different metabolic activities and carry the energy in the 
electron transport chain, where much of the ATP bioenergy, that runs every 
biological process of our body, is formed. NADH/NAD+ is mostly available in the 
respiratory unit of the cell, the mitochondria, but could also present in the cytoplasm. 
In the noeplastic process where intense oxygen consumption is required for the 
metabolism, the oxygen level might be lower, leading to a reduced pH-value that will 
influence the balance between NADH/NAD+ concentrations. NADH is highly 
fluorescent while NAD+ is not seen when the tissue is excited above 300 nm. If the 
balance is pushed towards a lower concentration of NADH, this might lower the 
blue-green fluorescence originating from NADH (Richards-Kortum and Sevick-
Muraca 1996; Drezek et al 2001; Pavlova et al. 2003; Mayevsky and Barbiro-
Michaely 2009). 
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      The blue-green autofluorescence from malignant and pre-malignant lesions has 
been reported lower than in healthy tissue in many in vivo studies (Ankerst et al 
1984; Nordstrom et al 2001; De Veld et al 2005). 
 
   1.2.4.2.4 Other Fluorophores 
 
     Tryptophan is the precursor of a range of metabolites, which are involved in a 
variety of aspects of human nutrition and metabolism (Keszthelyi et al 2009).  
Diagaradjane in his report concluded that tryptophan, collagen, and NADH are the 
key fluorophores that undergo changes during tissue transformation process and 
hence they can be targeted as tumour markers (fluorescence marker) to diagnose 
normal from abnormal tissues using the fluorescence technique (Diagaradjane et al 
2006). Other endogenous flurophores include flavins (Benson 1979; El-Hussein, et 
al, 2009) lipofuscin (Tsuchida, 1987), β-carotene (Andersson-Engels et al, 1991) and 
porphyrins (Alfano et al, 1984; Yang, et al, 1987) are also studied and considered as 
fluorescence markers. 
 
   1.2.4.2.5 Absorbers 
 
     The haemoglobin and melanin are absorbers their presence alters the recorded 
fluorescence spectrum emitted from the tissue. They absorb the excitation 
wavelength and can lower the over-all intensity of a recorded spectrum. Oxygenated 
(HbO2) and deoxygenated haemoglobin (Hb) have different absorption behavior. 
The strongest absorption peaks can be found at 414, 542 and 577 nm for (HbO2) and 
at 433 and 556 nm for Hb. The originated tissue fluorescence emission is absorbed 
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by haemoglobin and thus ‘supplementary’ peaks and valleys are created in the 
resulting fluorescence spectrum. One way to evaluate fluorescence spectra is to 
calculate intensity ratios at wavelengths with equal haemoglobin absorption 
(Andersson-Engels et al, 1990) as also used in the double ratio technique (Bogaards 
et al 2001) or to use a reflectance spectrum to estimate the concentration of 
haemoglobin and eliminate the blood interference (Muller et al, 2001). 
 
 1.2.4 The Photosensitizing Compounds 
 
     Many researches have been going on to investigate a variety of 
compounds looking for the ideal photosensitizer. There are several 
properties that are of interest to the investigators regarding the efficacy and 
usefulness of the compounds in both photodynamic methods. Some of these 
are: 
• A high degree of selective accumulation of the photosensitizer to the 
neoplastic tissue.  
• A high quantum yield for the generation of singlet oxygen to obtain 
an efficient treatment. 
• near infrared region wavelength light which has good tissue 
penetration 
• A destruction of the photosensitizer through photobleaching is 
required since this has no effect on the normal tissue. The low drug 
concentration will reduce the treatment damage threshold, in addition 
a very light doses is required for the therapy. 
                                                                            - 30 -                           1.2 Review of literature 
• A good tissue penetration of the compound is required to obtain active 
topical photosensitizer. 
• Short accumulation and clearance times in the tissues. 
    These properties are of interest in order to minimize a general skin 
photosensitivity (Stapleton and Rhodes,  2003).  
 
  1.2.4.1 Porphyrins 
 
     Based on the chemical structure as shown in Figure 1.2.10, Porphyrins 
make up a group of molecules having photosensitizing properties. These 
properties and tumor selective accumulation of haematoporphyrin were 
investigated in the first half of the last century (Rothemund, 1936). The 
absorption peak of porphyrins is at about 400 nm and a number of minor 
peaks at longer wavelengths, up to about 630 nm. The fluorescence is 
characterized by a dual-peaked emission in the red wavelength region, at 
about 630 and 700 nm. Li et al, measured the three-dimensional fluorescence 
spectra of blood and stated that fluorescence peaks were attributed to endogenous 
porphyrins, tryptophan, NAD(P)H and the finding obtained can be used to evaluate 
the distorting effect of blood on the autofluorescence signals of human tissues for 
optical biopsy (Li et al, 2006). Photofrin is a partially purified form of 
haematoporphyrin derivative, which in turn is obtained from preparations of 
haematoporphyrin with acetic and sulphuric acid. It consists of a mixture of 
several porphyrins, monomers as well as dimers and oligomers (Ankerst, 
1984). 
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     The first health agency approval for PDT with Photofrin was obtained in 
Canada in 1993 for prophylactic treatment of bladder cancer (Sternberg and 
Dolphin, 2003). Since then, further approvals have been obtained in the 
United States, Japan, and some countries in Europe (Kato, 1996; Calzavara-
Pinton et al, 2007). 
 
                                        
                       Porphyrins                                   Chlorin 
Figure 1.2.10. The main cores of the porphyrin and chlorin structures, respectively. 
The difference between them is that for chlorins at least one double bond in the 
pyrrole rings is reduced to a single bond (Harel and Manassen, 1978; Kadish et al, 
2003). 
 
 
  1.2.4.2 Chlorin  
 
     Meta-tetrahydroxyphenylchlorin (mTHPC), known under the trade name of 
Foscan. One well-known member of this group of molecules is chlorophyll 
(Erkoç and Erkoç 2002). The chemical structure of this molecule shows one or 
more double bonds in the pyrrole rings are reduced to a single bond, so is 
considered as a reduced porphyrins (Figure 1.2.10). One major difference 
between the two groups is that chlorins have the strongest absorption peak in 
the red part of the spectrum (640-700 nm) which gives the compound a green 
colour. Several chlorins compounds have been investigated as possible photo 
sensitizers for PDT. The most active of all photo sensitizers studied so far is 
foscan (Meta-tetrahydroxyphenylchlorin). The light doses needed for a 
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successful treatment is lower than for Photofrin which makes it an attractive 
product and has recently undergone clinical trials for head and neck cancer 
(D'Cruz, 2004; Lorenz, 2009). 
  
1.2.4.3 Phthalocyanines 
 
     This compound has become a subject for much research since been 
found photosensitizers with some attractive qualities. The absorption in the 
UV and blue part of the spectrum is low, resulting in a lower cutaneous 
photosensitivity (Anderson et al, 1997). The absorption spectrum reveals a 
single peak in the red wavelength region (670-690 nm) with the singlet oxygen 
quantum yield was measured at 546 nm, 630 nm, and on the far-red absorption peak, the result 
fluorescence spectrum exhibiting a single peak at about 700 nm (Fernandez, 
1997; Turker et al, 2009). 
 
  1.2.4.4 Texaphyrins 
 
     The texaphyrins are considered optimal metal coordinating expanded porphyrins. 
They involve a new series of synthetic porphyrin analogues that show promise as 
drugs for use in a range of medical therapies (Sessler and Miller, 2000). Texaphyrins 
(pentaazadentate macrocycles) have interesting photophysical properties and 
potential applications as photosensitizers. They exhibit a high efficiency in 
generating singlet oxygen, therefore could potentially be a photosensitizer and 
emitter for photodynamic detection and therapy applications (Lu et al, 2008). 
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      Texaphyrins are a new class of porphyrin-like photosensitizers. These 
compounds have a high absorbance peak in the near-infrared ranges 
between 730-770 nm. The long-wavelength absorption peak allows the 
treatment of thicker lesions, due to the increased penetration of light at these 
wavelengths (Kostenich, 1997). 
 
  1.2.4.5 Aminolevulinic Acid (ALA) 
 
     During the last few years, many research activities were published within 
the field of photodynamic detection and photodynamic therapy utilizing the 
fluorescence properties of the tissues. Investigations have been performed using 
the photosensitizer prodrug b-aminolevulinic acid (ALA) in their techniques. 
The mechanism of ALA metabolism in the tissues is explained that when the 
drug is administered to living tissue, it participates in the biochemical reactions. 
It takes part in the haem-cycle, where it will be converted to the fluorescent and 
photodynamically active compound named protoporphyrin IX (PpIX) (Kennedy 
and Pottier 1992). 
 
      Protoporphyrins have a chemical structure of tetrapyrroles which contains 4 
methyl, 2 propionic and 2 vinyl side chains. It is produced by oxidation of the 
methylene bridge of protoporphyrinogen. PpIX is an intermediate in heme 
biosynthesis, combining with ferrous iron to form protoheme IX, the heme prosthetic 
group of hemoglobin. Protoporphyrin IX is created by the enzyme 
protoporphyrinogen oxidase. The enzyme ferrochelatase converts it into heme. 
Protoporphyrin IX is the only naturally occurring isomer and occurs in small 
amounts in faeces. It is accumulated and excreted excessively in the faeces in 
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protoporphyria and variegate porphyria, in addition it is responsible for the brown 
pigment (Ooporphyrin) of birds' eggs. Protoporphyrin IX is used as a branch point in 
the biosynthetic pathway leading to Heme (by insertion of iron) and chlorophylls (by 
insertion of Mg and further side-chain transformation). Protoporphyrin IX can be 
used to treat liver disorders, mainly as the sodium salt. It has shown anti-HIV activity 
(Human Metabolome Database, 2010). 
 
      Studies on the porphyrin biochemistry have earlier been performed in 
relation to porphyric diseases. Berlin and his colleagues investigated the 
pharmacokinetics of radio-labelled ALA in humans and rats (Berlin et al, 1956). 
It is known that ALA is a naturally occurring precursor of heme. The native 
compound is not a photosensitizer, but in certain types of cells and tissues, it is 
metabolized to the photosensitizer PpIX in the body (Kennedy and Pottier, 1992). 
Intracellular porphyrin localization and photo-activation have been reported to occur 
first within the plasma membrane. After several hours of incubation, redistribution 
within the cell occurs to include the nuclear membrane and other organelles such as 
mitochondria and lysosomes (Berns et al, 1982; Shulok et al, 1990). 
 
Metabolism of ALA: 
 
     The properties of porphyrins and their metal complexes depend upon their ability 
to participate (mediator) in the oxidation reactions process. The chlorophylls 
(magnesium–porphyrin) are compounds that act as central receptors to solar energy 
utilisation, whilst haem (protoporphyrin IX iron chelate) acts to all biological 
oxidations. This compound has vital functions such as transport and storage of 
                                                                            - 35 -                           1.2 Review of literature 
oxygen, generation of cellular energy, detoxification, regulation of protein synthesis 
and cell development. Haem (iron protoporphyrin of haemoglobin) is synthesised in 
all mammalian cells, with the exception of red blood cells, which do not possess 
mitochondria (Kennedy and Pottier, 1992). 
 
     The mechanism and heam biosynthesis pathway is described as follows; 
 “The initial substrates in this pathway are succinyl CoA, which is derived from the 
citric acid cycle present in mitochondria, and the amino acid, glycine. A 
condensation reaction between these two substrates results in the formation of ALA 
in mitochondria. This step, catalysed by the enzyme ALA synthase, is rate limiting, 
tightly regulated and controlled by regulatory feedback inhibition (Rimington 1966; 
Marriott 1968). In the cytosol two molecules of ALA are condensed by the enzyme 
ALA dehydratase to form two molecules of water and one of porphobilinogen 
(PBG). The formation of a tetrapyrrole occurs by condensation of four molecules of 
PBG in a head-to-tail manner to form a linear tetrapyrrole, hydroxymethylbilane, a 
reaction catalysed by uroporphyrin I synthase, also known as porphobilinogen 
deaminase. Hydroxymethylbilane cyclises spontaneously to form uroporphyrin I, or 
is converted to uroporphyrinogen III by the combined action of uroporphyrinogen I 
synthase and uroporphyrinogen III cosynthase. Under normal conditions, the 
uroporphyrinogen formed is almost exclusively the III isomer, although in some 
circumstances the type I isomer is also formed in excess, for example in deficiencies 
of uroporphyrinogen III cosynthase. Uroporphyrinogen III is converted to 
coproporphyrinogen III by decarboxylation of all the acetate groups giving rise to 
methyl groups. The reaction is catalysed by uroporphyrinogen decarboxylase, which 
is also capable of converting uroporphyrinogen I to coproporphyrinogen I. 
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Coproporphyrinogen III then enters the mitochondria, where it is converted to 
protoporphyrinogen IX and then to protoporphyrin IX (PpIX). Several steps appear 
to be involved in this conversion: the mitochondrial enzyme coproporphyrinogen 
oxidase catalyses the decarboxylation and oxidation of two propionic side chains to 
form protoporphyrinogen; then oxidation of protoporphyrinogen to protoporphyrin is 
catalysed by another mitochondrial enzyme, protoporphyrinogen oxidase. The final 
step in haem synthesis involves the incorporation of ferrous iron into protoporphyrin 
in a reaction catalysed by haem synthase, more commonly known as ferrochelatase, 
another mitochondrial enzyme. This represents a second rate limiting step in the 
pathway to haem synthesis, regulated by a further negative feedback system”.  In 
addition, the diagram of the ALA metabolisim and the heam biosynthesis pathway as 
shown in Figure 1.2.11 has been published by Kelty et al, (2002). 
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Figure 1.2.11. Haem biosynthesis pathway Ref (Kelty et al, 2002).  
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      Studies on the distribution and pharmacokinetics of porphyrins stated that the 
compound accumulate rapidly in the mucosal layer, however slowly in the 
underlying muscular tissues (Loh et al,, 1993; Ackroyd et al, 1999). Other studies 
have stated that Protoporphyrin IX is a potent photosensitiser and demonstrated that 
sufficient PpIX is synthesised by exogenous ALA administration to produce a 
photodynamic effect following exposure to light, both in vitro and in vivo (Malik and 
H. Lugaci 1987; Divaris et al,  1990; Loh  et al, 1993; Leveckis 1994; Pottier et al, 
1996; Wyld, et al, 1997). It was also found that Photodynamic effect correlates with 
the intensity of PpIX fluorescence as observed by microscopy (Divaris et al, 1990). 
 
 1.2.5 Excitation Light Sources 
 
     The excitation light sources used for photodynamic detection can be 
divided into;  
• lamps   
• Lasers. 
 
      There are several factors that need to be considered in choosing the light 
source. 
• The size of the lamp should be suitable for operability of the system. 
• The size of the lamp should be suitable for portability of the system. 
• Low heat generation. 
• Suitable for the detection technique. 
• The wavelength should be appropriate for the in vivo detection 
application. 
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      The wavelengths at 337 - 410 nm are of special interest in the excitation of 
tissue autofluorescence and porphyrin fluorescence. One of these wavelengths 
is 405 nm. It coincides with the band of porphyrins, and is thus of special 
interest for PDD (Kwasny and Mierczyk, 2003). 
 
Wood's lamps were introduced and used in early work. They were then 
replaced by high-pressure mercury lamps and xenon lamps. 
The xenon lamp has a broad spectrum in the near- UV region, and needs to 
be filtered with an optical filter or a monochromator to give an appropriate 
excitation wavelength. 
Lasers have been introduced recently. They have several advantages over 
lamps for many applications because of: 
 
• Narrow wavelength region with high intensity emission can be 
achieved. 
• Highly paralleled beam allows efficient coupling of the light into 
optical fibres. 
• The continuous wave ranging from ultra violet (short wavelength) to 
Infra red (long wavelength) which are of special interest in the 
excitation of tissue autofluorescence and porphyrin fluorescence 
respectively (Babilas et al, 2006; Caplan, 1967; Murtagh, 1985; 
Princeton instruments, 2010). 
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1.2.6 Fluorescence Spectroscopy for Tissue Characterization 
 
     Fluorescence spectroscopy is a non-invasive technique which has the potential to 
characterise different tissues. Investigations have demonstrated the importance of 
this technique in the detection of the soft tissue lesions. It has the ability to delineate 
the borders between normal and malignant tissue and to guide to the most likely 
diseased tissue during the clinical examination for the purpose of biopsy sampling 
especially in those clinical specialities, where malignant tissue cannot be visualised 
or diagnosed easily by the eye (Alian et al, 1994). 
 
      Instrumentation based on laser-induced fluorescence spectroscopy, elastic 
scattering spectroscopy, Raman spectroscopy, and optical coherence tomography is 
presently being tested and compared with punch biopsies as the "gold standard. 
These techniques have shown the ability to identify dysplastic or malignant regions 
of tissue that would not be visible to the clinician (Bohorfoush, 2000). 
 
      The information from a fluorescence spectrum can be difficult to interpret since 
the fluorescence emission is dominated by a few fluorophores with broad and 
overlapping spectra. Mathematical multivariate tools are often required to separate 
the fluorescence from different fluorophores and to build models for tissue 
classification. The use of externally applied fluorescent tumour markers can enhance 
the discrimination substantially. Further, different fluorophores have different 
absorption peaks and fluorescence instruments utilising multiple excitation 
wavelengths may provide additional information (Wang and Mizaikoff , 2008). 
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      Clinical fluorescence spectroscopy of tissue was introduced as a diagnostic tool 
for malignant lesions in the 80’s and since then; several studies have been conducted 
pertaining to many various clinical applications (Profio et al, 1984). 
 
   1.2.6.1 Optical Spectroscopy 
 
     The traditional biopsy is still the gold standard for the diagnosis of oral lesions. 
The rationale for developing other techniques is to improve the detection of early 
premalignant changes in the oral mucosa. One of these techniques under 
investigation is optical spectroscopy. Optical spectroscopy or optical biopsy system 
(OBS) allows non-invasive physical and chemical characterisation of biological 
tissues. The structural and chemical composition of cells and tissues strongly 
influences their optical features, and therefore alterations in the optical characteristics 
may indicate the presence of diseased tissue. Optical spectroscopy may provide 
possibilities in the early detection of cancerous tissues in humans. Biochemical and 
structural or morphological information can be gained by measuring absorption, 
fluorescence, elastic scattering or Raman scattering. These Optical diagnostic 
techniques have become an adjuvant method to conventional detection methods for 
the head and neck malignancy (Upile et al, 2007). 
 
  1.2.6.2 Optical Biopsy Techniques in Head and Neck 
 
     The “Optical Biopsy” System (OBS) is a non invasive method for biological 
tissue differentiation which has been proposed as an auxiliary tool for cancer 
detection. It has been claimed that fluorescence spectroscopy is an efficient device 
                                                                            - 42 -                           1.2 Review of literature 
for distinguishing between normal and tumour tissues and also for differentiating 
dissimilar clinical lesions (Kurachi et al, 2004). 
 
     As noted above, the autofluorescence depends on biochemical, and morphological 
aspect in addition to the tissue architecture.  In many ways it is important to 
determine finger print fluorescence for normal and non normal tissue. 
 
     Recently there has been increased interest in “optical biopsy” systems using tissue 
spectroscopy to assess if those techniques can be used as an adjunct or alternative to 
histopathology in defining tissue involvement. In addition to aid diagnosis, treatment 
and follow-up, used to guide the more accurate delivery of treatment, eg 
photodynamic therapy (Upile et al, 2007).  
 
     The main techniques currently utilized in the detection of oral lesions are: 
 
1-Microendoscopy (morphology of the surface): Microendoscopy allows in vivo 
examination of the epithelium to obtain the histopathological grade image without 
the need to remove the tissue (Gynther et al, 2000). 
 
2-Elastic Scattering Spectroscopy (changes on cellular and subcellular level): Elastic 
Scattering Spectroscopy (ESS) is a technique that generates a wavelength dependant 
spectrum that reflects structural and morphological change within tissues. 
 
3-Raman Spectroscopy: A Raman spectroscopy is a form of in-elastic scattering and 
is generated by a shift in frequency in the incident excitation light, above and below 
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the wave length of the incident photones due to vibrational frequencies of the bio-
molecules that constitute the tissue. 
 
4-Fluorescence spectroscopy and imaging (biochemical changes in tissue): When 
cells interact with light they become excited and re-emit light of varying colours 
(fluorescence) and this can be detected by sensitive detectors (Swinson et al, 2006; 
Upile et al,,  2007). 
 
5- Optical Coherence Tomography (OCT) This new technology is been under 
investigation and shows useful results in the head and neck lesions detection. 
(Jerjes et al, 2010). 
 
  1.2.6.3 Fluorescence Detection Principles and Data Analysis 
             Methods 
 
     The data obtained from the fluorescence investigations are spectra 
emitted from the tissues. The type of data is dependent upon the type of 
equipment used in the detection.  
 
     They are of two types; 
• Point-monitoring systems used to characterize the sample in a single 
point form recordings of the fluorescence intensity or spectrum. 
• Imaging systems gives broader field of reading records. 
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     These two systems can give complementary information on the 
composition of fluorophores, and on changes due to the biochemical and 
structural changes. Several point-monitoring and imaging systems have been 
developed, and some have also turned into commercial products. Some of 
these systems rely on the tissue autofluorescence, while others are combined 
with the administration of fluorescent tumour markers. The red fluorescence 
emission can be used to investigate the accumulation of a photosensitizer in 
the sample. The detected signal can then be used as a measure on the 
concentration of the sensitizer in the examined tissue sample. 
 
      The approach in collecting data is to record the full spectrum of light 
emitted from the sample. The data collected is displayed, on the screen of 
the instrument, as a linegraphs distribution including the fluorescence 
intensity at all the recorded wavelengths of the light. At these wavelengths 
the data will show contribution from the tissue autofluorescence and the 
PpIX fluorescence.      
 
     Several techniques have been proposed for the evaluation of fluorescence 
spectra. They can be managed by different methods; 
 
• One statistical approach is to use stepwise multivariate linear 
regression (MVLR). This method relies on the shape of the 
normalized spectra. On a training set, the intensities at a number of 
wavelengths are multiplied with different weights to obtain 
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discrimination between normal and diseased tissue (Madhuri et al, 
2003; de Veld et al, 2004). 
• Principal component analysis (PCA) and neural network analysis (NNA) 
has also been used in the evaluation of fluorescence spectra (Nayak et 
al, 2006; O'Dwyer et al, 2008).  
• Fluorescence ratios are an approach used to avoid artefacts in the 
data. This technique has been extensively used for tissue 
characterization following the administration of fluorescent tumour 
markers.  
 
      A wavelength around 405 nm should be used for a good excitation of 
porphyrins. This is not an optimal wavelength for investigations of the 
autofluorescence, since most of the tissue endogenous fluorophores (as 
shown in figure 1.2.8) have their main excitation wavelength at shorter 
wavelengths, below 360 nm.  
 
      5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) fluorescence 
has shown high sensitivity for the assessment of soft tissue lesions.  Diagnosis of 
the oral lesions using this technique has been used as a reliable method in 
detecting oral premalignant and malignant lesions in vivo using different designed 
instruments (Zheng et al, 2002; Zheng et al, 2004; Sharwani et al, 2006). Some 
of these instruments are commercially introduced to the markets. 
 
     The system used in the thesis was developed by Professor Miles Padgett        
from the Department of Physics and Astronomy, University of Glasgow. Nadeau et 
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al, (2002) 1st described this (compact fluorescence spectroscopic) tool for in vivo 
point monitoring of aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) 
fluorescence and autofluorescence, as a non-invasive method of differentiating 
normal and cancerous tissue. Their results illustrate the potential of the system to be 
used for fluorescence monitoring in a variety of clinical applications. Subsequently, 
many clinical trials on body systems were conducted at Ninewells hospital 
University of Dundee and some of these investigations have been published in 
scientific journals (Nadeau et al, 2002; Nadeau et al, 2004; Ibbotson et al, 2006; 
O'Dwyer et al, 2008; Eljamel et al, 2008; Lesar et al, 2009). 
Details of the system will be described later in the Patients and Methods 
section.  
 
   1.2.6.4 The Use of Optical Biopsy Systems in the Clinical 
               Investigations 
 
     1.2.6.4.1 Studies on Animal Samples 
 
     Alfano et al, in 1984 first described the use of autofluorescence spectroscopy in 
vivo to differentiate between normal and malignant tissues on the rat and mouse 
kidney, prostate and bladder samples. Since then several authors have registered their 
findings with this technique. 
 
      The optical technique was used on animal models for the detection of chemically 
induced carcinoma. Autofluorescence spectroscopy on specimens of normal buccal 
pouch mucosa (normal), epithelial hyperkeratosis (hyperkeratosis), epithelial 
dysplasia (dysplasia), and squamous cell carcinoma (SCC)  were analysed using 330 
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nm excitation to discriminate the lesions. The results concluded that this technique is 
a useful diagnostic tool for in vivo diagnosis of oral pre-cancers and cancers in 
DMBA-induced hamster buccal pouch carcinogenesis model (Wang et al, 2003). 
While at the lateral border of the tongue in a hamster samples using two excitation 
wavelength 442-532 nm the spectra results were analyzed comparing with the 
histopathology diagnosis, the investigator suggested using multiple wavelength 
excitations for a broader tissue fluorescence investigation (Kurachi et al, 2005). 
 
    1.2.6.4.2 Studies on Human 
 
     The technique of autofluorescence spectroscopy has been used on human and 
animal in the mid 80’s to detect endogenous porphyrin fluorescence in tumours of 
the oral cavity (Harris and Werkhaven, 1987).  Several other studies were conducted 
to utilise the application of this technique on human in detection of early oral 
cancers. Dhingra et al used Laser induced autofluorescence to examine areas of oral 
neoplasia and contra lateral areas of normal oral mucosa. They found the differences 
most marked at two intensities, namely 370 nm and 410 nm, and they also noted an 
increase in the fluorescence in the red wavelength (>600) in malignant areas. This 
was felt to be due to higher concentration of endogenous porphyrins (Dhingra et al, 
1996). Gillenwater et al, (1998) used autofluorescence to look at neoplastic and non-
neoplastic oral mucosa and found that the fluorescence intensities were less for 
abnormal than normal sites. They showed that the ratio of red spectrum (>600nm) to 
the blue spectrum (455-490nm) was greater in areas of abnormal disease. 
 
      The usefulness of fluorescence spectroscopy (FS) was examined on 130 oral 
lesions. The investigators suggested that FS is useful as a tool in oral tissue 
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pathology diagnosis (Onizawa et al, 1999). Betz et al, (1999) reported that there are 
spectral differences between normal and dysplastic tissues in spectrophotometric 
analysis in the green spectral range. The differences were found in 94% of the cases 
studied. De Veld et al investigated the influence of anatomical location on healthy 
mucosa autofluorescence on volunteers. They found normalisation spectra except for 
the dorsal site of the tongue and vermilion border of the lip (de Veld et al, 2003). 
Using fluorescence intensity in the 502–523 nm range, the individual characteristics 
on healthy oral mucosa autofluorescence spectral differences were studied on 
volunteers. It was found that there was statistically significant difference in the 
gender, colour, and alcohol consumption (De Veld et al, 2004). 
 
      The possibility of using near-infrared autofluorescence as a diagnostic technique 
in cancer detection was investigated. The investigators utilized various types of 
normal and malignant tissue samples in their investigation. Comparing the data 
showed differences between measurements taken from normal tissues and that of 
malignant nature, which could provide the basis for detection of cancer and 
delineation of tumor margins (Demos et al, 2004). 
 
 1.2.7 Clinical Manifestations of the Suspicious (Potentially 
          Malignant) Oral Lesions 
 
     In the title of this thesis the term suspicious is referred to all lesions that have 
similar clinical manifestations and potentially malignant in the differential diagnosis 
(the white, red, red and white and/or ulceration). This includes location of these 
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lesions in all sites of the oral cavity which gives the impression that the lesion might 
be suspicious or has premalignant potential. 
 
      In a World Health Organization (WHO) Workshop, held in 2005, the 
terminology, definitions and classification of oral lesions with a predisposition to 
malignant transformation have been discussed. The term ‘‘potentially malignant” 
was preferred above ‘‘premalignant” or ‘‘precancerous” (Warnakulasuriya et al, 
2007), furthermore, it has been recommended to abandon the traditional distinction 
between potentially malignant lesions and potentially malignant conditions and to 
use the term ‘‘potentially malignant disorders” instead (van der Waal I, 2009). 
 
      In this review, attention will be paid to leukoplakia, lichen planus, erythroplakia 
as well as other oral lesions since these are the main lesions included and listed when 
formulating the differential diagnosis in this study. 
 
   1.2.7.1 Oral Hyperkeratotic Lesions (Leukoplakia) 
 
     Leukoplakia is at present defined as “A white plaque of questionable risk having 
excluded (other) known diseases or disorders that carry no increased risk for cancer” 
(Warnakulasuriya et al, 2007). The World Health Organization defines the term 
“leukoplakia” (Greek for “white, flat area”) as “a white patch or plaque that cannot 
be characterized clinically or pathologically as any other disease”. The term is a 
clinical description of the lesion only; the use of the term is restricted to instances 
when no other diagnosis can be given based on clinical appearance alone. Upon 
further histologic investigation, microscopic diagnosis of clinical leukoplakic lesions 
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can range from hyperkeratosis to dysplasia, carcinoma in situ, and invasive 
squamous cell carcinoma (Noonan and Kabani, 2005). 
 
      Leukoplakia was found significantly more prevalent among males. Petti reported 
in his systematic review including 23 primary studies from all over the world that the 
point estimates was approximately 2.6% (Petti, 2003). Leukoplakia may affect any 
site of the oral and oropharyngeal cavity. Location of a leukoplakic lesion on 
nonkeratinized mucosa at high-risk sites for developing oral cancer, such as the floor 
of the mouth, the lateral and ventral tongue, and the soft palate, increases the 
likelihood of malignant transformation. Clinical observation indicates that one third 
of oral cancer cases are associated with an adjacent area of leukoplakia (Noonan and 
Kabani, 2005). 
 
      Leukoplakia can be subdivided in a homogeneous type (flat, thin, uniform white 
in colour) and a non-homogeneous type. The non-homogeneous type has been 
defined as a white and red lesion “erythroleukoplakia”, that may be either irregularly 
flat “speckled” or nodular. Verrucous leukoplakia is yet another type of non-
homogeneous leukoplakia. Although verrucous leukoplakia usually has a uniform 
white appearance, its verrucous texture is the distinguishing feature from 
homogeneous (flat) leukoplakia.  
 
      Verrucous leukoplakia is clinically indistinguishable from the clinical aspect of 
verrucous carcinoma. Proliferative verrucous leukoplakia (PVL) is a subtype of 
verrucous leukoplakia (Hansen et al, 1985), being characterized by multifocal 
presentation, resistance to treatment and a high rate of malignant transformation 
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(Cabay et al, 2007; van der Waal and Reichart, 2008), PVL seems more prevalent 
among elderly women and considered unique in its predilection (nearly four to one 
over men), PVL is generally diagnosed in the seventh decade of life. Studies reported 
that 70% to nearly 100% of PVL lesions progress to squamous cell carcinoma, with 
the gingiva and tongue being the sites showing the highest incidence of 
transformation (Batsakis et al, 1999; Silverman and Gorsky, 1997). In reviewing the 
cases, it was noticed that months to years may elapse from the time of initial 
recognition of the process to its ultimate transformation to invasive carcinoma. No 
apparent link between human papilloma virus and use of tobacco products has been 
firmly established with regard to PVL (Fettig et al, 2000). Given that PVL probably 
represents a disease that is multifactorial in nature, it is difficult to anticipate 
specifically who is at high risk for developing the condition. (Silverman and Gorsky, 
1997; Van der Waal, 2009). The importance of awareness of the clinician of the 
colour changes is of significance to the progression of the lesion to verrucous 
carcinoma or squamous cell carcinoma, although the effectivness of follow up has 
not yet been proven (van der Waal and Reichart, 2008). 
 
   1.2.7.1.1 Frictional (Irritational) Keratosis 
 
     Another oral mucosal lesion with known aetiology is frictional keratosis. It is 
important to distinguish this lesion from leukoplakia. Frictional keratosis is a white 
lesion often found on areas close to a traumatic insult. This change may be present 
underneath a removable partial or complete denture or on an edentulous area that has 
not been restored and is used for mastication. The lesion appears “clinically” as a 
rough hyperkeratotic area. Frictional keratosis represents a reactive epithelial 
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response to trauma from mastication. No treatment is generally recommended for 
frictional keratosis unless the character of the lesion indicates otherwise. The 
recurrence rate after any type of treatment varies depending on the period of follow 
up (van der Waal, 2010), therefore biopsy is a step required for the treatment plan. 
 
    1.2.7.1.2 Tobacco-Associated Oral Lesions 
 
     Smoking and tobacco use is by far the most important etiologic factor in a 
significant number of oral mucosal lesions. The proportion of both smoking and 
smokeless tobacco among individuals with leukoplakia is high, and a relationship is 
evident between the tobacco habit and the anatomical location of the leukoplakia. 
Cultural and demographic differences are contributing factors in pattern of tobacco 
usage and oral lesions. In the Eastern and South Asian study communities were 
likely to combine chewing with smoking and drinking, and women exhibited the 
highest prevalence of oral lichen planus, oral submucous fibrosis and oral 
leukoplakia (Lee, et al, 2010). In the central European countries shows high 
correlation between cigarette smoking and oral leukoplakia and the incidence and 
mortality from oropharyngeal cancer ranks among the highest in the world (Bánóczy 
J et al, 2001). Exposure of the oral mucosa to smokeless or chewing tobacco leads to 
a distinct clinical and histological changes. One of the most worrisome oral mucosal 
disorders produced by chronic habitual use of smokeless tobacco is leukoplakia. The 
leukoplakic changes associated with smokeless tobacco use are clearly defined in 
areas of the oral mucosa that come in direct contact with tobacco. 
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      Tobacco associated lesion looks gray-white in colour with surface fissures and 
indistinct borders. Its clinical appearance is characterised by a brownish-red 
discolouration of the oral mucosa with an irregular epithelial surface that has a 
tendency to desquamate or peel off (Reichart,  and Philipsen, 1998). Changes in the 
oral mucosa following chronic smokeless tobacco use are considered premalignant 
changes, but the risk of developing squamous cell carcinoma from smokeless 
tobacco use is markedly lower than that associated with other forms of tobacco use 
such as cigarette smoking and betel quid chewing (Bouquot and Meckstroth, 1998). 
Biopsy of any residual lesions is critical, because carcinomatous transformation may 
occur (Kaugars et al, 1989). 
 
   1.2.7.2 Erythroplakia 
 
     In contrast to oral leukoplakia, the term ‘erythroplakia’ (erythroplasia) was used 
to describe red lesions of the oral mucosa (Cawson et al, 1996). Erythroplakia (in 
Greek for “red, flat area”) is defined in similar way to leukoplakia as “A fiery red 
patch that cannot be characterized clinically or pathologically as any other definable 
disease” (Pindborg et al, 1997; Wamakulasuriya et al, 2007). 
 
      It has generally been accepted that oral erythroplakia is much less common than 
oral leukoplakia (Scully 2004). The prevalence of the lesion ranges between 0.02% 
and 0.83% (Peter et al, 2005). 
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     Aetiology and pathogenesis of oral erythroplakia are poorly understood. 
Predisposing factors are widely unknown, but it has been suggested that tobacco and 
alcohol use are probably involved in most cases (Scully, 2004).  
 
      The erythroplakic lesions may have a smooth and velvety surface or may also be 
seen with other morphological characteristics. They may have an irregular, red 
granular surface interspersed with white or yellow foci, which may be described as 
granular erythroplakia. There may be numerous, small irregular foci of leukoplakia 
dispersed in the erythroplakic patch, and this has been called speckled leukoplakia 
(Pindborg, 1963). Erythroplakic areas may also be found in association with or 
adjacent to areas of leukoplakia. Oral erythroplakia is soft to palpation and does not 
become indurated or hard until an invasive carcinoma develops in it (Bouquot and 
Ephros, 1995). It may be impossible to distinguish between erythroplakia, 
erythematous candidiasis, nonspecific inflammatory processes, and vascular lesions 
on clinical presentation alone, for this reason, biopsy is a must to establish a 
definitive diagnosis. It is not uncommon to find multiple foci of erythroplakia. 
Erythroplakia occurs most often on the floor of the mouth, palate, retromolar region, 
and tongue and generally presents in an individual in the sixth to seventh decade of 
life (Shafer and Waldron, 1975). Oral erythroplakia is highly of representing 
carcinoma in situ or invasive squamous cell carcinoma at the time of diagnosis; 
therefore, once erythroplakia is identified, immediate action should be taken to 
excise the tissue (Shafer and Waldron, 1975). Van der Waal reviewed the potentially 
malignant disorder and recommended that erythroplakias could be treated by cold 
knife or laser excision. He stated that there are no data from the literature about 
recurrence rate after surgical excision of erythroplakias (Van der Waal I, 2010). 
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   1.2.7.3 Inflammatory Associated Lesions 
     1.2.7.3.1 Lichen Planus 
 
     Lichen planus is a chronic inflammatory lesion involves the skin as well as the 
oral mucosa. It is considered as mucocutaneous autoimmune disease which can 
affect the oral mucosa, skin, scalp, nails and genital mucosa (Sumairi et al, 2007). It 
has been reported that the disease affect middle-aged patients and more commonly 
seen in females than males (Sugerman et al, 2002). Oral lichen planus could also be 
seen in children although rare in incidence (Laeijendecker et al, 2005; Patel, 2005). 
The prevalence of OLP is approximately 1% (van der Waal, 2009) with variation 
ranges between 1.9% in the Swedish population (Axell and Rundquist, 1987), 2.6% 
in the Indian population (Murti et al, 1986) and 0.5% in a selected Japanese 
population (Ikeda 1991), however is a relatively uncommon mucosal disorder in 
Malaysia and prevalent in 0.38% of the population (Zain et al, 1997). 
 
      Clinically, the lesion can present as white striations (Wickham’s striae), white 
papules, white plaque, erythema, erosion or blisters The buccal mucosa, dorsum of 
tongue and gingiva are commonly affected. OLP usually presents as a symmetrical 
and bilateral lesion or multiple lesions. It can occur in six types of clinical variants 
namely reticular, papular, plaque like, erosive, atrophic and bullous and some 
variants can co-exist in the same patient. Burning sensation and sometimes pain 
usually accompany the erosive, atrophic or bullous type lesion (Andreasen, 1968) 
(Pindborg, 1997). The clinical differential diagnoses include lichenoid drug 
eruptions, lichenoid lesions associated with contact hypersensitivity to restorative 
materials, leukoplakia, lupus erythematosus and graft versus host disease (GVHD). 
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Direct immunofluorescence can aid in distinguishing OLP from other lesions 
especially vesiculo-bullous lesions such as pemphigus vulgaris, benign mucous 
membrane pemphigoid and linear IgA bullous dermatosis (Ismail et al, 2007; van der 
Waal, 2009; Schlosser, 2010). 
 
      Oral lichenoid reactions (OLR) are considered variants of OLP. They may be 
regarded as a disease by itself or as an exacerbation of an existing OLP, by the 
presence of medication or dental materials. Oral and cutaneous involvements have 
been reported. It has been associated with numerous drugs, although only some of 
these have been confirmed. Drugs such as beta blockers, dapsone, oral 
hypoglycemics, non-steroidal anti-inflammatory drugs (NSAIDs), penicillamine, 
phenothiazines, sulfonylureas and gold salts have been associated with lichenoid 
reactions (Rice and Hamburger 2002). Other than drugs, lichenoid reactions have 
also been associated with dental materials. Lichenoid reaction as an allergic reaction 
to dental materials has been widely reported. These materials include antiseptics, 
local anaesthetics, ultraviolet radiation, latex gloves, rubber dams, mouthwashes and 
other dental hygiene materials, besides, the materials used during the restorative 
procedures as metals, impression materials, cements, acrylics, and adhesives (van der 
Waal, 2009; Restrepo and Ardila, 2010). Many studies have documented contact 
hypersensitivity to dental materials such as composite (Lind, 1988) and amalgam 
(Thornhill  et al,  2003; Sahebjamee et al, 2009) presenting as lichenoid reactions. 
Some studies also showed improvement of symptoms or recovery of oral lichenoid 
lesions following replacement of causative restorations (Thornhill et al, 2003; 
Sahebjamee et al, 2009). In most cases, OLR are indistinguishable from idiopathic 
OLP, clinically or histologically (van der waal, 2009). 
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      After carrying out updated review of the different diagnostic criteria proposed for 
OLLCs (oral lichenoid contacts) searching the Pubmed® and Cochrane® databases, 
the reporter concluded that the diagnosis of these lesions is still difficult and 
controversial, however, these authors consider that the histopathological study is not 
always necessary, except when their clinical presentation is atypical in order to 
exclude the existence of malignancy. On this point, they consider that the 
histopathological study is always necessary because these lesions do not usually 
fulfil all the characteristic histopathological criteria of OLP and are diagnosed as 
compatible with OLP or OLL (Cobos-Fuentes et al, 2009). 
 
     Direct immunofluorescence examination is only used as an adjunct to the above 
method of diagnosis and to rule out specific autoimmune diseases such as pemphigus 
and pemphigoid. Histopathologic features of OLP and OLR are similar with some 
suggestions of certain discriminatory features by some authors (Ismail et al, 2007). 
Direct and indirect immunofluorescence study and cutaneous patch test may play a 
role in differentiating these lesions. Although the exact aetiology is unknown, OLP is 
recognized as a chronic disease of cell-mediated immune damage to the basal 
keratinocytes in the oral mucosa that are recognized as being antigenically foreign or 
altered (Magro et al, 1997). 
 
     Although the malignant transformation does not exceed 1% of the cases, in recent 
years the differentiation between oral lichen planus (OLP) and oral lichenoid lesions 
(OLL) has become important, since the latter might have a greater malignant 
potential (Cortés-Ramírez et al, 2009; van der Waal, 2009). The erosive and atrophic 
types most commonly undergo malignant transformation (Barnard et al, 1993). 
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Biopsy is recommended to assess dysplasia, however malignant transformation of 
OLP is still controversial and further prospective studies are required. 
 
   1.2.7.3.2 Oral Candidiasis 
 
     Infection with Candida albicans is most often responsible for oral candidiasis. 
Candida can be routinely isolated from the oral cavity of healthy persons, with 
variation in relation to hygiene status (Darwazeh et al, 2010). Alteration of the oral 
environment due to exposure to chemotherapeutic (Epstein et al, 2002), radiation 
treatment (Azizi and  Rezaei, 2009) and immunodeficiency status (Soysa et al, 2008) 
may encourages overgrowth of the oral microflora. 
 
      The classification of oral candidiasis often refers to the clinical feature of the 
lesion and the acute or chronic nature of the process (Holmstrup and Axell, 1990). 
Classification of oral candidiasis could be divided into three clinical forms: 
pseudomembranous candidiasis (thrush), erythematous or atrophic candidiasis, and 
hyperplastic candidiasis (candidal leukoplakia). Biopsy and/or culture are often 
necessary to confirm the diagnosis and exclude dysplasia or invasive tumour from 
the benign lesions (Bagan and Scully, 2008). The candidal lesion add additional 
complexity to the clinical diagnostic process, therefore, dentists, otolaryngologists 
and pediatricians should be familiar with the clinical appearances of chronic 
mucocutaneous candidiasis to make an accurate diagnosis (Liu, Hua, 2007). 
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 1.2.8 Early Malignant Detection Methods 
 
 
     At the present time early detection and diagnosis of clinically suspicious 
(premalignant potential) oral lesions is still based on history of the patient and 
thorough inspection of all oral mucosal sites. It is suggested that visual examination 
of the oral mucosa is effective in reducing mortality from oral cancer in individuals 
exposed to risk factors. It is believed that simple visual examination and clinical 
experience are well known to be limited by subjective interpretation and by the 
potential occurrence of dysplasia and early oral squamous cell carcinoma within 
areas of normal-looking oral mucosa. As a consequence, adjunctive techniques have 
been suggested to increase our ability to differentiate between benign abnormalities 
and dysplastic/malignant changes as well as to identify areas of dysplasia/early 
OSCC that are not visible to naked eye (Fedele, 2009). 
 
     The vast majority of oral neoplasms were diagnosed from lesions aroused from 
the mucosal surface. The incidence of occurrence of squamous cell carcinoma is 
considered the highest among other oral neoplasms. Diagnosis of cancerous lesions 
from a multitude of other red, white, or ulcerated lesions of the oral cavity is a big 
challenge for the clinicians. Most oral lesions are benign, but many have an 
appearance that is confusing with a malignant lesion, and some previously 
considered benign are now classified premalignant because studies have shown them 
statistically correlated with subsequent cancerous changes based on the clinical and 
histopathologic diagnoses (Bokor-Bratić et al, 2004). On the contrary, some 
malignant lesions seen in an early stage may be mistaken for a benign change. Any 
oral lesion that does not regress spontaneously or respond to the usual therapeutic 
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measures should be considered potentially malignant or malignant unless proven 
otherwise (histologically) (Mashberg, 1978; Silverman et al, 1984). 
 
      The applications of the recently investigated diagnostic techniques in the 
detection of the suspicious oral lesions which include toluidine blue, cytology, brush 
biopsy, chemiluminescence and tissue autofluorescence is reviewed. 
 
   1.2.8.1 Toluidine Blue Staining 
 
     Toluidine blue (TB), also known as tolonium chloride, is a vital dye that is 
believed to stain nucleic acids. Hence, it has been used over decades as a diagnostic 
aid for the detection of oral cancer (Seoane Lestón and Diz Dios, 2010). TB was used 
for the identification of mucosal abnormalities and as a useful way of demarcating 
the extent of a potentially malignant lesion prior to excision (Mashberg, 1983; 
Epstein et al, 2003; Gandolfo et al, 2006). Analysis of current evidence suggests that 
TB is good at detecting carcinomas, but its sensitivity in detecting dysplasias is lower 
(Warnakulasuriya and Johnson, 1996). In addition, controversy exists regarding the 
colour perception in identification of oral mucosal lesions and subjective 
interpretation of mucosal staining and criteria for positive results or clinical decision 
making (e.g. dark royal blue versus pale blue staining) (Güneri et al, 2010). At the 
present time, TB is considered as a reliable aid and has been used as a marker to 
differentiate lesions at high risk of progression in order to improve early diagnosis of 
oropharyngeal carcinomas (Allegra et al, 2009).  
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   1.2.8.2 Cytology 
 
     Exfoliative cytology (cell scrapings) technique serves as an adjunct to clinical 
diagnosis under certain conditions. It enables screening and provides microscopic 
material in patients not indicated to surgical biopsy. However, cytologic smears are 
used infrequently and the final diagnosis as well as the treatment plan is not 
established on the basis of cytologic findings alone. Smears are most helpful in 
differentiating inflammatory conditions, especially candidiasis, from dysplastic or 
neoplastic surface lesions. Ogden et al reported that quantitative cytophotometric 
analysis may be a useful adjunct to the detection of recurrence of malignancy, prior 
to it becoming visible, clinically (Ogden et al, 1989). They also stated that cytology 
may be helpful in detecting field change in oral cancer, especially if this method is 
used in conjunction with staining (Ogden et al, 1991, 1993). Cytology may also be 
helpful when ulcerations following radiation are suspicious and biopsy is not 
indicated in real time (Perez-Sayans et al, 2009). 
 
     Investigators in the re-evaluation of the oral cytology reported that, although 
conventional cytology may be useful in oral squamous cell carcinoma and potentially 
malignant lesions, liquid-based cytology gives better results, enhances both the 
sensitivity and specificity, and also provides material for further investigations, e.g. 
DNA ploidy studies, microhistology, etc (Ogden and Cowpe 1989; Tucker et al, 
1994; Ogden et al 1994; Navone, 2009). 
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   1.2.8.3 Oral Brush Biopsy 
 
     The oral brush biopsy is also known as OralCDx Brush Test system. It involves 
collecting epithelial sample of cells from a mucosal lesion representing the 
superficial and deep layers of the epithelium (Drinnan, 2000). The test is of low-risk 
clinical technique, therefore specifically designed to investigate mucosal 
abnormalities that would otherwise be large or multiple or the patients refuse biopsy. 
The brush is a non invasive device used for epithelial cell collection and samples, 
fixed onto a glass slide, stained with a modified Papanicolaou test and analyzed 
microscopically via a computer-based imaging system (Divani et al, 2009). Highly 
suspicious lesions with cellular morphology changes for epithelial dysplasia or 
carcinoma is reported as positive or atypical. Results are defined as negative when no 
abnormalities can be found. Modified technique using liquid based cytology with 
specialized oral brush improves the sensitivity and specificity and is considered as a 
useful tool for screening of oral premalignant and malignant lesions (Delavarian et 
al, 2010). The test is considered an intermediate diagnostic step as a scalpel biopsy 
must follow when an abnormal result is reported (Fedele, 2009). 
 
   1.2.8.4 Chemiluminescence 
 
     Chemiluminescence using blue or white light (ViziLite™) has been evaluated and 
considered as a diagnostic aid in the detection of oral cancer and potentially 
malignant epithelial lesions. It was suggested that chemiluminescence is a more 
reliable diagnostic tool than tolonium chloride in the detection of oral cancer (Ram 
and Siar 2005) The technique is conducted by application of oral rinse with a 1% 
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acetic acid solution for 30–60 seconds then the lesion examined and evaluated using 
a chemiluminescent light (wavelength of 490 to 510 nm) (Epstein et al, 2008). The 
theory behind this technique is that the acetic acid removes the glycoprotein barrier 
and slightly desiccates the oral mucosa, the abnormal cells of the mucosa then 
absorbing and reflecting the blue/white light in a different way with respect to 
normal cells. Hence normal mucosa appears blue, whereas abnormal mucosal areas 
reflect the light (due to increase in the nuclear/cytoplasmic ratio of epithelial cells) 
and appear brighter, sharper and with distinct margins (Epstein et al, 2006; Farah and 
McCullough, 2007). 
 
   1.2.8.5 Tissue Fluorescence Imaging 
 
     A number of new diagnostic aids to conventional oral examination have recently 
been introduced to assist in the early detection of oral neoplasia. In particular, 
autofluorescence imaging has emerged as a promising adjunctive technique to 
improve early identification of oral premalignant lesions (Shin et al, 2010). Laser-
induced fluorescence diagnostics can be used as an imaging system for detecting 
premalignant and malignant lesions of oral mucosa. The technique utilizes the 
variation in the colour and intensity of light emitted from the tissues after excitation 
with short wavelength light.  The concept is based on the findings that changes in the 
cellular structure such as pleomorphism, hyperchromatism and mitosis and 
thickening of keratin layer of the epithelium as well as changes of the subepithelial 
stroma alter the distribution of tissue fluorophores which later reflects on the 
behaviour of tissue autoflorescence (De Veld et al, 2005). 
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     Imaging system has recently been developed by LED Medical Diagnostics Inc. in 
partnership with the British Columbia Cancer Agency and is marketed as VELscope 
system. It increases the clinician's ability to detect oral changes that may represent 
premalignant or malignant cellular transformation, however presence of false 
positive findings are possible in the presence of highly inflamed lesions (Kois and 
Truelove, 2006). This result was supported by Shin et al who stated that recent 
studies of wide-field autofluorescence imaging in low-prevalence populations 
suggested that benign lesions such as inflammation may give rise to false-positive 
results, therefore automated image analysis should be investigated to maximize 
overall diagnostic performance for early detection of oral neoplasia.  (Shin et al, 
2010). 
 
   1.2.8.6 Tissue Fluorescence Spectroscopy 
 
     Fluorescence spectroscopy is a technology that has shown great promise during 
initial investigations. Tissue autofluorescence has been used in the screening and 
diagnosis of precancers and early cancer of the lung, uterine cervix, skin and, more 
recently, of the oral cavity (Gillenwater et al, 1998; De Veld et al, 2005). The 
autofluorescence spectroscopy system consists of optical fibre that produces various 
excitation wavelengths and a spectrometer that receives and records on a computer 
and analyzes, via dedicated software, the spectra of reflected fluorescence from the 
tissue. The advantage of this technique is the elimination of the subjective 
interpretation of tissue fluorescence changes (Inaguma and Hashimoto, 1999; Lingen 
et al, 2008).  
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      Various photosensitising agents have been introduced. They can be 
used to increase the contrast in the fluorescence signal between normal 
tissue and malignant and premalignant lesions. The properties of these 
photosensitisers are that in excess it results in accumulation of intracellular 
substance which increases tissue fluorescence (Onizawa et al, 2002). 
 
      5-Aminolevulinic acid (5-ALA) is one of these agents has shown sensitivity for 
the assessment of systemic and oral soft tissue lesions as well. The principal of 5-
ALA induced PpIX is that in excess it results in accumulation of intracellular 
porphyrins or especially of PpIX which increases tissue fluorescence. Subsequent 
irradiation of the lesion with visible light matching the main absorption peak of PpIX 
(405nm) leads to red fluorescence emitting from PpIX peaking at (635nm) (Leunig et 
al, 1996; Betz et al, 2002). The difference in fluorescence ratio between normal and 
premalignant/malignant lesion makes detection and analysis by fluorescence light 
more applicable in the discrimination between malignant and non malignant lesion 
(Ebihara et al, 2003; Müller et al, 2003). Dysplastic and malignant tissues, as well as 
having different spectral characteristics, tend to have increased red fluorescence and 
decreased green fluorescence. Significant increase in the red/green fluorescence ratio 
is said to be an accurate predictor of oral malignancy using autofluorescence (de 
Vield et al, 2004) and 5-ALA (PpIX fluorescence) (Zheng et al, 2002). 
 
     The principle of using fluorescence constructed optical diagnostic instrument 
(spectroscopy) seems to be a useful method for distinguishing lesions from healthy 
oral mucosa, in general. The detection would be distinct especially when malignant 
tumours are compared to healthy mucosa. The technique has been under 
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investigation in detection of the suspicious lesions and furthermore in performing 
guided surgical biopsies and photodynamic therapy. 
 
      Various fluorescence spectroscopy diagnostic systems has been introduced and 
more researches are needed to support the clinical application in order to help 
experienced clinicians at improving their ability to detect premalignant and 
malignant lesions in high-risk individuals attending the specialised clinics. 
Experienced surgeons use some of the described optical diagnostic aids or probes to 
improve the identification of a lesion's margins and extensions in the operatory 
setting, although it is not known the impact these techniques have on the patients’ 
survival and risk of disease recurrence (Fedele, 2009).  
   
     Photodynamic detection (PDD) using Compact fluorescence spectroscopy and 
ALA has been investigated in detecting suspicious lesions in different organ systems 
(in Ninewells hospital). This study investigates their application in assessing 
clinically suspicious oral lesions. 
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 AIM OF STUDY 
 
 
      The purpose of this investigation was to: 
 
1- Detect the fluorescence intensity ratio (FIR) measurements (ratio of 
PpIX fluorescence at 635nm and autofluorescence at 500nm, i.e. red/green 
ratio or 635/500nm) at ten oral anatomical sites to map and create baseline 
readings for normal oral mucosal site fluorescence. 
 
2- Detect the effect of the participant’s individual characteristics (e.g. 
tobacco use) on the fluorescence intensity ratio measurements taken from the 
normal oral mucosa. 
 
3- Use the fluorescence intensity ratio (FIR) measurements to determine; 
 
a- any differences between the lesion and the normal oral site 
      readings. 
 
b- whether the FIR from clinically suspicious oral lesions is 
       associated with the histopathology grade. 
 
c- the sensitivity and specificity of the technique in assessing 
       clinically suspicious (premalignant) oral lesions for potential 
                                     malignant change.
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Optimization the Clinical Trial 
Investigational Medicinal Products 
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      When undertaken a clinical trial of an investigational medicinal product (CTIMP) 
the trialist should be fully aware of the scientific, administrative and regulatory 
compliance issues relevant to the design of such a trial in the host country. 
Compliance with these issues is mandatory to ensure safety of the patient. In this 
chapter, these issues are reviewed and the steps and measures considered in the trial 
explained clarifying the requirements for the CTIMP. 
Clinical research may be defined as the research method(s) conducted by the 
investigator(s) to study the association(s) between effect of therapies experienced by 
participants and their health condition. A clinical trial refers to a trial to evaluate new 
drugs, instruments and other interventions, in addition to assessing the safety and 
efficacy of experimental treatment methods and assessing whether a new 
intervention is better than the standard therapy (Sheffield Children's NHS Foundation 
Trust, 2009).  
The Medicines and Healthcare products Regulatory Agency (MHRA) is a 
government organisation which was set up in 2003 to bring together the functions of 
the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA). 
Now, the MHRA also looks after blood and blood products, working with UK blood 
services and the healthcare providers to improve blood quality and safety. 
 
The principal aim of the Agency is to ensure the safety of the public’s health. It 
does this by making sure that medicines and medical devices (from painkillers to 
pacemakers) work properly and are acceptably safe; and by responding quickly when 
new incidents are highlighted. No product is completely free of risk but the MHRA’s 
decisions are taken to ensure that these risks are minimised to acceptable level. 
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2.1 History of the UK regulations 
 
In order to understand why there is such an organization as MHRA, it is helpful 
to be reminded of the evolution of health care regulation in the United Kingdom.  
 
The regulation of medical devices began in the mid 1990s. The Department of 
Health had been established to ensure high standard of quality and safety of medical 
equipment. The Medical Devices Directorate (MDD) in effect became the Medical 
Devices Agency in 1994 which then merged with its medicines counterpart in 2003 
to become the MHRA. The Committee on the Safety of Devices is an independent 
group of experts which advises the MHRA. 
 
In the 1950s and early 1960s, Thalidomide was prescribed to relieve morning 
sickness in the first few months of pregnancy. This therapy had seriously caused 
unpredicted birth defects and as a result of this drug regulations in the UK were 
created. To prevent a similar occurrence, the Committee on Safety of Drugs was 
established in 1963. This subsequently became the Committee on Safety of 
Medicines (CSM) under the terms of the Medicines Act of 1968, which provided the 
legal framework for the control of medicines in the UK. In 2005 this committee 
became the Commission on Human Medicines (CHM). 
 
The Medicines Control Agency was established in 1989, and merged with the 
Medical Devices Agency (MDA) to become the MHRA in 2003. The Commission 
on Human Medicines provides independent expert advice to the MHRA (MHRA 
2009). 
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2.2 The UK clinical trial regulations 
 
The UK clinical trial regulations were initially published in 2004. The laws were 
relating to the implementation of Good Clinical Practice (GCP) in the conduct of 
clinical trials on medicinal product for human use. The regulations were amended in 
2006 to implement European directives in 2005. Other miscellaneous amendments 
included specific requirements to report serious breaches to the approved protocol. In 
2006 second amendment created an exception of the incapacitated adults to be 
included in the clinical trials and established new rules for the inclusion criteria. 
Further amendment with respect to the ethics committee was done in 2008. These 
amendments were reported; however no consolidated published version is available 
(Canary 2004, 2006, 2008).  
 
2.3 Good Clinical Practice (GCP) 
 
 International Ethical and Scientific Quality Standard for the design, conduct, 
performance, monitoring, auditing, recording, analyses and reporting clinical trials 
that involve participation of human subjects. In addition, assurance that the clinical 
trial data are credible and accurate and that the trial subjects rights, integrity and 
confidentiality are protected. 
 
The World Medical Association set out the Declaration of Helsinki in 1964 
describing ethical principles for medical research involving human subjects. 
Currently, it is necessary to obtain ethical approval for any research carried out 
within the NHS or University in the UK. Further and separate approvals are also 
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required for researches involving the use of medicinal products or equipment for 
human use (Clinical Trials). 
 
Historically, the Declaration was originally adopted in June 1964 in Helsinki, 
Finland, in part because of human experimentation that occurred during the 2nd world 
war. It has since undergone six revisions (the most recent at the General Assembly in 
October 2008) and two clarifications, growing considerably in length from 11 to 32 
paragraphs. The declaration is an important document the history of research ethics 
as the first significant effort of the medical community to regulate research itself, and 
forms the basis of most subsequent documents. Revisions were in (1975-1983-1989-
1996-200) Clarifications of articles 29, 30 (2002-2004)-2008. 
 
It is a mandatory quality assurance system that drug companies and 
university/hospitals have to set up to ensure that their clinical trials are performed in 
compliance with the national and international regulations. 
 
Most of the international companies established their set of procedures up to the 
highest standards (FDA or EU GCP) to ensure that the data generated by their 
clinical trials will be accepted universally by all authorities. Every company is free to 
decide upon the content and format of their SOP 's. PharMed GCP, SOP’s and Audits 
(Podoorsem, 2009). 
In order to comply with the terms of IHC GCP (International Harmonization 
Conference and Good Clinical Practice) and UK legislation, the University and NHS 
has to ensure its research staff are aware of their responsibilities and are working to 
appropriate standards. The University of Dundee has accredited a range of Standard 
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Operating Procedures (or Guidelines) for use in Clinical Trials using Investigative 
Medicinal Products. 
 
The Research Governance Framework for Health and Community Care 
recommends that a senior individual must be designated as the chief investigator (CI) 
or principal investigator (PI) for any research undertaken involving participants’ or 
their organs, tissue or data. 
  
2.4 Going about setting up a clinical trial 
 
It is mandatory the PI be aware of the current regulations and should have a plan 
to ensure compliance with ICH GCP and other issues before setting up the trial. 
.  
As example in this trial, the thesis author arrived in the UK and started this 
project in November 2007. The application process for approvals is lengthy and 
requires the applicant to have sound background and knowledge of the submission 
pathways for CTIMP. For this reason the chief investigator (CI) had submitted all the 
required applications and obtained the approvals from the authorities to conduct the 
clinical trial in 2006 in order to complete the study programme within the time frame 
of the UK Universities which ranges between 3-4 years. 
  
The author gained knowledge of conducting CTIMPS by attending the workshops 
of IHC GCP (International Harmonisation Conference for Good Clinical Practice) 
before starting the trial and updated his knowledge by attending the same workshop 
one year later to gain a good background in GCP. In addition to all the clinical trial 
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seminars offered by Tayside Clinical Trial Unit at Ninewells Hospital for the staff  
and researchers to improve his background. Thus he become aware of the regulation 
and to be eligible to conduct a Clinical Trials. The attendance certificates are shown 
in appendix 1. 
 
The PI and colleagues prepared the study Protocol, Trial Master File in Dundee 
and Site Investigation File (CIF) in Glasgow including the associated documents to 
set up the trial. 
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2.4.1 Acronyms  
 
Commonly used acronyms were listed in the following table! 
AE/SAE/SAR/SUSAR 
Adverse Effect/Serious Adverse Effect/Serious Adverse 
 Reaction/Suspected Unexpected Serious Adverse 
       Reaction 
CRF  Case Report Form   
CT Clinical Trial 
CTA Clinical trial Authorisation  
CTIMP/IP 
Clinical trial investigational Medicinal Product/ 
Industrial Product 
CTU Clinical Trial Unit 
EudraCT 
European Union Drug Regulating Authorities Clinical 
 Trials   
GCP Good Clinical Practice 
GMP/GPP Good Manufacturing Practice 
IB Investigators Brochure 
SmPC Summary of Product Characteristics 
IMP 
An Investigational Medicinal Product or drug used in a  
CTIMP which may be a test drug or a comparator or 
 Placebo 
IRAS 
Integrated Research Application System  
 
ISRCTN 
International Standard Randomised Controlled Trial  
Number  
MA Marketing Authority 
MHRA Medicines and Healthcare products Regulatory Agency 
MREC Multicentre Research Ethic Committee  
PI/CI Principal Investigator/Chief Investigator 
PL 
The Product Licence that confirms the drug has a MA 
 from the regulatoryAgency 
QP 
Qualified Person or quality control expert employed by 
 the manufacturer to give assurances about a drug’s 
 quality and fitness for use in practice.  The process is 
 called ‘QP  release’ 
QP (IMP) 
 
 Refers to QP release for a drug manufactured, packaged 
 and supplied specifically for a clinical trial 
QP (MA) 
 
Refers to QP release for a drug manufactured, packaged 
 and supplied for use in clinical practice 
REC Research Ethic Committee 
SOP’S Standard Operating Procedures 
TMF/SMF/IMF 
Trial Master File/ Site Master File/ Investigation Master 
 File 
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2.4.2 Preparing and writing a protocol 
 
The chief investigator (CI) of the study should prepare a protocol to conduct the 
trial with the content and structure of protocols for clinical trials of investigational 
medicinal product. The protocol should be constructing to cover important 
methodological considerations and requirements specified under Good Clinical 
Practice. The title should include a brief outline of the study design, medicinal 
product(s), route of administration, method of detection, patient population and 
setting. 
 
2.4.2.1 Purpose of the study and aims 
 
      The protocol should state the purpose of performing the study and the impact on 
the patient’s health. They should include the primary and secondary objectives. 
 
2.4.2.2 Methods and study design 
 
      The credibility of results obtained the scientific methodology of a study are 
largely dependent upon the study design. 
 
The study design should include; 
 
• A description of the design of the study. 
• The expected duration for which each patient will participate in the 
       study.  
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• Description of all procedures to be performed in sequence, identifying 
      what is standard and nonstandard. 
• Information referenced to other documents such as the Investigators 
      Brochure or summary of product characteristics for licensed medicinal 
      products should be explained in details in this section. 
 
2.4.2.3 Information added to the protocol 
 
The following information should be clearly identified; 
  
• Details about Full name or the trade name if licensed drug in the UK 
      and Europe. 
• Information about the - UK or EU License. 
• Potential risks and benefits to patients should be summarized. 
• The proposed route of administration (e.g. topical %-ALA) dosage 
      (e.g.3%), and application period (e.g.15 min). 
• Description of, packaging, labelling and dosage form of products. 
• Description of disposal procedures during the trial. 
• Details of the source and who will supply the products. 
• The shelf life and arrangements for storage and other issues. 
 
2.4.2.4 Patient selection 
 
The protocol should include; 
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• Source of patient recruited for the trial, for example in this study, they 
       were referred patients attending the oral medicine or oral surgery 
       clinic having suspicious oral lesions. 
• Number of centres involved in the trial. This study recruited patients 
       in two sites in Dundee (Clinical Research Centre at Ninewells 
      Hospital) and Glasgow (Southern General Hospital). 
• The expected number of eligible participants. This protocol 
       anticipated a total of 50 patients after statistical advice from Prof. 
       Donnan re p of study (25 in each site), however the achieved number 
       of 35 patients (27 at Dundee and 8 at Glasgow) could not reach the 
       target number. 
 
2.4.2.5 Inclusion criteria 
 
 The protocol should define who is eligible for the study. This protocol stated that 
inclusion criteria are all patients over 18 years of age and having suspicious 
(potentially malignant) oral lesion. 
  
2.4.2.6 Exclusion criteria 
 
The protocol should consider contra-indications to be included in the trial. This 
protocol involved pregnant women and patients younger than 18 years. 
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2.4.2.7 Patients’ compliance 
 
Recording of patient compliance and details of the follow-up should be provided. 
An explanation and the instruction (patient information sheet) were given to each 
patient recruited. A record of patient compliance information and details of follow up 
was done by providing the patient with contact details and two weeks review. 
 
2.4.2.8 Randomisation or blinding 
 
Avoiding bias was not taken by randomisation method since the study was a 
diagnostic test accuracy trial. The spectra results were compared with the gold 
standard (surgical biopsy). 
 
2.4.2.9 Withdrawal of participants 
 
The patient’s withdrawal criteria should be written in the protocol. This should 
include when and how to withdraw patients or participants, the follow up procedures 
for withdrawn participant and data should be reported in details in the CRF.  
 
2.4.2.10 Data collection 
      
 Detailed list of all data should be provided including.  
• The Source of the data (e.g. patient questionnaires, patient notes, electronic 
data…etc). 
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• Who will collect the data (form and type of data e.g. continuous or 
binary...etc)? 
• The data should be collected in a special form (data collection forms) and 
should be kept as appendices. 
 
2.4.2.11 handling the data 
 
The protocol should state who is responsible of collecting and recording the data. 
Procedures for collection, storage, duration of maintenance, security and 
management of data should be described including Data Protection. 
 
2.4.2.12 Final protocol details 
 
The following information is required to be included in the protocol: 
 
• Sponsor 
• Funder 
• Chief Investigator 
• EudraCT number 
• CTA number 
• MREC number 
• Register with a Protocol registration scheme 
• Version number & date 
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2.4.3 Approvals required for the trial 
 
Prior to the trial commencing, approvals are mandatory and should be obtained. 
The requirements of the approvals are related to the design or type of the study. The 
CTIMP requires Research Ethics Committee, Research and Development and 
MHRA approval. 
 
In order to understand the procedure, it would be useful to explain the steps that 
were followed for this trial and the required approvals obtained, as an example. 
 
The CI had contacted the University of Dundee (UoD) Tayside Clinical Trials Unit 
(TCTU) to discuss sponsorship. 
 
1-University of Dundee had to ensure a scientific review for the study protocol, 
Informed Consent Form (ICF) and Patient Information Sheet (PIS), so that the TCTU 
(Tayside Clinical Trial Unit) committee assess the risk of the study and possible 
sponsorship. After assessment of the scientific quality of the protocol and the 
proposed research accepted, a delegation letter was sent from TCTU to the CI 
confirming the clinical trials authorisation and insurance. The documents should be 
in place before applying for REC (Research Ethic Committee) approval. Because the 
legal side was evolving during the study, the insurance was put in place after the trial 
started. The University requires that all applications are made using the Integrated 
Research Application System (IRAS) online application form which could be 
accessed through a website (https://www.myresearchproject.org.uk) The Site 
Specific Information form (SSI) would then be completed to assess the suitability of 
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the site chosen e.g. at Dundee (Ninewells Hospital) and Glasgow (Glasgow Southern 
General Hospital) and of the research team at these sites. 
 
2-Submission of   Part A and B of the application form and   supporting 
documentation direct to the REC within 4 working days of booking (getting the 
number) from the Central Allocation System (CAS) or Local Ethic Committee. The 
multi sites trial within one domain required CAS or local REC application booking. 
Then the clock was started for 60 days and a letter confirming the validation was sent 
(5 days). Because this study involved both Dundee and Glasgow, the REC 
application went to Glasgow. 
 
3- Research and Development (R&D) management approval is required at each 
site before research can begin. An application for R&D management approval may 
be made alongside the application for ethics approval. For multi-site studies, early 
discussions were encouraged with the identified hosts. 
 
The Site Specific Information Form (SSIF) could also be used for R&D 
management approval. 
 
The responsibility for site specific application (SSA) was transferred to R&D 
during 2007. Final R&D approval can not be confirmed until after a favourable 
ethical opinion has been received. 
 
4-Medicines and Healthcare products Regulatory Agency (MHRA) application 
for clinical trial authorisation form was completed and all the associated 
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documentations submitted for approval. The guide for the applicants is shown in 
figure 2.1. 
 
2.4.4 Preparations of Trial Master File (TMF) 
 
It is the responsibility of everyone who wants to conduct a clinical trial to 
establish and maintaine Trial Master File (TMF) and it should comply with the 
principles of good clinical practice (GCP) for clinical trials of investigational 
medicinal products (CTIMPs).  
 
The University policy of the Trial Master File (TMF) is that the file should 
contain all the essential documents (*) and should be stored in a lockable cabinet or 
room. 
 
For multicentre studies, the Chief Investigator (CI) must ensure that adequate 
investigational site files (ISFs) are in place at individual sites. The Principal  
Investigator (PI), being the lead investigator at the site person while PI is considered 
the CI in single site studies. The PI may delegate the task of setting up the ISF to a  
member of the research team and write it in a form of a document and kept in the  
------------------------------------------------------------------------------------------------------                                                                           
*[those documents which individually and collectively permit evaluation of the conduct of a trial and the 
quality of the data produced and they serve to demonstrate the compliance of the investigator, and sponsor with 
the principles of Good Clinical Practice and with all applicable regulatory requirements. Essential Documents 
also serve a number of other important purposes. For example: they can greatly assist in the successful 
management of a trial by the investigators and sponsor, and they are also the ones which are usually monitored by 
the sponsor and inspected by the regulatory authority(ies)]. 
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delegation log. The PI is responsible for updating the ISF with any relevant new 
documentation as the study progresses and to ensure that the ISF is made available to 
trial monitors and representatives of the MHRA. In addition, for reviewing the ISF to 
ensure that all the required documents are present and maintained for at least five 
years after the completion of the trial for archiving.  
 
The PI is also responsible of all new or amended documents (apart from the subject 
ID log, recruitment log and consent forms) and to be issue of minor amendments, 
sent to the CI for the Trial Master File (TMF).  
 
2.4.5 Records for staff training 
 
The member of staff involved with establishing and running a clinical trial must 
have a Training Record kept in a TMF. It is the responsibility of the CI/PI to ensure 
that all staffs are suitably trained to conduct CTs and have sufficient training and 
efficiency to conduct the trial specific procedures. As a minimum, they must show 
evidence of GCP. 
 
Good Clinical Practice (GCP) workshops in the Clinical Research Centre (CRC) 
or similar GCP course should be attended by all the staff and documented proof of 
attendance must be kept in the training record. In addition, the staff should be aware 
of any applicable regulatory requirements pertaining to the clinical trial conduct.  
Training records must be reviewed regularly to identify gaps. 
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2.4.6 Other documents 
 
The protocol, patient information sheet (PIS) and informed consent form (ICF) 
must be approved by an ethics committee, local NHS R&D departments, the MHRA 
(if applicable) and any other appropriate regulatory approval bodies before potential 
participants are approached to enter a trial. 
 
      In accordance with the principles of GCP all subjects taking part in research 
studies should be fully informed about the study that they have been asked to 
participate in and written consent will be obtained before any study specific 
procedures were carried out. 
 
[In conducting this trial, the investigators were keen to explain the procedure to 
the patients in detail (non scientific words) that it is completely voluntary and he or 
she would withdraw at any time without providing a reason and without prejudicing 
the future oral surgery care. They were also given PIS and the information about 
possible of benefits to other patients in the future. The patients were given enough 
time to read the information about the research this is usually at least 24 hours before 
the procedure. 
 
The ICF should be on headed paper, have a version number and date. Only the 
most recent approved version of the ICF was used for obtaining informed consent to 
comply with SOP in conducting the trial. As the PIS or IC are updated, the up todate 
version should be recorded on the sheet, as well as in the TMF. Copies of the ICF 
were also kept in the dental hospital notes. The staff named on the Delegation of 
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Responsibility Log are allowed to obtain informed consent from participants, 
although mistakenly at the start, a couple of cases were signed by unauthorized staff 
member (their names were not on the delegation Log), all the required measured 
were taken to ensure no further breach to the trial Standard Operation Procedure].  
 
The ICF should be signed and dated by the participant and the person obtaining 
informed consent as witness at the time of conducting the procedure making sure the 
patient is fully aware of the trial and happy to participate. The original copies of the 
ICF should be kept in the patient’s note. Moreover, the patient need consent to the 
taking of photos. 
 
The trial investigators should check and update the confidentiality measures of 
the obtained documents in the TMF, i.e. not including the name, age and CHI 
number of the patient. The confidential information is kept in the CRF.  
 
2.4.7 Some other considerations 
 
There are certain considerations should be taken in account: 
 Risk Assessment & Trial Monitoring 
 Delegation of responsibilities when absent 
 Protocol amendments & violations 
 Closure & Archiving 
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2.5 Pharmacovigilance: What are these? 
 
NHS Tayside acted as the Pharmacovigilance sponsor. The role is delegated to 
the Pharmacovigilance section of Research Development Services based at 
Ninewells Hospital & Medical School. Investigators are requested to notify any 
SAEs or SARs ‘immediately’.  ‘Immediate’ means at the earliest convenient time 
after the person has become aware of the event, if possible within 24 hours. 
 Adverse event (AE) 
 Serious Adverse Event (SAE) 
 Adverse Reaction (AR) 
 Serious Adverse Reaction (SAR) 
 Suspected Serious Adverse Reaction (SSAR) 
 Suspected Unexpected Serious Adverse Reaction (SUSAR) 
 Define serious? 
 Who checks for this?    
  
      Measures should be considered when SUSAR occurs; 
 
• The initial report should be submitted by email. 
• A signed copy of the Detailed Written Report should be sent by post. 
• The detailed written report, which should follow as soon as possible 
thereafter, will contain all of the information that is required by the sponsor 
for onward reporting to MHRA and the Ethics Committee.  
      The investigator should also retain a copy of the detailed follow-up report in the 
CRF. 
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2.6 Role of trials pharmacist regarding drug 
 
These measures should be taken in account: 
 Procedures for Manufacturing & Assembly  
 Packaging & Labelling & Storage 
 Investigators Brochure 
 Has the drug Marketing Authorisation (MA)? NB original packaging 
 Otherwise Trial specific Qualified Person release 
 Note Exemption 37 in hospital trial protocol amendments & violations 
 Substantial amendments 
            e.g. add or delete PI  
 Any change in Protocol 
            e.g. Gliolan v raw product, change to inclusion criteria  
 
2.7 Closure and archiving 
 
An End of Trial Study Report should be sent to the MHRA and relevant Ethics 
Committee within 12 months of the end of the trial. The summary of the final report 
may be enclosed with the end of study declaration (sent within 90 days of the end of 
the trial, or within 15 days if the project is terminated early), or sent to the MHRA 
and relevant ethics committee subsequently. Titles of these activities are shown in 
Appendix 1 (Series of seminars and workshops introduced by Tayside Medical 
Science Centre (TASC) and Tayside Clinical Trial Unit TCTU 2007-2010). 
 
 
 
Figure 2.1 CTIMP Application guide 
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3.1 Reliability of the Compact Fluorescence 
Spectroscopy and 5-ALA as Photodynamic Detection 
(PDD) Method in the Oral Cavity 
 
 
 
3.1.1 Introduction 
 
 
      Intracellular accumulation of 5-ALA induced PpIX results in increased tissue 
fluorescence. Differences in the fluorescence intensities between normal and lesion 
tissue are crucial if the PDD technique is to be a reliable method for detecting 
malignant change. To that end, reliability is essential. 
 
      Initially, intra and inter patients’ variation in the fluorescence intensity levels was 
noticed. In addition, the high fluorescence intensity measurements at some normal 
anatomical sites such as that of the dorsal tongue further emphasized the need to 
check the reproducibility of the instrument as a measurement tool in the oral cavity. 
Hence the following pilot study was undertaken to assess the reproducibility of the 
technique. 
 
Aim of the study was to detect the reproducibility of the compact fluorescence 
spectroscopy for measurements taken from the oral mucosa using ALA mouthwash 
and the detection of fluorescence with the OBS. 
 
3.1.2 Methodology  
 
 
      The study included six patients (PDD004D-9D). The patients were 3 males and 3 
females. To confirm the reliability of the photosensitizer and the compact fluorescence 
spectroscopy as a diagnostic tools used in the detection of fluorescence, the standard 
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operating procedure was followed and the protocol (explained in the Patients and 
Methods section) was applied.  
  
3.1.2.1 Data collection 
 
      Measurements were taken from 6 patients who were referred to Dundee Dental 
Hospital/ Unit of Oral Surgery and Medicine clinic, for the diagnosis of suspicious 
oral lesions. The patients recruited were informed and consented for the procedure of 
the trial. 
  
      Four fixed points were selected from each patient. They were three points taken 
from well identified anatomical locations of the oral mucosa and one from lesions at 
any mucosal site: 
 
1- Cheek (right parotid papilla). 
2- Tongue (in the middle 2mm away from the tip). 
3- Floor of the mouth (mid points between the Wharton’s ducts). 
4- Lesion sites (one point was chosen from the lesion site). 
 
      Two readings from the same site were taken by the same investigator. After 
making sure the probes were clean and no bubbles of saliva covering the fibreoptic 
probe  surface, the procedure was performed by guiding the probe into the oral cavity 
and putting the tip over the mucosa with the direction perpendicular to the tissue 
surface with minimum pressure at the site selected. Then the tissue was exposed to 
excitation of light at 405nm by pressing the foot control or the (Go) button on the 
screen of the computer. The spectra were stored on the computer by pressing site 
                                                                        - 91 -                            Chapter 3.1 Pilot Study 
 
with the same direction to produce (and save) the 2nd reading. The two readings were 
taken in about 3-5 second time. The saved data were stored as Excel files on the 
computer and later were grouped as 1st set and 2nd sets of readings for the 
comparisons. 
 
      The total fluorescence emitted measurement system (FEMS) readings were 
recorded and saved onto the computer for statistical analysis.  
 
3.1.2.2 Data analysis 
 
      The measurements at 500nm (autofluorescence) and 635nm (PpIX fluorescence) 
were obtained from the Excel files and tabulated into 1st and 2nd readings for 
comparison and analysis to detect the reproducibility of the readings was as follows: 
• Comparing the absolute intensity at 500nm of the 1st and 2nd readings. 
• Comparing the absolute intensity at 635nm of the 1st and 2nd readings. 
• Comparing the fluorescence intensity ratios of the 1st and 2nd readings. 
• Comparing the spectral line graphs.  
 
3.1.3 Results 
 
      A total of 48 spectra were taken from six patients. The age ranged from 36 to 84 
years of age, and the average was 58.5 years. The lesion sites were taken from the 
case report forms and the intensity peaks of the fluorescence were taken from the 
Excel files stored on the computer. 
The fluorescence intensity peaks of the measured sites were classified as 1st and 2nd 
readings at 500nm and 635nm as shown in table 3.1.1. 
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 Table 3.1.1. Shows site of the lesions, the absolute fluorescence intensities (FI) at 500nm, 
635nm wavelength and the fluorescence intensity ratio (FIR) at 635/500 of the 1st and 2nd 
readings.  
 
FI 500nm FI 635nm FIR 
Patient 
number 
Sites of 
the 
Readings 1st Read 2nd  Read 1st Read 2nd  Read 1st Read 2nd Read 
Buccal 
mucosa 
141.2107 141.2113 28.79367 28.792 0.20390572 0.203893 
  Tongue 
 
4.16633 4.165 328.923 328.921 78.947899 78.97263 
Floor of 
the mouth 
52.74933 52.74267 163.1737 163.1727 3.09337957 3.093751 
1 
PDD04D 
Lesion site 
 
81.48433 81.461 195.823 195.7837 2.40319826 2.403404 
Buccal 
mucosa 
76.409 76.402 20.71433 20.71367 0.27109804 0.271114 
Tongue 
 
317.6247 317.6243 321.4743 321.4747 1.01211996 1.012122 
Floor of 
the mouth 
123.8757 123.842 85.17733 85.17533 0.68760322 0.687774 
2 
PDD05D 
Lesion site 
 
56.149 56.14133 299.68 299.647 5.33722773 5.337369 
Buccal 
mucosa 
56.803 56.8 6.177667 6.176333 0.108756 0.108738 
Tongue 
 
67.454 67.28867 48.228 48.497 0.71497613 0.720731 
Floor of 
the mouth 
80.56867 80.55533 10.077 19.07133 0.12507343 0.236748 
3 
PDD06D 
Lesion site 
 
29.264 29.29733 90.94267 91.07433 3.10766368 3.108622 
Buccal 
mucosa 
75.17667 75.17833 32.913 32.90967 0.4378087 0.437755 
Tongue 
 
417.601 418.203 394.33 394.326 0.94427456 0.942906 
Floor of 
the mouth 
294.9277 294.9513 61.66267 61.65833 0.20907724 0.209046 
4 
PDD07D 
Lesion site 
 
123.137 123.199 57.175 57.15167 0.46432023 0.463897 
Buccal 
mucosa 
706.623 706.62 60.51367 60.51267 0.08563784 0.085637 
Tongue 
 
29.7437 29.654 82.28867 82.72933 2.76659158 2.78982 
Floor of 
the mouth 
65.47867 65.476 29.463 29.444 0.44996332 0.449691 
5 
PDD08D 
Lesion site 
 
461.1293 461.296 128.4197 128.4863 0.27848957 0.278533 
Buccal 
mucosa 
66.09 66.08933 28.499967 28.49767 0.43122964 0.431199 
Tongue 
 
28.88233 28.786 53.926 54.958 1.86709313 1.909192 
Floor of 
the mouth 
23.94433 24.275 14.441 14.393 0.60310729 0.592915 
6 
PDD09D 
Lesion 
site 
 
42.35367 42.387 23.45767 23.312 0.55385212 0.54998 
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3.1.3.1 Comparison at 500nm 
 
      A comparison between the 1st reading and the 2nd reading at 500nm was ploted 
in the tables. The summery table shows similar distribution of the data in relation to 
the mean, median, inter quartile range and standard deviation. However the means 
were deviated from the medians which represent skewed non normal distribution.  
 
Group 
No.of 
Readings 
Mean Median 25% 75% Std Dev 
1st reading 
(500nm)  
24 142.619 71.315 47.552 132.543 173.010 
 
 
2nd reading 
(500nm) 
24 142.652 71.233 47.565 132.527 173.064 
 
Table 3.1.2. Summary statistics of the 1st and 2nd readings at 500nm. 
 
 
 
      The difference in the median values between the two groups using Mann-
Whitney U Statistic= 285.000 284.000, T = 591.000 (P = 0.959). This indicates there 
was no statistically significant difference (p>0.05) between the 1st and 2nd readings at 
500nm wavelength. 
 
      Figure 3.1.1 shows the 1st fluorescence intensity of the 1st reading in comparison 
with the 2nd reading at 500nm. The bars were equal in values for both readings in 
spite of the difference in the values which were related to the sites that obtained 
from. Sites 10 and 22 showed very slight differences between the 1st and 2nd 
readings. 
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Figure 3.1.1. Comparison of the 1st and 2nd readings at 500nm wavelength. 
 
 
3.1.3.2 Comparison at 635nm 
 
      The same method of analysis was applied for comparison between the 1st and 2nd 
readings at 635nm wavelength since the data were obtained from the same spectra. 
The summary table shows the data description (table 3.1.3). 
 
Group No of Readings Mean Median      25%       75% Std Dev 
1st Reading (635nm) 24 106.928 58.844 28.647 145.797 115.548 
2nd Reading (635nm) 24 107.370 58.832 28.645 145.830 115.207 
 
Table 3.1.3. Summary statistics of the 1st and 2nd readings at 635nm. 
 
 
      The difference in the median values between the two groups using Mann-
Whitney U Statistic= 284.000), T = 592.000, (P = 0.942), there was no statistically 
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significant difference (p>0.05) between the 1st and 2nd readings at 635nm 
wavelength. 
 
      Figure 3.1.2 shows the 1st fluorescence intensity of the 1st reading in comparison 
with the 2nd reading at 635nm. There were some minor differences in bars 4, 11 and 
15; however the other bars were equal in value. 
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Figure 3.1.2. Comparison of the 1st and 2nd readings at 635nm wavelength. 
 
 
3.1.3.3 Comparing the Fluorescence intensity ratios 
 
      The fluorescence intensity ratio (FIR or red green ratio) could be obtained by 
dividing the value of the fluorescence intensities at 635/500nm wavelengths. Table 
3.1 shows the values of each variable. The FIR of the 1st and 2nd readings’ mean, 
median, inter quartile range and standard deviation is shown in table 3.1.4. 
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Group 
No.of 
Readings 
Mean Median 25% 75% Std Dev 
1st reading  24     4.379   0.578 0.275 2.135 15.937 
2nd reading  24 4.387 0.571 0.275 2.156 15.940 
 
Table 3.1.4. Summary statistics of the 1st and 2nd readings FIR values. 
 
      The difference in the median values between the 1st and 2nd FIR values was T = 
585.000 using Mann-Whitney U statistic= 291.000 (P = 0.959). There was no 
significant difference between the FIR of the 1st and 2nd readings.  
 
      The data (FIR) distribution (maximum, minimum, median and inter quartile 
range) of the 1st and 2nd readings were shown in figure 3.1.3. 
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Figure 3.1.3. Comparison of the FIR between 1st and 2nd readings. 
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3.1.3.4 Comparing the spectral line graphs 
 
      The spectra obtained from six patients were averaged in relation to location to 
show the variation at each site and to detect the reliability of the compact 
fluorescence spectroscopy in taking the 1st and 2nd measurements. Spectrally the line 
graphs of the two readings at each site showed identical distribution which indicate 
there was no variation in the readings obtained from the same site whether the 
measurement was taken from the lesion or normal locations as shown in the 
following figures (3.1.4-7). 
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Figure 3.1.4. Average of the six readings obtained from the normal buccal mucosa. A -1st 
readings, B-2nd readings, C-combined 1st and 2nd readings. 
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Figure 3.1.5. Average of the six readings obtained from the normal floor of the mouth. A-1st 
readings, B-2nd readings, C-combined 1st and 2nd readings. 
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Figure 3.1.6. Average of the six readings obtained from the normal tongue sites. A-1st 
readings, B-2nd readings, C-combined 1st and 2nd readings. 
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Figure 3.1.7. Average of the six readings obtained from the lesions at different oral sites. A-
1st readings, B-2nd readings, C-combined 1st and 2nd readings. 
  
 
-50
0
50
100
150
200
250
0 200 400 600 800 1000 1200
Wavelength (nm)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
)
1st
Reading
    
-50
0
50
100
150
200
250
0 200 400 600 800 1000 1200
Wavelength (nm)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
)
2nd
Reading
 
 
-50
0
50
100
150
200
250
0 200 400 600 800 1000 1200
Wavelength (nm)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
)
1st
Reading
2nd
Reading
 
 
 
 
B A
C 
                                                                        - 102 -                            Chapter 3.1 Pilot Study 
 
3.1.4 Discussion 
 
      The instrument was used to detect skin fluorescence at the photobiology and 
dermatology unit at Ninewells hospital. Marked inter- and intra-subject variation in 
ALA-induced PpIX fluorescence occurs in normal human skin. ALA application 
time, body site and the state of the stratum corneum are all determinants of PpIX 
fluorescence within subjects and these factors need to be taken into account 
(Ibbotson et al, 2006). This instrument was also used in a pilot study for 
photodynamic detection of oral cancer, in which further studies was recommended 
(O’Dwyer et al, 2008). In clinical application, inter- and intra-subject variation at the 
oral sites was noticed which led to a decision of check the reproducibility of this 
instrument in intra oral application.  
 
      Reliability and reproducibility of the method tools needed to be checked 
carefully. The null hypothesis was that there was no difference between reading 1 
and reading 2. All the standard measures were to assess the reproducibility of the 
technique based upon 5-ALA mouth rinse and the OBS system (compact 
fluorescence spectroscopy) applied in the oral cavity. The clinical protocol (including 
darkness of the operating room) was applied to all participants (PDD004-9). One 
regard to the cleanness of the probe (from air bubbles of saliva) direction of 
application (perpendicular to the tissue surface) and gentle pressure applied to the 
oral mucosa were all taken in account (since these factors may alter the light emitted 
by the probe and light collected from the tissues).  
 
      In a study using autofluorescence spectroscopy, de Veld et al, found that total 
fluorescence intensities were highly inconsistent, both intra- and inter-individually 
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(de Veld et al, 2003). The use of ratios of emission peaks at a single wavelength was 
not investigated in their study. However, they anticipated that ratio-techniques and 
statistical methods applied to normalized spectra would be more accurate than 
techniques that rely on the absolute intensity for their diagnostic ability. These 
techniques would reduce inter-patient variability as well as reproducibility, since 
spectral shape seems more consistent than fluorescence intensity. 
 
      Light emitted from the probe of the instrument used in this project was at 405nm 
wavelength. It has been reported that using 405nm excitation wavelength, 
fluorescence emitted from endogenous fluorophores such as collagen, elastin, NADH 
and the oxidized form of flavin adenine dinucleotide are located in the green 
spectrum (Catherine et al, 2009). This instrument has been programmed to detect the 
autofluorescence at 500nm.  
 
      The principal of 5-ALA induced PpIX is that in excess it results in accumulation 
of intracellular porphyrins or especially of PpIX which increases tissue fluorescence. 
Subsequent irradiation of the lesion with visible light matching the main absorption 
peak of PpIX (405nm) leads to red fluorescence emitting from PpIX peaking at 
(635nm). 
 
      The absolute fluorescence peaks of each reading in this pilot study were recorded 
at 500nm and 635nm scale of the X axis of the line graphs that displayed on the 
screen of the instrument.   
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      The statistical analysis showed very similar distribution of the data both at 
500nm and 635nm for each site. In spite of the fact that the comparison of the 
absolute fluorescence intensities of both wavelengths as a source of the fluorescence 
intensity ratio (FIR) measurements would be enough to check the reliability of the 
method, it was considered worthwhile comparing the FIR of the 1st and 2nd readings, 
since the FIR value more accurately expresses the biochemical and structural 
changes of the cells. This value will be used for the results of this research. In 
addition, it was noted that the identical shapes of the 1st and 2nd spectral line graph 
readings that ranged between 430-730nm as shown in the result figures, would 
represent the distribution of fluorescence emitted from the natural fluorophores 
(autofluorescence) and enhanced fluorescence (drug or PpIX fluorescence) of the 
tissue cells excited by 405nm wavelengths would support the result analysis. 
 
      Numerically and graphically the results were closely related. The absolute 
fluorescence intensities of the 500nm and 635nm which represented the values 
depicted on the bar graphs were nearly identical. Since the FIR values of the two 
readings were similarly distributed regarding the minimum, maximum, medians, and 
inter quartile range and there was no significant difference between the two readings, 
this result supported the reliability and reproducibility of the use of the instrument in 
intraoral measurements using ALA mouthwash. The null hypothesis was confirmed. 
There was no significant difference between reading 1 and reading 2.  
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3.2 Determination of the Elevated Red Spectrum 
(635nm or PpIX) Fluorescence Peak of the Tongue 
Mucosa 
 
3.2.1 Introduction 
 
      Tongue is a muscular organ located on the floor of the mouth and covered with 
specialised mucosa. The mucosa covering the tongue is thick and keratinised with 
papillae projecting from the surface. The mucosa is different from the other oral 
coatings due to the presence of the various forms of papillae and taste buds, and thus 
called specialised mucosa. The tongue coating is sensitive and in many instances 
might be altered duo to local or systemic factors. These features make it unique when 
considering lesion diagnosis and application of adjunctive diagnostic techniques (e.g. 
toluidine blue).  
 
      After oral topical application of the photosensitiser (5-ALA), a fluorescence glow 
was primarily noticed when using the Wood’s lamp. Spectrally, the spectroscopic 
line graphs of the tongue surface mucosa (Photodynamic Detection method) showed 
elevated red (635nm) peaks, therefore the FIR measurements were increased in 
comparison with other normal oral mucosal sites (leading to a false positive in 
respect of potential dysplasia). 
 
Aim of the study was to understand why there was elevated red (635nm) 
fluorescence peaks from the normal dorsal surface of the tongue; is it due to drug 
trapped in superficial cells, and/or bacterial reduction of ALA to PpIX? 
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3.2.2 Methodology 
 
      Four volunteers participated in this experimental study. The trial was conducted 
in the photobiology unit at Ninewells hospital. The application of the trial was to 
some extent consistent with the protocol regarding preparation of drug and method of 
the spectroscopic measurements described in the Patients, Materials and Method 
section.  
 
      One 5-ALA vial of 1.5g was dissolved in 50ml distilled water and divided into 
four equal amounts. The concentration of the drug was the same as that prepared for 
the patients recruited for the trial. Each participant had used 12.5ml of the prepared 
drug and held it in his/her mouth for 15 minutes. After rinsing with the drug and 
reminding participant not to eat, drink or smoke, 90 minutes later the OBS reading 
were obtained from the dorsal tongue for the participant in a dark room, The tongue 
was scraped with a Cytobrush (MedScand, Colgate Medical Ltd, England) for one 
participant and the wood spatula used for the other 3 participants. The collected 
coatings were kept in the freezer for the later HPLC (high pressure liquid 
chromatography) analysis. The method applied was to quantify compounds present 
in the dorsal tongue scraped material and to detect porphyrin levels as an indication 
of whether the fluorescence is due to PpIX within bacterial or superficial tissues 
(bleeding was not obtained).  
 
      Samples of whole saliva were collected in plastic tube to detect protoporphyrin 
levels as control to the HPLC result analysis. 
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      The second OBS readings were taken after scraping the tongue surface from the 
same site as the previous (1st ) reading for data comparison for pre and post tongue 
scraping fluorescence (FIR or red/green ratio) analysis. 
       
      Furthermore, for one participant readings were taken from the contra lateral side 
of the dorsal tongue before and after using 2%chlorhexidine (disinfectant) 
mouthwash. The tongue scraped material was collected using a plastic spatula for 
HPLC result analysis.  
 
3.2.3 Results 
 
      Few samples of tongue scraped material were collected for HPLC analysis. A 
total of 8 spectral (readings) were collected. These were 4 pre scraping and four post 
scraping spectra. The absolute fluorescence intensity peaks at 500nm, 635nm and 
their ratios (635/500nm) of pre-scraping and post-scraping measurements are shown 
in table 3.2.1. The level of pre-scraping and post-scraping fluorescence intensity 
ratios is shown in figure 3.2.1. The post-scraping FIR was increased in participants 1 
and 4, participant 2 showed reduction in FIR, however participant 3 showed no 
difference in post-scraping FIR.  
 
 
Pre scraping Post scraping Participant 
500nm 635nm Ratio 500nm 635nm Ratio 
1 218.934 453.1167 2.0696 217.6997 546.743 2.511 
2 24.20367 25.924 1.071 26.42067 22.47467 0.85 
3 227.7123 668.3893 2.9352 227.7123 668.3893 2.9352 
4 191.0317 440.344 2.305 110.3267 448.4667 4.065 
 
Table 3.2.1. Pre and post-scraping fluorescence intensities at 500nm and 635nm readings and 
red/green ratios of the tongue. 
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Figure 3.2.1. Pre and post scraping fluorescence intensity ratio or red/green 
ratio of four participants’ tongue. 
 
 
 
 
 
      From the contra lateral side of the tongue of one participant (volunteer 4), one 
reading was obtained, then chlorhexidine mouth wash was applied and the 2nd 
reading was obtained for the comparison i.e. two extra spectra were obtained from 
one participant one before and one after application of chlorhexidine. The 
fluorescence intensity measurements were summarised in table 3.2.2. There was 
reduction in the FIR (635/500nm) measurement in post scraping site after 
chlorhexidine mouth rinse application was noticed as shown in figure 3.2.2.  
 
 
Pre scraping Post scraping Participant 
500nm 635nm Ratio 500nm 635nm Ratio 
1 154.8657 594.9307 3.841 172.683 476.877 2.761 
 
Table 3.2.2. Pre and post scraping fluorescence intensities at 500nm and 635nm readings and 
red/green ratios of the tongue after chlorhexidine mouthwash. 
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Figure 3.2.2. Pre and post scraping fluorescence intensities ratio (635/500nm) or red/green 
ratio of the tongue after chlorhexidine mouthwash. 
 
 
 
HPLC analysis 
 
 
      Using HPLC, Protoporphyrin was detected in only one sample of the tongue 
scrape. The level of Protoporphyrin in the saliva of the participant was   5.4 +/- 0.4 % 
and in the tongue scrape was 5.5%. However the other samples were not analysed 
because the amounts were below the level of quantifications.   
 
      The 2nd sample of tongue tissue was obtained from one participant who used 2% 
chlorhexidine mouth wash after 5-ALA mouth rinse. The level of Protoporphyrin  in 
the saliva was 33.8% while in the tongue scrape was 71.0%.   
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3.2.4 Discussion 
      In reviewing the literature, previous studies concluded that different tissues have 
different pharmacokinetic responses in the rate they syntheses protoporphyrin, and its 
conversion to heme products (Vaidyanathan et al, 2000). In human subjects, ALA-
induced protoporphyrin IX (PpIX) fluorescence images from the normal tongue were 
compared to images obtained from patients with squamous cell carcinoma (SCC) of 
the tongue (Thong et al, 2007). Tongue mucosa showed red fluorescence at 635nm 
using autofluorescence spectroscopy (de Veld et al, 2003).  
      Our observation of the tongue glowing with the Wood’s lamp (and the OBS 
detection if fluorescence at 635nm) and different spectra line-graphs readings 
motivated the investigators to try to understand why the normal dorsal tongue was 
fluorescing. Prior to conducting a clinical trial a pilot study was undertaken to see if 
it would be worth submitting a more formal request for a full clinical investigation. 
The results of this preliminary study were contradictory. 
      The volunteers participated in this pilot study were investigators and 
photobiology unit staff members. 
      Collection of tongue scrapings were tried using the Cytobrush, wooden tongue 
blade and plastic blade since the investigators were unsure which one was the best 
method to collect samples of dorsal tongue for HPLC protoporphyrine detection. 
 
      The readings in one volunteer (2nd) showed slight reduction in the tongue 
fluorescence intensity ratio (FIR), while in another volunteer (3rd) there was no 
change in the FIR readings; however there was post scraping increase in the FIR of 
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two volunteers (1st and 4th). The result was not conclusive but the variation could be 
attributed to the method of scraping which was not standardised since the method of 
collecting tongue sample using the Cytobrush was different from that of the tongue 
blade i.e. the post application bacterial collection and/or mucosal irritation might 
have influenced the post scraping fluorescence measurements. 
 
      Unfortunately the Cytobrush and plastic spatula were the only methods that could 
collect samples of superficial tongue tissue, while the wooden tongue blades were 
not useful since the liquid was absorbed by the wood so the samples could not be 
detected and analysed by the HPLC to quantify the protoporphyrin level. HPLC was 
able to detect and quantify the Protoporphyrin percentage present in the saliva 
samples as control.  
 
      Protoporphyrin (as a precursor of heme) accumulates in cells of all living 
organisms, such as erythrocytes and bacteria (Thunell, 2000; Latunde-Dada, 2009). 
Detection of this element represents the level of the cellular presence and activity in 
the samples. Saliva, as well as the tongue scrape, showed evidence of Protoporphyrin 
however there was no difference in the amount present in both samples (saliva and 
tongue scrape) collected from the participant.  
 
      There was a difference in the protoporphyrin percentage between the tongue 
scrape tissue and the saliva in the samples obtained from the pre and post 
chlorhexidine mouth rinse application. This might be due to the effect of 
chlorhexidine on the bacteria in the saliva (flora) if the bacteria contained PpIX i.e. 
the chlorhexidine removed some PpIX positive bacteria. 
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      There was a slight reduction in the pre and post scrape FIR measurements taken 
from the dorsal tongue which could be due to reduction of the red (635nm or PpIX) 
fluorescence peak resulted from the removal of the superficial layer of the tongue 
coating that presumably contain living cells and microorganisms that contained 
PpIX. A previous study using the Cytobrush to obtain oral cell failed to detect basal 
cell (Ogden et al, 1991) hence we can be confident that the tongue scrapings were of 
superficial dead cell and not actively dividing cells that could have taken up and 
metabolized the ALA to PpIX intracellularly. 
 
      The sample size was too small and there was inadequate evidence to conclude 
why the tongue FIR measurements were higher in comparison with other normal 
mucosal sites, although there was a suggestion that oral bacteria were responsible. 
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4.1 Instruments 
 
     4.1.1 The Compact Fluorescence Spectroscopy or Optical 
              Biopsy System (OBS) 
 
      The instrument used for this investigation was a computer based system 
composed of spectrometer, cables (connection, control and fibre-optic) and laptop 
downloaded with software to analyse the spectrums of light emitted from the tissue 
for the result analysis as shown in figure 4.1.  
 
      The instrument has previously been used in a number of trials conducted at 
Ninewells hospital to detect the lesions in various organ systems both for the 
photodynamic detection and photodynamic therapy. The results have been published 
in scientific journals (Nadeau et al, 2002; Nadeau et al, 2004; Ibbotson et al, 2006; 
O'Dwyer et al, 2008; Eljamel et al, 2008; Lesar et al, 2009). 
 
      A detailed description of the compact fluorescence spectroscopic tool and graphs 
were detailed in the review of literatures section. 
 
      The system schematic diagram of the experimental set-up is shown in figure 4.2.   
The system incorporates a 5 mW GaN diode laser, emitting at 405 nm, the 
wavelength at which the highest absorption peak of the PpIX spectrum occurs. This 
laser is coupled via a 600 µ m core optical fibre into an electronic shutter, which also 
contains a blocking filter to prevent small amounts of 635 nm light emitted by the 
GaN laser from reaching the oral mucosa. The electronic shutter ensures that the oral 
mucosa is only exposed to light from the laser for the duration of the measurement. 
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Due to the high efficiency of the optical design, a 1 second exposure to light at an 
intensity of 0.5 mW/cm2 is sufficient to produce measurable fluorescence spectra. A  
bifurcated fibre couples this excitation light to the oral mucosa and the fluorescence 
to a compact spectrometer for spectral analysis. The spectrometer, preceded by a 455 
nm long-pass filter to remove the backscattered excitation light, has a resolution of 
10 nm and wavelength range of 430 to 730 nm.  All aspects of the instrument’s 
operation are controlled using a laptop PC and custom written software. The acquired 
spectra are analysed using pre-recorded spectra and a least squares fitting routine to 
obtain the relative strengths of the background optical fibre fluorescence, tissue 
autofluorescence, PpIX fluorescence and photoproduct fluorescence. These various 
spectra are shown in Figure 4.3, as they would appear in a fluorescence spectra from 
a measurement made on subjects to whom 5-ALA has been administered (heavy dark 
line). The spectral components due to the other fluorescence signals are shown by the 
lighter grey lines (figure 4.3).  
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Figure 4.1. Photograph of the Optical biopsy system (OBS). 
 
 
 
Figure 4.2. Schematic of the OBS used to perform the measurements (Nadeau et al, 2004). 
                                                                 - 116 -    Chapter 4 Patients, Materials and Methods 
 
 
 
Figure 4.3. Graph of the overall fluorescence measured (dark line), and its components  
(grey lines) (Nadeau et al, 2004). 
 
 
 
 
   4.1.1.1 Probe of the system 
 
      We have used the probes with different lengths developed to be used for the oral 
cavity readings Figure 4.4. The width is of 2mm in diameter and consists of optic 
fibre for illumination and fluorescence detection. The probe emits light transferred 
from the system cable and deliver 405nm excitation wavelength since results from 
previous studies suggested that this wavelength is located within the range of 
wavelengths which produce the greatest discrimination between normal and 
abnormal tissue (Vengadesan et al, 1998; Eker et al, 2001). The probe also collects 
the fluorescence emitted from the tissue to be transferred to the spectrometer through 
the system fibre-optic cable. 
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Figure 4.4. Fibre optic probe is connected to the OBS. 
 
      The probe is the only component requires sterilization which was sterilized with 
100% ethylene oxide (EtO) to a sterility assurance level and the device is packaged 
in a heat sealed pouch.  
 
      The investigator had to fill out the sterilization form at the photodynamic 
centre/Ninewells hospital and submit the probes soon after finishing the trial since 
the sterilization requires two weeks for the probes to be used again. 
   4.1.1.2 How does the OBS work? 
 
 
      After insuring all the cables of the laptop and the instrument were connected 
together and plugged in the electric source, the instrument was turned on by pressing 
the green lighted button on the front side of the instrument (Figure 4.1) and turning 
the laptop on.  The laptop was pre-installed with OBS program software designated 
for this purpose and the software existed as an icon on the screen. A foot paddle 
connected to the instrument through a cable plugged in the laptop to switch on the 
laser light for 1 second for tissue illumination, or the alternative when the cable was 
not available by asking the assistant nurse to press a Go button on the screen of the 
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laptop. The collected light is analysed in the form of graphs in real time and 
displayed on the screen of the laptop (Figure 4.1).    
 
      The results of the graphs displayed on the screen of the computer, colours of the 
backgrounds and the fluorescence lines, could be copied from Excel file and 
transferred to Word and copied as shown on Figure 4.5. The green line represent the 
fluorescence of the cells due to the presence of the naturally occurring fluorophores 
and the presence of the photosensitizer drug 5-ALA picked up, metabolized and 
changed to protoporphyrine IX (PpIX), while the yellow line graph represents the 
background (BG) scattered light subtracted from the total fluorescence to display the 
final outcome graphs that finally exist on the screen.  
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Figure 4.5. Graph of the fluorescence measured as shown in the screen (results) . 
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   4.1.1.3 Recording and saving the data by the OBS 
 
 
      The instrument has the ability to measure the tissue fluorescence at any 
wavelength ranged between 339nm up to 1000nm. The spectra of light are analysed 
and saved on the laptop in the form of Excel files. Emission and collection of light 
from the tissue for 1 second is stored in a form of one Excel file of that site. The file 
contains three columns; each one consists of 2048 values or numbers. The first 
column represents the wavelength ranges between 339nm up to1000nm, the second 
column is the readings of the fluorescence emitted by the tissue and the third column 
is the readings of the background subtracted from the overall fluorescence reading.  
  
      Each wavelength (339nm-1000nm) has been registered three times. This was to 
analyze three readings of fluorescence and background to draw and display the 
outcome graph on the screen as shown in Figure 4.5. 
 
      On the screen of the laptop there was a slot to show the Fluorescence intensity 
ratio (FIR) (red/green ratio) or the ratio of the location of the two cursers over the 
wavelengths required for the investigation at the moment of the reading. 
 
      On the right side of the screen, there were slots used to type name of the patient 
and the diagnosis of the lesions. To comply with the rules of the Ethics in conducting 
the clinical trials in maintaining and protecting the confidentiality of the patients the 
slot of the name was typed by the participant ID e.g. (PDD001D, PDD002D….etc) to 
identify the Excel files, while the other slots were left unidentified. 
 
 
                                                                 - 120 -    Chapter 4 Patients, Materials and Methods 
 
 
4.1.2 Short Wavelength Lamps 
 
 
   4.1.2.1 Wood’s Lamp 
 
      The woods lamp was invented by an American physicist called Robert Wood in 
(1868-1955).  It is now called the "Wood's Light" or "Wood's Lamp". It is a 
diagnostic tool used in dermatology by which ultraviolet light is shone (at a 
wavelength of approximately 365 nm) onto the skin of the patient. The clinician then 
observes any subsequent fluorescence. For example, porphyrins, associated with 
some skin diseases, will emit pink colour fluorescence. It has many uses, both in 
distinguishing fluorescent conditions from other conditions, and in locating the 
precise boundaries of the condition Figure 4.6. a. The wavelength of fluorescence 
emitted by the woods lamp is further checked by the physicist (Professor Harry 
Moseley) in Photodynamic Therapy/Dermatology and Photobiology centre at 
Ninewells hospital and the wavelength fluorescence is shown in Figure 4.6 b. The 
instrument was used to identify the oral lesions boundaries and glowing areas of the 
lesion to be measured by the OBS. 
   4.1.2.2 Torch Lamp 
 
       The device was developed by the University of Dundee/ Electronic engineering 
department (PhD student). The lamp uses Led chip material based on GaN ultra violet 
light. The wavelength emitted is 395nm as shown in Figure 4.7. a&b. The device has a 
switch to change the current from 20 to 30mA and gives different intensities of light. 
The handle of the probe is small and adjustable so could be used to access the tiny 
lesions at distant sites intra orally. The instrument was used when received and started 
the application in PDD09D and lasted in PDD27D. The data of 20mA was collected  
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 Figure 4.6. a. Wood’s lamp is shone 365nm wavelength   b. Wavelength emitted by the lamp. 
 
 
           
Figure 4.7. a. The torch lamp is shone 395nm wavelength.      b. Intensity of fluorescence emitted  
                                                                            by the lamp at different 
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since 30mA was upgraded in the middle of the trial. 
 
4.2 The Mouth Rinses 
 
   4.2.1 Chlorhexidine 
 
      The mouth rinse was used before the use of the photosensitizer to disinfect the 
bacterial flora of the oral cavity. 0.2% concentration chlorhexidine gluconate is a 
bacteriostatic chemical that kills both gram-positive and gram-negative microbes 
although it is less effective with some gram-negative microbes (WHO, 1998). The 
mouth was bathed with 5ml of chlorhexidine for 2min before the use of 5-ALA mouth 
rinse 
 
   4.2.2 Photosensitizer prodrug (5-ALA) 
 
      Vials of 5-aminolevulinic Acid 1.5g were used for this trial. It was supplied by 
Medac GmbH postfach 30 36 29 D-20312 Hamburg. The generic drug was ordered for 
preparation as a mouth rinse as per protocol to Ninewells Hospital, Photodynamic 
Therapy Centre. The Drug was present in clear vials and stored at room temperature in 
the pharmacy room in a dark cabinet. A digital thermometer monitored the temperature 
which should not exceed 25C (figure 4.8).  
 
Figure 4.8. Vial of the photosensitizer. 
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4.3 Patients Recruitment 
  
      The steps of the procedure were followed at both sites of the trial (Dundee and 
Glasgow) in an attempt to standardize the method of the trial. The clinical nurse 
specialist (Carol Goodman) was assisting the author at the beginning and 
coordinating the trial in Glasgow, since she had jobs at both sites.  
      Patients were recruited for three sites, Dundee Dental Hospital/Oral Medicine 
and Diagnosis Clinic, the Oral and Maxillofacial clinic at Ninewells hospital and 
patients referred to the maxillofacial clinic at Glasgow Southern General Hospital. 
The patient’s criteria for recruitment were as follows;  
 
   4.3.1 Inclusion Criteria 
 
 
• Men and women age over 18 years. 
• Willing to participate in the trial. 
• Oral lesions affecting the mouth lining. 
• Able to use the mouthwash for 15 minutes. 
• Able to comply with instructions. 
• Be able to sign and date a valid consent form prior to entering the trial. 
 
 
In addition to women were eligible to enter and participate in this study: 
 
• Non-childbearing potential (postmenopausal or physiologically incapable of 
becoming pregnant e.g. Hysterectomy). 
• Child bearing potential and has negative pregnancy test (urine or serum) at 
screening. 
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   4.3.2 The Exclusion Criteria 
 
• Younger than 18 years. 
• Those participants who couldn’t give their own informed consent. 
• Pregnant women/women pregnancy test will be offered. 
• Breast feeding women. 
• Patients who have porphyria. 
• Patients with known malignancy. 
 
 
      Patients with known malignancy were excluded as designed in the protocol, 
however, amendments of the protocol were submitted to REC, MHRA and local R&D 
and approvals were obtained to include oral malignancy patients since few dysplastic 
lesions were recruited in Dundee and Glasgow were slow in recruitment. The only 
known cases recruited were the last two cases in Dundee (PDD026D & PDD027D) 
before the MHRA inspection.   
 
      The patient information leaflet (Patient information sheet/Protocol code number 
CG/7657- Version 5-2007-07-07 see appendix 3 A-C) was given to each patient agreeing 
to take part in the trial and the procedure was discussed in detail. A consent forms (V4 
AUG 07 upgraded to V5 and V6 January 2009 see appendix 2 A&B) were completed 
and signed by the subject and the authorised person. The original copy of the consent 
form was kept in the medical or the dental notes, additional copies were kept in the TMF 
or CIF and for the patient. The consented patients were given enough time before the 
procedure and informed that they have the right to drop out of the trial at any time. 
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4.4 The Clinical Procedure 
 
      It was planned that the patients would be tested at the Oral & Maxillofacial Unit; 
Ninewells Hospital as the Optical Biopsy System (OBS) was kept in the Photobiology 
and Physics laboratory at Ninewells Hospital. However the limited access to the 
maxillofacial clinic and the constraints we had faced to conduct the trial led us to change 
the venue to the photodynamic centre then later had to move to the Clinical Research 
Centre to continue the trial and to reach the target number of patients designated in the 
protocol.  
 
      The patients were asked to come at 15 minute intervals for the mouthwash with at 
least 2 patients per session since the drug was costly. 
 
      On the day of the trial, the patients were examined clinically by the investigator and 
the Case Report Forms (CRF) (see appendix 4 A-G) filled out with detailed description 
of all the information required for the documentation of the history, systemic condition 
and clinical description of the oral lesions.  
 
      Each patient participated in the trial was coded PDD---D (e.g. PDD001D, 
PDD002D….etc) to maintain the confidentiality of the patient and comply with the ICH-
GCP and signed by the investigators who were only authorised to conduct the trial.  
The case report forms, standard copies designed by the trial investigators at TCTU and 
the additional forms designed by the author were filled out and signed by the investigator 
before starting the mouth rinse and taking the intraoral measurements. 
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      The clinical method was conducted by offering the subject a glass of drinking water 
prior to the trial procedure to quench their thirst as they were not be permitted any food, 
drink or smoke for 90 minutes after the photosensitizer mouth rinse application. 
Chlorhexidine antiseptic mouthwash (conc. 2%) was given to the participant to cleanse 
the oral cavity of bacteria and plaque for 1-2 min prior to the ALA mouth rinse. 
ALA mouth rinse was prepared by adding 50 ml of fresh or distilled water measured 
using hypodermic syringe to the contents of one Vial of ALA (1.5g). The Vial was 
shaken to ensure the ALA dissolved completely in the water, and then the content was 
divided into two equal amounts of (25ml) in plastic cups to be used for each patient. 
While the 1st patient used his mouth rinse, the other glass was kept in a dark place to 
ensure it was not affected by light. 
 
      The patients recruited would each get an ALA mouth rinse that they would have to 
rinse around their mouths for 15 minutes and after every 4-5 minutes they were allowed 
to spit out and refresh the rinse.  They were encouraged to ensure the rinse wet all the 
mucosal surfaces. This procedure was repeated for 15 minutes and the time checked by 
using a digital timer clock. 
 
      The patient was asked to leave the clinic and to return after 90 minutes insisting that 
no food, drink or smoke could be consumed at this stage. 
  
      Before taking the measurements, the OBS was set and the references were stored by 
using dark piece of rubber blocked the end of the excitation and emission probe to 
subtract the background from the overall fluorescence spectra. Calibration performed by 
taking several readings of the backgrounds in the dark to establish a baseline reading 
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before each procedure. The background reading is automatically removed by the system 
from any future readings and true fluorescence was displayed. The graph lines and 
colours were displayed on the screen of the computer as shown in figures 4.1&5.    
 
      On return to the clinic the patient was sat on the chair and the room was made dark. 
The short wavelength Lamp (Wood’s lamp and Torch lamp as shown in figures 4.6 & 
4.7 ) were shone to see any glowing (fluorescence) of the lesion to be registered on the 
CRF for the comparison with results of the OBS probe. 
 
      The measurements were taken in the dark field, but the probe was guided intra 
orally with the aid of the short wavelength light (SWL) to detect the glowing areas 
and to identify the sites of the readings. In addition, to avoid any background light 
that may affect the measurements or potentially photo-bleach the photosensitizer. 
 
      The Torch Lamp was used to identify the boundaries of the oral lesions.  For 19 
patients, the lamp was used as an adjunct with the Woods lamp to assist “clinically” in 
detecting the glowing spots of the suspected sites and defining the lesion borders. 
 
      After the (SWL) readings were taken, Optical Biopsy System was used to take the 
measurements and the data saved on the memory of the laptop. Setting the OBS was 
done at the beginning of each patient to update the reference before taking the 
measurements. The next step was to store the fluorescence and set the lines on 500nm 
and 635nm (500nm was set by the soft wear as ALA autofluorescence and 635nm PpIX 
fluorescence) to be ready for the intra oral readings. 
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The readings were taken from  
• Predetermined specific oral anatomical sites,  
• The lesion and normal sites more than 5mm away from the lesion and recorded 
on a special form designed for this purpose (see appendix 6).  
 
4.5 Readings Obtained for the Trial 
 
      When commencing the trial, the PI (Prof. Ogden) had taken the readings from the 
1st three patients since the author had to be watching how to do the procedure and 
conduct the trial. The PI had observed difference in the intensity peaks of 
fluorescence between locations and when taking the readings from the normal tongue 
mucosa in particular. In view of this, it was thought necessary to obtain data from 
specific oral sites to investigate the influence of anatomical location on normal 
mucosal fluorescence. 
 
   4.5.1 Oral Anatomical Sites  
 
      To detect the variability of fluorescence intensity ratio (FIR), we investigated the 
influence of anatomical location on normal oral mucosal fluorescence characteristics 
to determine if site altered the spectral response. 
Ten intra oral normal sites (anatomical sites) were chosen to obtain the readings to map 
out the oral cavity FIR and study the fluorescence tissue emission behaviour of the 
various oral mucosal types (keratinised and non keratinised mucosa). 
 The selected oral anatomical sites were clearly identified and represent the oral mucosal 
coating. 
                                                                 - 129 -    Chapter 4 Patients, Materials and Methods 
 
 
      These points (as shown in Figure 4.9. A and B) were: 
1. Incisive papilla palate.  
2. Mid palate near the palatine suture. 
3. 2mm away from the tip of the tongue. 
4. 3cm on the dorsal surface of the tongue away from the tip. 
5. 5mm from the ventral surface of the tongue away from the tip. 
6. Floor of the mouth in the mid submandibular salivary gland orifices  
      (Mid Wharton’s duct). 
7. Right cheek near the parotid opening. 
8. Left cheek near the parotid opening. 
9. Gingival site at the lower labial region above the lower lip fraenum 
attachment. 
10. Lower lip above the fraenum attachment. 
 
      A list of these sites and the required biopsy sites readings were printed on a paper 
sheet and kept in the TMF records. The readings for every patient were kept with the 
CRF for archiving (see appendix 5). 
 
      The author has chosen the oral anatomical sites for the following reasons: 
1- These sites included keratinized and non keratinized mucosa. 
2- These mucosal surfaces are subjected to different mechanical, thermal 
(smoking) and microbial irritations. 
3- Could be accessed precisely and repeatedly in obtaining the measurement 
from different patient. 
4- Easy to access these sites by the probe in a darkened room. 
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A       
B        
Figure 4.9. A & B. Anatomical sites of the oral cavity. IP incisive papilla, MP mid palate, TT tip 
of tongue, DT dorsal tongue, VT ventral tongue, FM floor of mouth, RC right cheek, LT left 
cheek, GN gingival, LP lip. 
 
                                                                 - 131 -    Chapter 4 Patients, Materials and Methods 
 
 
   4.5.2 Lesion Sites 
 
 
      The suggestion in the beginning of the trial was made to take five readings from each 
lesion. These readings were supposed to be taken from the upper, anterior, lower, 
posterior and middle sites of the lesion as designed in the protocol. The biopsy should 
excise the whole lesion so that all the reading sites could be included for the fluorescence 
and biopsy or histopathology comparison, however most of the surgical biopsy obtained 
from the lesions were 5mm in size (punch biopsy) that means it was not applicable in 
practice to include five readings in small size biopsy, for this reason it was rather more 
precise to take two readings from each 5mm biopsy site excised and examined under the 
microscope.  However, all the readings obtained from a few excisional biopsies were 
included for the analysis and recorded as 1st and 2nd readings in the result tables.     
Readings in a form of Excel files (saved and stored on the desktop of the computer) 
were taken from the biopsy site and one reading from the normal site.  
 
      The punch biopsy was taken from the most suspicious site clinically and with the 
highest fluorescence peaks of the OBS. The area from which to take the normal 
fluorescence readings “in theory” were the contralateral sites. However in practice a 
significant number of lesions were bilaterally distributed. Hence readings were taken 
from the same anatomical site of the oral cavity but more than 5mm away from the 
lesion borders. 
 
      Once the patient has finished the OBS readings, the biopsy was performed in the 
theatre room. The type of the surgical biopsy was decided depending upon the case; 
however punch biopsy was done for most of the patients with suspicious lesions.  
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      The excisional biopsies were done in the theatre room under general anaesthesia, 
while the Punch biopsies were done in the clinic under local anaesthesia. 
 
      Punch biopsy was conducted by giving the patient local infiltration anaesthesia and 
biopsy was taken by using size 5mm punch biopsy knife. Vicryl silk suture was used to 
close the wound and instruction for wound healing was given to the patients. The 
patients were asked to come back two weeks later at Dundee Dental Hospital/Oral 
Medicine Clinic for review of any side effect of the drug, trial and surgical procedure. 
The sample of tissue biopsy was fixed in 10% formalin and sent with the pathology 
information sheet to the pathology lab for the microscopic examination report. 
The same procedure was followed in Glasgow. 
 
      The study was prospective in design and the fluorescence readings were collected 
based on the clinical and spectroscopic findings only. The definitive diagnosis used for 
the comparison was microscopic examination reported by the pathologist who had no pre 
report information about the spectroscopic findings.   
 
4.6 Data Acquisition  
 
      The data obtained from the patients were Excel files for each reading 
representing the fluorescence intensity level of the assessed tissue site (lesion or 
normal).  
 
      The X axis of the graph (displayed on the screen of the computer and saved on 
the file) is representing the wavelengths of the spectra ranges from 339nm up to 
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1000nm (figure 4.5). The Y axis of the graph is representing the fluorescence 
intensity level of the tissue in each wavelength which is measured in arbitrary unit 
(a.u). 
 
      The spectra program of the instrument saves three fluorescence intensity readings 
at each wavelength so the average of each reading at 500nm and 635nm was taken 
and recorded in the tables (see appendix 7 table index 7.1). 
 
      The ratios were obtained by dividing the fluorescence intensity readings at 
635nm and 500nm wavelengths (red/green) and the results displayed in the result’s 
tables (see appendix 7 table index 7.2-7). 
 
      As mentioned before the system could provides us with the ratios of any 
wavelengths automatically by adjusting the curser over the column on the screen of 
the laptop using the laptop mouse pad manually at any wavelengths required for the 
assessment and displays this reading in a slot exists on the screen and on real time. 
However the ratios were taken from the Excel files for the following reasons;  
 
• Working in the dark room hampered the accuracy in obtaining the results. 
• Saving time writing the readings. 
• Extension of the clinical or the chair work and increase the patient’s 
suffering. 
• Requires additional assistance at the time of the clinic. 
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4.7 Data Analysis 
 
      SigmaStat and SigmaPlot software packages were used for analysing the data and 
drawing the graphs for the results (Sigmaplot, 2010).  
 
      Descriptive analyses were conducted for median values of FIR at each site with 
graphical representation of the data. Box plot were graphed to observe the 
distribution of the values and the relations of the variables. 
 
   4.7.1 Anatomical Sites 
 
      Analysis of the ratios of the intensities at the red (635nm) and green (500nm) 
regions of the spectrum was made (table index 3). An analysis of variance was 
performed to determine whether the average peak fluorescence intensity ratios for all 
normal oral mucosa differed among sites. 
The data were analysed using one way ANOVA to compare the relation of the 
fluorescence intensity ratios of the readings obtained from the patients as a test 
variable and the anatomical sites as a factor.  
 
4.7.2 Individual Characteristics 
 
      The same set of spectral data obtained from each patient were analyzed to detect 
variance in the fluorescence intensity ratio at the sites (categorised in relations to the 
anatomical sites) and the individual characteristics which include the age, gender, 
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and presence of the metabolic disease, presence of dental prosthesis, smoking and 
alcohol consumption (see appendix 7 table index 7.4&5). 
 
      A t test was used to compare the relation between each character that was 
normally distributed and Mann-Whitney test used to test a non-normally distributed 
data. 
 
• The age groups were classified into young (less than 50 years) and old (above 
50 years) to compare the FIR between the age groups.  
• The gender was grouped into male and female groups. 
• The systemic diseases considered in the comparison were metabolic diseases 
that might influence the fluorescence of the tissues and the diseases included 
were diabetes and thyroid (hypo or hyper) function.  
• Presence of removable or fixed prosthesis and absence of prosthesis were 
considered in the comparison of the FIR between the two groups analysis. 
 
• The effect of smoking: smokers (smoke at least one cigarette a day) were 
compared to non smokers. 
• Alcohol was defined as any regular intake (regardless of the number of the 
units)  compared to those who abstained (this was because of the difficulty of 
reliability assessed exact alcohol intake) 
 
4.7.3 Lesions and Normal Sites 
 
      Fluorescence intensity ratios at 635/500nm (red/green) from abnormal sites were 
compared with those from normal sites.  
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Readings of the spectra were obtained from the lesions were categorised into 1st and 
2nd readings (see appendix 7 table index 7.6&7.7), however in table index 6.7 more 
than two readings were taken from the excised lesions, they were listed in two 
categories and considered as lesion site readings.  
 
      One way ANOVA was applied to compare the two readings from the lesion and 
normal sites (table index 7). Further analysis was done by merging the two readings 
of the lesion to be considered as a disease sites and compared with the normal sites 
by using Mann-Whitney test (non normal distribution test) to detect the difference 
between the lesion and normal sites.  
 
      Readings obtained from the normal sites were used for the comparison and the 
lesions were classified in a range of lesions based on the histopathological diagnosis.  
The diagnosed lesions were grouped into three categories for the results analysis: 
 
• Benign hyperkeratosis; were lesions histologically showed no evidence of 
inflammatory reaction.  
• Inflammatory keratotic lesions; were red and white lesions showed 
inflammatory cell infiltration such as lichen planus or lichenoid lesions 
and/or superimposed by fungal infections.  
• Dysplastic; were lesions showed evidence of dysplasia without considering 
the stage and neoplasm. 
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      Spectra line graphs were averaged in relation to the sample size and displayed in 
the result graphs to assist in spectra comparison interpretation. 
 
      Sensitivity and specificity as well as the predictive values of the Fluorescence 
Intensity Ratio (FIR) in the detection of the premalignant lesions were also assessed. 
e detection of the premalignant lesions were also assessed. 
 
 
 
 
 
 
 
                             Chapter 5 
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      A total of 35 patients were recruited and consented. They were 27 patients 
recruited at the Dundee site (Ninewells hospital/Clinical Research Centre) and 8 
patients at the Glasgow site (Southern Glasgow hospital). 
 
Limitation in recruiting patients and problems associated with conducting a CTIMP 
will be discussed later.   
 
      A total of 426 spectra were obtained from 35 patients recruited for the trial (see 
appendix 7 index tables). The spectra were light emitted and collected by the 
compact fluorescence spectroscopy from the tissue site and stored by the computer in 
a form of Excel files. Each Excel file contains spectra readings from one tissue site 
saved and stored in the computer of the instrument.  
 
      The level of 500nm (green) peak indicates the autofluorescence tissue emission 
which is expected to be high because it represents fluorescence emission reflected 
from the normal tissue. While 635nm (red) peak indicates PpIX fluorescence that (as 
explained previously is associated in theory with a change toward malignant 
phenotype) occurs due to alteration in the chemical or structural components of the 
tissues. High fluorescence intensity ratio (635/500nm or red/green ratio) indicates 
alteration in the normal tissue fluorophore emission due to PpIX accumulation 
resulting from the cellular metabolism of 5-ALA (assumed not to occur in normal, 
non diseased tissue).  
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      Management of the FIR was done by comparing all the readings as raw data 
without exclusion of the extreme values (outlier), while very extreme values were 
excluded in drawing the graphs only using SigmaStat or SigmaPlot package. 
 
5.1 Fluorescence intensity ratio (FIR) measurement at the oral 
       anatomical sites 
 
 
      A decision to map out the fluorescence intensity ratios of the normal oral 
mucosal sites was made after noticing false positive readings from some areas, of the 
normal oral mucosa and of the tongue in particular, for the 1st three patients recruited 
for the trial. For this reason, these patient’s readings were excluded from the trial 
analysis since their readings were not taken from the exact sites that were chosen for 
the patient in the rest of the study. 
As a result of these observations, a total of 292 spectra (readings) were taken from 10 
oral anatomical sites (figure 4.9) of 32 patients consented and recruited for the trial 
(see appendix 7 table Index 7.1, 2&3).  
 
      The gender of the patients was 16 males and 16 females. The age ranged from 
21-84 with the mean age 59.2 years and Standard deviation 15.3 years.  
 
      Ten sites were selected to compare the FIRs and the sites included for this study 
were examined clinically and spectroscopically. The oral anatomical sites were listed 
in a sheet (see appendix) designed to record the observations and stored in the trial 
master file (TMF) and the data were saved in the computer (University web in 
compliance with the SOP) for the results analysis. 
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Table Index 7.1 (see appendix 7) showed the fluorescence readings of each patient at 
500nm and 635nm at 10 anatomical sites. 
Table Index 7.2&3 showed the fluorescence intensity ratios at the anatomical sites 
for each patient. The ratios of the readings were obtained by dividing the value of the 
fluorescence intensity at 635/500 which represents the red/green ratio and the values 
of each ratio were recorded. This value could be obtained from the computer screen 
of the instrument or from the excel data file. There were data taken but not included 
(IN) and missing or not obtained (NO) values, since the sites were not fit the criteria 
of site selection or due to technical errors. 
 
      Descriptive statistics were calculated for each variable. The variables in the study 
were fluorescence intensity ratio at 635/500nm (red/green ratio) of the normal 
mucosa at different anatomical sites (table 5.1).   
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Anatomical Site 
No. of 
Patients 
Minimum Maximum 25% 75% Median Mean 
Standard 
Deviation 
Incisive Papilla (IP) 32 0.440 5.570 0.855 2.675 1.760 1.948 1.295 
Mid Palate(MP) 26 0.1000 4.120 0.670 2.160 1.130 1.439 1.049 
Tip Tongue 2mm (TT) 31 0.350 3.940 0.910 2.598 1.480 1.703 0.987 
Dorsal Tongue 3cm  
(DT) 
32 0.360 4.840 0.815 1.695 1.225 1.519 1.060 
Ventral Tongue (VT) 25 0.210 5.610 0.410 1.093 0.580 1.043 1.218 
Floor Mouth (FOM) 31 0.140 3.380 0.397 1.475 0.610 1.028 0.911 
Right Cheek  (RC) 32 0.120 1.730 0.250 0.900 0.470 0.613 0.433 
Left Cheek (LC) 31 0.1000 4.900 0.285 1.210 0.710 0.868 0.943 
Gingiva (GN) 26 0.150 5.140 0.530 1.280 0.865 1.112 1.011 
Lip 26 0.220 3.090 0.630 1.710 0.865 1.179 0.831 
 
Table 5.1. Summary of the data statistical description. Sample size ranged between 26 and 
32 patients. 
 
 
      An overview of the findings was made. Median values were noticeably lower 
than mean in most measurements which indicates that the data were skewed and non-
normal in distribution. The inter-quartile range of the 25% and 75% were recorded to 
show the range of the distribution of the data which varied between sites, as a result, 
the median values of the FIR are more reliable since they are less affected by the 
extreme values. 
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      Highest and lowest median values ranged between (1.76 – 0.47) with the highest 
value that of the IP followed by TT, DT, MP, GN, LIP, LC, FOM, VT and the lowest 
was of the RC respectively.  
 
      The mean values of the normal anatomical sites did not vary that much with the 
median, maximum and minimum values. The highest median and mean FIR values 
of the IP were 1.76 and 1.948 followed by the tongue (1.480, 1.703) and the lowest 
were that of the RC (0.47, 0.613). There was a variance in the dispersion in the 
values which can be demonstrated by the differences in the standard deviation of the 
different sites which indicates the differences in the FIR at some sites.  
 
      SigmaStat or SigmaPlot package was used to obtain the values (p values) which 
stands for the probability of difference. 
 
      The significance of the difference in the FIR was obtained by applying Analysis 
of Variance (ANOVA) which recommended Holms sidak method as a powerful 
procedure used for both pairwise and multiple comparison testing and to determine 
which pairs of sites tend to be different e.g. IP vs. RC. The outcome shows the 
differences in the mean values among all the groups were greater than would be 
expected by chance; there was a statistically significant difference (P = <0.001) 
between all the groups and summery of the results is shown in table 5.2. 
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Source of Variation DF SS MS F P 
Between Groups 9 45.922 5.102 5.151 <0.001 
Residual 282 279.332 0.991   
Total 291 325.254    
 
Table 5.2. Summary of the result analysis among the groups. Degree of  
Freedom DF, Sum square SS, Mean square MS, F and p values. 
 
 
      There were some sites that did not differ from each other in comparison between 
all the groups while others shown highly significant difference (P =0 .001). To 
explore more in depth the difference of the FIR at each anatomical site, the following 
tables illustrate the variability of FIR at the oral anatomical sites using two levels of 
significance (0.05 and 0.001). The pairwise comparisons between the anatomical site 
means, t values, unadjusted p value and level of significance at 0.05 and 0.001 level 
of each anatomical site measured are shown in the following tables (Table 5.3, A-I). 
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Table 5.3 (A-I). Summary of the oral anatomical site fluorescence intensity ratio using 0.05 
and 0.001 statistical levels. 
 
A-Incisive Papilla (IP) 
 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 IP vs. RC 1.335 5.365 0.000000169 Yes Yes 
2 IP vs. LC 1.080 4.306 0.0000229 Yes Yes 
3 IP vs. FOM 0.920 3.667 0.000293 Yes Yes 
4 IP vs. VT 0.905 3.405 0.000757 Yes Yes 
5 IP vs. GN 0.836 3.180 0.00164 Yes No 
6 IP vs. LIP 0.769 2.926 0.00371 Yes No 
7 IP vs. MP 0.509 1.935 0.0539 No No 
8 IP vs. DT 0.429 1.723 0.0860 No No 
9 IP vs. TT 0.245 0.978 0.329 No No 
 
 
      Table 5.3. A. shows that IP has FIR levels higher than most of the oral 
anatomical sites and this is clear when compared at both 0.05 and 0.001 level of 
significance. There is a significant difference at 0.05 with RC, LC, FOM, VT, GN, 
and LIP; however there is no significant difference with MP, TT and DT. There was 
no significant difference between the three sites and the IP (at P=0.001) which had 
similar FIRs high when compared with the rest of the oral sites.  
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B-Tip of the Tongue (TT) 
No Comparison Diff of Means T Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 TT vs. RC 1.090 4.345 0.0000195 Yes Yes 
2 TT v s. LC 0.835 3.302 0.00108 Yes Yes 
3 TT vs. FOM 0.675 2.668 0.00807 Yes No 
4 TT vs. VT 0.659 2.465 0.0143 Yes No 
5 TT vs. GN 0.590 2.230 0.0265 Yes No 
6 TT vs. LIP 0.524 1.979 0.0488 Yes No 
7 TT vs. MP 0.263 0.995 0.321 No No 
8 TT vs. DT 0.184 0.732 0.465 No No 
  
 
 
      The FIR of TT was high when compared with other sites at level 0.05. This was 
particularly so when compared with the RC and LC. The least was with the lip. The 
difference of the FIR of the TT was non significant if compared with the MP and DT. 
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C-Dorsal Tongue (DT) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 DT vs. RC 0.906 3.642 0.000322 Yes Yes 
2 DT vs. LC 0.651 2.597 0.00990 Yes No 
3 DT vs. FOM 0.491 1.958 0.0513 No No 
4 DT vs. VT 0.476 1.791 0.0743 No No 
5 DT vs. GN 0.407 1.548 0.123 No No 
6 DT vs. LIP 0.340 1.295 0.196 No No 
7 DTvs. MP 0.0798 0.304 0.762 No No 
 
 
      The FIR readings of DT was high when compared with RC and LC, however 
there was no significant difference at both 0.05 and 0.001 when compared with the 
other oral sites.  
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D-Mid Palate (MP) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 MP vs. RC 0.826 3.145 0.00184 Yes No 
2 MP vs. LC 0.571 2.159 0.0317 Yes No 
3 MP vs. FOM 0.411 1.554 0.121 No No 
4 MP vs. VT 0.396 1.421 0.157 No No 
5 MP vs. GN 0.327 1.184 0.237 No No 
6 MP vs. LIP 0.260 0.943 0.346 No No 
 
 
      MP readings were significantly different at 0.05 when compared with RC and 
LC, however the FIR was not significant different from other sites of the oral cavity 
at 0.001 level.  
 
E-Lip 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 LIP vs. RC 0.566 2.154 0.0321 Yes No 
2 LIP vs. LC 0.311 1.175 0.241 No No 
3    LIP vs. FOM 0.151 0.570 0.569 No No 
4 LIP vs. VT 0.136 0.487 0.627 No No 
5 LIP vs. GN 0.0665 0.241 0.810 No No 
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      The FIR of LIP was the least highly ranked when compared with other oral sites. 
There is only significant difference at 0.05 when compared with RC. 
The rest of the oral sites GN, VT, FOM, LC and RC had no significant difference in 
the FIR when compared with one another in a pairwise at both levels of significance.  
 
F-Gingiva (GN) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 GN vs. RC 0.499 1.901 0.0583 No No 
2 GN vs. LC 0.245 0.924 0.356 No No 
3 GN vs. FOM 0.0842 0.318 0.750 No No 
4 GN vs. VT 0.0691 0.248 0.804 No No 
 
 
G-Ventral Tongue (VT) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 VT vs. RC 0.430 1.620 0.106 No No 
2 VT vs. LC 0.175 0.656 0.512 No No 
3 VT vs. FOM 0.0151 0.0566 0.955 No No 
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H-Floor of the Mouth (FOM) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 FOM vs. RC 0.415 1.656 0.0989 No No 
2 FOM vs. LC 0.160 0.634 0.526 No No 
 
 
I-Left Cheek (LC) 
No Comparison Diff of Means t Unadjusted P Level 0.05  Sig Level 0.001  Sig 
1 LC vs. RC 0.255 1.016 0.310 No No 
 
 
      Figure 5.1 shows the distribution of the data at different anatomical sites. The 
variation was expressed by the inter quartile range between the different locations 
and the median values between IP, TT, DT in particular, which were spectrally 
distinct and to some extent with MP and LIP relatively different, while the other 
spectral line graphs were overlapped and the values showed no statistically 
significant difference between the groups.  
     
      In viewing the graphs, relevant systematic spectral differences was observed 
between IP, DT and TT, while not for the rest of the oral sites (VT, FOM, RC, LC, 
GN, Lip i.e. the non keratinized sites). 
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Spectra interpretation 
 
       The technique of the OBS and the outcome graph results (figure 4.5) was 
discussed in the Patients, Material and Method section. The fluorescence line graph 
started (the recorded data) from 339nm up to 1020nm wavelength (pre-programmed 
OBS system). The spectrometer had a wavelength range of 430 to 730nm and the 
acquired data were analysed by the computer to display the final graph. 
 
      Figure 5.3 shows the averaged spectra obtained from the anatomical sites of all 
the participants. The line graphs were displayed in colours to discriminate the spectra 
excitation and emission fluorescence intensity level of each anatomical site. 
The line graphs started at 405nm wavelength (excitation wavelength of the diode 
laser emitted by the OBS) and the outcome did not show data till 430nm where the 
line graphs were noticed start rising up due to cellular emission of light in a blue 
wavelength range which was supposedly induced by certain endogenous 
fluorophores (mentioned in the review of lit figure 1.3.8 and 1.3.9). The endogenous 
fluorophore emissions (autofluorescence) continue rising and reach a peak at 500nm 
(green wavelength). The line graphs at this level showed a variation in the 
autofluorescence intensity level between the different oral locations with the highest 
to the lowest being RC, LC, GN, FOM, LIP, DT, TT, IP, VT and MP respectively. 
The fluorescence intensity level for all the anatomical sites then drops down when 
the wavelength reaches 600nm since there is no autofluorescence emission. At 
635nm the fluorescence intensity peaks rises again up to the peak which assumed to 
represent the PpIX emission wavelength. The emission ranged (from highest to 
lowest) IP, TT, DT followed by GN, LIP, MP, FOM, VT, LC, and RC respectively. 
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There were overlaps in both autofluorescence and PpIX fluorescence emission peaks 
in some anatomical locations as shown in the graphs of figure 5.3. 
 
      Normalisation of the spectra by transforming the data to the logarithm value is 
reliable method for statistical analysis and graphic interpretation. Graphs after 
normalisation of the spectra are shown in figure 5.4. 
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Figure 5.1. Fluorescence intensity ratio at (635/500nm) or red/green ratio of the normal oral mucosa at different anatomical sites. IP incisive papilla, MP mid 
palate, TT tip of the tongue, DT dorsal tongue, VT ventral tongue, FM floor of the mouth, RC right cheek, LC left cheek, GN gingiva, LP lip. 
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 Figure 5.2.  Normalization of fluorescence intensity ratio data of the normal oral mucosa at different anatomical sites. IP incisive papilla, MP mid palate,  
TT tip of the tongue, DT dorsal tongue, VT ventral tongue, FM floor of the mouth, RCright cheek, LC left cheek, GN gingiva, LP Lip. 
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Figure 5.3 Average fluorescence spectra excitation at (405) and emission recorded from the oral anatomical sites.  IP incisive papilla, MP mid palate, TT tip 
of the tongue, DT dorsal tongue, VT ventral tongue, FM floor of the mouth, RC right cheek, LC left cheek, GN gingiva, LP Lip. 
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Figure 5.4. Average-scale, normalized fluorescence spectra recorded from the oral anatomical sites.  IP incisive papilla, MP mid palate, TT tip of the tongue, 
DT dorsal tongue, VT ventral tongue, FM floor of the mouth, RC right cheek, LC left cheek, GN gingiva, LP Lip.
 
 
 
  
 
5.2 Fluorescence intensity ratio (FIR) measurements in relation to 
       the individual characteristics 
 
      As stated before, we have observed variations in person-to-person fluorescence 
intensity peaks at the same oral anatomical sites. This observation suggested that 
tissue fluorescence is altered due to variation in individual characteristics. 
Our hypothesis is that the alteration in the FIR was corresponded to the variation in 
individual characteristics such as; 
 
• Age 
• Gender 
• Presence of dental prosthesis 
• Presence of metabolic disease 
• Smoking habit 
• Alcohol consumption 
 
      The same set of data obtained from the oral anatomical sites of 32 patients which 
were 292 spectra readings were utilized for this part of result analysis (see appendix 
7 table Index 7.4).  
 
      The age ranged 21-84 with the mean age 59.2 years and Standard deviation 15.3 
years. The information regarding age, sex, medical and dental history and habits 
were obtained from the patients and recorded in the CRFs (case report forms), in 
addition to a special form designed by the author for this purpose (see appendix 
4&5), finally tabulated and used for the statistical analysis.  
  
      Unfortunately, the Glasgow site didn’t comply with the instructions to collect 
some of this information, so that the non-obtained data were treated as missing 
values. 
 
      Table Index 7.4 showed the individual characteristics and the fluorescence 
intensities at 500nm and 635nm of the oral anatomical sites for each patient. 
 
      The 1st three patients’ readings (PDD01, 02, 03) were not included because they 
were not taken from the sites chosen to be tested, therefore indicated as NI. The non 
obtained values were indicated as NO in the previous tables, however in these tables 
were indicated as missing Mi to avoid confusion with the non-parametric values of 
the individual characteristics (Yes & No and M&F). 
Table Index 7.5 showed the individual characteristics and the approximated FIR 
values (for statistical analysis) of the oral anatomical sites for each patient. 
 
 
   5.2.1 Comparison of FIR measurements of the oral anatomical sites 
             between the two age groups 
 
      A total of 292 FIR measurements obtained from the anatomical sites of 32 
patients were utilized for this part of study. 
 
      Since the number of the patients was limited, and of the young age group in 
particular, we have classified the ages into two groups, less than 50 years and over 50 
years and for the comparison. 
Table 5.4 showed the statistical description of the FIR readings of both age groups. It 
was observed that there was variation in the mean and median values between the 
age groups. The inter quartile range and the standard deviation of the data for both 
  
groups were similar which indicate the FIR readings were distributed approximately 
in the same pattern. 
 
Age groups 
No. of 
Patients 
No. of  FIR read Max Min Mean Median 25% 75% 
Std  
Dev 
Less than 50 9 86 4.240 0.1000 1.341 1.070 0.480 1.730 1.085 
over 50 23 206 5.610 0.1000 1.213 0.900 0.470 1.500 1.046 
 
Table 5.4. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites obtained from both age groups. 
 
      Comparison of the FIR readings between the two groups (male and female) using 
Mann-Whitney Rank Sum Test (non normal distribution data) found the difference in 
the median values between the two groups was not significant (P = 0.446). 
Therefore, there was not a statistically significant difference (p>0.05) between the 
FIR of the oral anatomical site readings obtained from the two age groups. 
 
      Comparison of the FIR values distribution; inter quartile range and the median 
values of the ages less than 50 and over 50 were shown in figure 5.5. 
 
     The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the age group. They were classified into two age groups and 
plotted in two line graphs to show the spectral lines distribution in one plot for the 
comparison as shown in figure 5.6. 
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Figure 5.5.  Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to age 
groups. 
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Figure 5.6. Average fluorescence spectra of all oral anatomical sites of the two age groups. 
 
  
   5.2.2 Comparison of FIR measurements of the oral anatomical sites  
             between the two genders 
  
      Gender of the patients included for this part of the trial was 16 males and 16 
females. The FIR measurements of the data sets were divided into two groups 
according to the sex of the patient. The data for this analysis were obtained from 
table Index 7.5.  
 
      The FIR measurements obtained from all the anatomical sites of the males were 
compared with that of the females. 
 
      A total of 292 readings (FIR) were analysed statistically obtained from 32 
patients. Table 5.5 showed the statistical description of the FIR readings of both 
genders. It was observed that there was a very slight difference in the mean and 
median values between male and female. The inter quartile range and the standard 
deviation of the data for both genders were approximately have the same pattern, 
which indicates closely similar distribution of the FIR readings (figure 5.7.).  
 
    
Gender 
No. of 
Patients 
No. of  FIR read Max Min Mean Median 25% 75% 
Std 
Dev 
Male 16 152 5.610 0.1000 1.254 0.850 0.470 1.650 1.136 
Female 16 140 5.140 0.180 1.244 0.950 0.460 1.590 0.971 
 
Table 5.5. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites obtained from both genders. 
 
  
      Comparison of the FIR readings between the two groups (male and female) using 
Mann-Whitney Rank Sum Test (non normal distribution data) found the value (P = 
0.455) was no statistically significant difference (p>0.05) between the two genders. 
 
Comparison of the FIR values distribution; inter quartile range and the median values 
of the male and female are shown in figure 5.7. 
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 Figure 5.7. Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to 
gender. 
 
  
      The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the gender. They were classified into male and female groups 
and plotted in two line graphs to show the spectral lines distribution in one plot for 
the comparison. It has been noticed there is difference in the line graphs between 
  
male and female as far as the autofuorescence and PpIX fluorescence, however the 
peak fluorescence intensity ratios were relatively approximate in relation to the 
values as shown in figure 5.8. 
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Figure 5.8. Average fluorescence spectra of all oral anatomical sites of the two genders. 
 
 
   5.2.3 Comparison of FIR measurements of the oral anatomical sites in 
             relation to the presence of dental prosthesis   
 
      Presence of removable or fixed prosthesis was anticipated as a factor might have 
influence on the oral mucosal fluorescence due to microbial accumulation, physical 
irritation and the inflammatory consequences of the tissues. 
 
  
The FIR measurements obtained from all the anatomical sites of the cases with dental 
prosthesis were compared with that of the non prosthesis. 
 
      A total of 218 readings (FIR) obtained from 24 patients were analysed 
statistically. The patients who were using prosthesis and included for the analysis 
were 12 and patient without prosthesis were12 too. 
 
      Presence of one or both removable prosthesis and any fixed prosthesis regardless 
of the number of units was considered as present (prosthesis), otherwise considered 
absent (non prosthesis). The FIR readings statistical description of the patients with 
prosthesis and non prosthesis are listed in table 5.6. 
 
State 
No of 
Patients 
No. of  FIR 
read 
Max Min Mean Median 25% 75% Std Dev 
Prosthesis 12 108 5.570 0.120 1.145 0.900 0.465 1.480 0.939 
Non Prosthesis 12 110 5.610 0.1000 1.512 1.125 0.540 2.270 1.269 
 
Table 5.6. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites of patients with prosthesis and non prosthesis. 
 
 
Comparison of the FIR between the patients with prosthesis and non prosthesis, 
using Mann-Whitney Rank Sum Test, found that the value (P = 0.063) was no 
statistically significant difference (p>0.05) in the FIR readings between the two 
groups. Comparison of the FIR values distribution, inter quartile range and the 
median values of the prosthesis and non prosthesis are shown in figure 5.9.  
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Figure 5.9. Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to 
presence of dental prosthesis. 
  
 
 
      The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the presence or absence of dental removable or fixed 
prosthesis. They were classified into prosthesis and non prosthesis groups and plotted 
in two line graphs to show the spectral lines distribution in one plot for the 
comparison. The line graphs show noticeable variation in the PpIX fluorescence 
which indicates the lower red green ratio of the presence of prosthesis spectrally as 
shown in figure 5.10. 
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Figure 5.10. Average fluorescence spectra of all oral anatomical sites in relation to presence 
of dental prosthesis. 
 
 
 
 
   5.2.4 Comparison of FIR measurements of the oral anatomical sites in 
            relation to presence of the metabolic diseases 
 
      History of the systemic diseases was collected from the patient recruited for the 
trial. Metabolic diseases like diabetes and thyroid (hypo or hyper) function were 
suspected to have influence on the cell chemical or structural components.  
The FIR measurements obtained from all the anatomical sites of the cases who were 
having metabolic diseases was compared with that who had metabolic diseases was 
compared with those who did not have metabolic disease. 
 
      A total of 218 readings (FIR) were analysed statistically, obtained from 24 
patients. They were 192 readings obtained from 20 recruited cases that didn’t have 
  
metabolic diseases and 26 readings obtained from 4 having metabolic diseases. The 
cases that had diseases were indicated as disease, while the others as non disease in 
the summary table (table 5.7). 
 
Status 
No. of 
Patients 
No. of FIR 
Readings 
Max Min Mean Median 25% 75% 
Std 
Dev 
Disease 4 26 2.740 0.320 1.062 0.875 0.510 1.220 0.716 
Non 
Disease 
20 192 5.610 0.1000 1.366 0.980 0.500 1.855 1.172 
 
Table 5.7. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites of disease and non disease. 
 
 
 
      The sample size, mean and median values and the inter quartile range of the FIR 
that were collected from the two groups showed non normal distribution data, 
therefore Mann-Whitney Rank Sum Test was used to compare between the two 
groups (disease and non disease).  
The value found was P = 0.465, therefore there was not statistically significant 
difference (p>0.05) between the FIR values of the readings obtained from cases with 
metabolic disease and non metabolic disease. 
 
Comparison of the FIR values distribution, inter quartile range and the median values 
of the disease and non disease are shown in figure 5.11. 
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Figure 5.11. Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to 
presence of metabolic diseases. 
 
 
 
 
      The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the presence or absence of systemic or metabolic diseases. 
They were classified into disease and non disease groups and plotted in two line 
graphs to show the spectral lines distribution in one plot for the comparison.  It was 
noticed variation in the peak intensities of the autofluorescence and PpIX between 
the two groups; however the red/green ratios of these peaks were relatively parallel 
as shown in figure 5.12. 
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Figure 5.12. Average fluorescence spectra of all oral anatomical sites in relation to the 
presence of metabolic diseases. 
 
 
 
 
   5.2.5 Comparison of FIR measurements of the oral anatomical sites in 
             relation to smoking  
 
      The information was collected from the patient information sheet about smoking 
habit regardless of the number of cigarette per day. They were divided and classified 
into two groups; smoker and non smoker.  
The FIR measurements obtained from all the anatomical sites of the smokers and the 
non smokers was compared statistically. 
 
      A total of 218 readings (FIR) were analysed statistically obtained from 24 
patients. They were 116 readings obtained from 12 patients who were smoking 
cigarette and 102 readings obtained from 12 non smokers.  
  
The cases that had smoking habit were indicated as smoker, while the others as non 
smoker in the summary table 5.8. 
 
Status 
No of 
Patients 
No of FIR 
Readings 
Max Min Mean Median 25% 75% 
Std 
Dev 
Smoker 12 116 5.610 0.1000 1.387 1.045 0.505 1.855 1.222 
Non 
Smoker 
12 102 4.240 0.120 1.265 0.920 0.500 1.520 1.017 
 
Table 5.8. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites of smokers and non smokers. 
 
 
      There was very slight difference in the mean and median values which indicates 
skewed and non normal data distribution. The difference in the median values 
between the two groups was assessed using Mann-Whitney Rank Sum Test. We have 
found the probability was (P = 0.727) which indicates that there was no significant 
difference (p>0.05) between the FIR of the smoker and non smoker readings.   
 
Comparison of the FIR values distribution, inter quartile range and the median values 
of the smokers and non smokers are shown in figure 5.13. 
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 Figure 5.13. Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to 
smoking habit. 
 
 
 
 
 
      The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the presence or absence of smoking habit. They were 
classified into smokers and non smokers groups and plotted in two line graphs to 
show the spectral lines distribution in one plot for the comparison. The 
autofluorescence peaks look the same with slight elevation in the smokers PpIX peak 
as shown in figure 5.14. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. Average fluorescence spectra of all oral anatomical sites in relation to the 
presence of smoking habit. 
 
 
 
 
 
   5.2.6 Comparison of FIR measurements of the oral anatomical sites in 
             relation to alcohol drinking 
 
      The information was collected from the patient information sheet about alcohol 
drinking regardless of the number of cigarette per day. They were divided and 
classified into two groups; uses of alcoholic and non uses of alcohol.  
The FIR measurements obtained from all the anatomical sites of the alcoholic and the 
non alcoholic were compared statistically. 
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      A total of 218 readings (FIR) were analysed statistically obtained from 24 
patients. They were 126 readings obtained from 13 patients who were alcohol users 
and 92 readings obtained from 11 non alcohol users. 
The group that used alcohol was indicated as alcohol, while the other as non alcohol 
in the summary table (table 5.9). 
 
Status 
No of 
Patients 
No of FIR 
Read 
Max Min Mean Median 25% 75% Std Dev 
Alcohol 13 126 5.610 0.1000 1.424 1.020 0.550 1.910 1.233 
Non alcohol 11 92 5.570 0.150 1.202 0.960 0.475 1.505 0.964 
 
Table 5.9. Descriptive statistics summary of the FIR measurements of the oral anatomical 
sites of alcohol users and non alcoholic users. 
 
 
Slight differences were observed in the mean and median values which indicate 
skewed and non normal data distribution.  
The difference in the median values between the two groups was assessed using 
Mann-Whitney Rank Sum Test. The analysis showed that the probability was P 
=0.344, which indicates that there was no significant difference (p>0.05) between the 
FIR of the alcohol and non alcohol users of the oral anatomical site readings.   
 
Comparison of the FIR values distribution, inter quartile range and the median values 
of the alcohol and non alcohol groups are shown in figure 5.15. 
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Figure 5.15. Fluorescence intensity ratio at (635/500nm) or red/green ratio in relation to 
alcohol consumption. 
 
 
      The spectra of all oral anatomical sites obtained from the sample size were 
averaged in relation to the presence or absence of alcohol consumptoion. They were 
classified into alcohol and non alcohol groups and plotted in two line graphs to show 
the spectral lines distribution in one plot for the comparison. The autofluorescence 
peaks look slightly elevated in non alcohol group while the PpIX peaks were the 
same level of the two groups as shown in figure 5.16. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16. Average fluorescence spectra of all oral anatomical sites in relation to alcohol 
consumption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 Fluorescence intensity ratio (FIR) measurements in  
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       detecting the oral lesions 
 
      A total of 134 spectral readings were obtained from 47 surgically biopsied areas 
taken from 35 patients for this part of the trial and included in the result analyses.  
Three PDD readings (3, 34, and 35) and some lesion and normal sites (see appendix 
7 table Index 7.6&7) were not obtained because of management difficulties and/or 
technical errors.   
 
      As mentioned previously, the method of collecting the data which were tabulated 
by including all the readings obtained from the biopsy areas and listed in two 
columns of readings (table Index 7.6), that was because two readings were obtained 
from most of the lesions which were surgically punch biopsied. The table showed the 
number of the biopsies obtained from each patient, site of the biopsy, 
histopathological diagnosis and the fluorescence intensity levels at 500nm and 
635nm and their ratios (red/green ratio) for the lesion and normal sites. The 
measurements of PDD001-27 were done in Dundee and PDD028-35 in Glasgow. 
Table Index 7.7 (appendix 7) showed the approximated values of the fluorescence 
intensity ratios that were used for the statistical analysis. 
Readings not obtained from the patients or some biopsies sites because of technical 
errors or management difficulties were listed as NO. 
 
 
 
 
    5.3.1 Detecting the lesion and normal sites 
  
 
      All the lesion site readings and the normal site readings (more than 5mm away 
from the lesion) obtained were compared statistically to detect the reliability of the 
OBS and 5-ALA in the detection of the clinically suspicious oral lesions in general.  
 
Two methods of comparison were followed between the lesions and normal sites. 
They were: 
 
      1-Comparison between the 1st readings, 2nd readings and normal readings. This 
method was conducted to assess the reliability of the two readings obtained from the 
lesions and the normal sites for the detection of the oral lesions.  
 
      The mean, median, standard deviation and other values were listed in the 
summary table 5.10. 
 
Site 
No of FIR 
Read 
Max Min Mean Median 25% 75% Std Dev 
Lesion 1st Reading 46 15.000 0.0900 1.885 1.290 0.670 2.430 2.331 
Lesion 2nd Reading 45 7.090 0.120 1.730 1.360 0.680 2.275 1.483 
Normal Reading 43 2.120 0.0900 0.802 0.690 0.310 1.108 0.557 
 
Table 5.10. Descriptive statistics summary of the 1st, 2nd lesion and normal sites FIR.  
 
      The three groups of readings were compared using one way analysis of variance. 
The FIR data were non-normally distributed, therefore Kruskal-Wallis One Way 
  
Analysis of Variance on Ranks test was applied to compare between the groups (the 
three readings)  
 
      The differences in the median values among the three groups was great (H = 
15.507 with 2 degrees of freedom) so there was a statistically significant difference 
(P = <0.001) between the lesion readings and normal site. 
Using Dunn’s Method for all Pairwise Multiple Comparison Procedures, there was 
statististically non-significant difference between the 1st and 2nd readings, while there 
was a statistically significant difference between each of the lesion readings   (1st and 
2nd ) when compared with the normal site readings as shown in table 5.11. 
 
Comparison Diff of Ranks Q P<0.05 
Lesion 2nd Reading vs Normal Reading 29.263 3.534 Yes 
Lesion 2nd Reading vs Lesion 1st Reading 2.035 0.250 No 
Lesion 1st Reading vs Normal Reading 27.229 3.306 Yes 
 
Table 5.11. Pairwise comparison between the groups. 
 
 
      Comparison of the readings and the FIR values and the description were plotted 
in figure 5.17.  
 
 
  
1st Reading                2nd Reading                    Normal
   lesion                          lesion
                               Site of Reading
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 R
a
ti
o
0
2
4
6
8
 
Figure 5.17. Fluorescence intensity ratio at (635/500nm) or red/green ratio of the 1st and 2nd 
Lesion and normal site readings. 
 
 
      To compare the measurements spectrally, the figures show the average of each 
sample size obtained (1st, 2nd lesion and normal sites) in one line graph. Number of 
FIR Readings (46, 45 lesion and 43 normal as shown in table 5.8) was averaged to 
form the three line graphs for the spectra comparison. We drew two graphs, on real 
time measurements as obtained from the patients (figure 5.18 ) and the spectra after 
normalization (transform the data to Logarithm values) to give better spectra 
comparison interpretation (figure 5.19). The line graphs of the two lesion site 
measurements and the fluorescence intensity peaks were noticed lower in the 
autofluorescence (green or 500nm) region when compared with the normal spectra 
  
which was higher. However, the 1st and 2nd lesion readings were at the same level at 
PpIX (red or 635nm) region (Figure 5.18).  
 
      There was a difference in the green region peaks of the 1st and 2nd lesion readings 
which may affect the red/green ratio (FIR), but the difference was statistically non 
significant.  
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Figure 5.18. Average fluorescence spectra of 46 1st and 45 2nd lesion and 43 normal site 
readings. 
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Figure 5.19. Normalization of the average fluorescence spectra of 46 1st and 45 2nd lesion and 
43 normal sites. 
 
 
      2- The 2nd method of comparison was conducted between lesion sites and normal 
sites using the same sets of readings.  
The 1st and 2nd readings obtained from the lesion sites, which consisted of all types of 
lesions, were merged together to form one single group (91 readings) and indicated 
in the tables and figures as lesion sites. These readings were compared with the 
normal sites (43 readings) and categorized into two groups, lesion sites (1st & 2nd 
readings combined) and normal sites.  
  
      Descriptive statistic of the FIR levels were calculated and summarized in table 
5.12. 
 
 
 
 
  
 
Site No of FIR Read Max Min Mean Median 25% 75% Std Dev 
Lesion Sites 91 15.000 0.0900 1.808 1.350 0.680 2.305 1.949 
Normal Sites 43 2.120 0.0900 0.802 0.690 0.310 1.108 0.557 
 
Table 5.12. Descriptive statistics summary of FIR readings at the lesion and normal sites 
 
 
      The results showed that the mean values were noticeably higher than the median 
values of the FIR of the lesion and normal sites, this indicates that the distribution of 
the data were skewed and non normal in distribution at both sites.  
There was a noticeable difference between the minimum and maximum values which 
indicate variation in the data obtained from the lesion sites. Dispersion of the data 
was also indicated by the high standard deviation which emphasis the variation in 
cellular fluorescence emission or FIR values of the different oral lesion types, it was 
also noticeable in comparison with the normal sites. Furthermore, it was also 
indicated by the inter quartile range.  
The inter quartile range of the lesion site shows the data were taken from different 
kinds of oral lesions (hyperkeratosis, inflammatory lesions, and dysplastic lesions) 
which interpret the variation of the FIR values obtained from these locations as 
plotted in figure 5.20.  
 
      Comparison between the two readings in non normal data distribution, Mann-
Whitney rank sum test was recommended to detect the probability. The analysis 
  
showed that the statistically significant difference in the median values between the 
two groups rejected the null hypothesis that there was no difference between the 
fluorescence of the lesion and normal (Mann-Whitney U Statistic= 2781.000, T = 
2078.000); therefore, there was a highly significant difference between the lesion and 
normal site readings (P = <0.001). 
 
      Comparison and the distribution of the data were shown in figure 5.20. 
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Figure 5.20. Fluorescence intensity ratio at (635/500nm) or red/green ratio of the lesion and 
normal site readings. 
 
 
      The box plot graphs shows the data distribution, the inter quartile range, and 
median values. The total sample size of the lesion (91) and normal (43) spectra as 
  
shown in table 5.10 were averaged to draw the two line graphs of the lesion and 
normal site readings for comparison. 
 
      The spectra graphs show the variability in the fluorescence intensity peaks at the 
autofluorescence (green or 500nm) and PpIX (red or 635nm) regions. Both real time 
measurements and spectra after normalization show the difference which the 
red/green ratios (FIR) were statistically significant as shown in figures 5.21 and 5.22 
respectively.  
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Figure 5.21. Average fluorescence spectra of 91 lesion and 43 normal sites 
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Figure 5.22. Normalization of the average fluorescence spectra of 91 lesion and 43 normal 
sites. 
 
 
 
   5.3.2 Detecting clinically suspicious oral lesions 
 
      The same set of readings (FIR) were classified according to the biopsy results 
and analysed statistically. 
       
      Neither the investigators, who took the fluorescence measurement nor the 
pathologist, who wrote the reports were aware of each other outcome i.e. they were 
blinded to the findings. The values of the FIR were classified into three groups 
according to the microscopic reports obtained from the pathologist who diagnosed 
the biopsies microscopically.  
 
 
 
  
      The classification was based on the following microscopic findings; 
  
1- Hyperkeratotic; Lesions show thickness of the keratin layer (parakeratosis or 
orthokeratosis) with no evidence of any inflammatory cell infiltrate of the 
submucosa (lamina properia) or superimposed with candidiasis. 
2- Inflammatory lesions: Keratotic and non keratotic lesions showed evidence of 
band of inflammatory or lymphocytic infiltration in the submucosa 
(Lichenoid reaction and lichen planus) and /or superimposed with 
candidiasis. 
3- Dysplasia; cellular atypia, severe dysplasia and squamous neoplastic changes.   
 
      FIR readings of the diagnosed lesions were compared with one another and with 
the normal site readings. Summary table (table 5.13) showed sample size (No of FIR 
Read) obtained from each location and the descriptive statistics.  
 
 
  Site                  No of FIR Read      Max       Min       Mean     Median       25%        75%       Std Dev 
Normal                         43             2.120     0.0900        0.802     0.690            0.310       1.108         0.557 
Hyperkeratotic            26           15.000     0.0900       1.757     1.180              0.460       2.080         2.834 
Inflammatory lesion  47            5.340      0.130          1.644    1.100              0.625        2.365        1.469 
Dysplasia 18             7.090     0.850           2.309    1.890             1.350        3.100        1.456 
 
Table 5.13. Summary of the FIR measurements descriptive statistics of the groups (type of 
the lesions). 
 
  
      Since the data were unequal in size and not normally distributed Kruskal-Wallis 
One Way Analysis of Variance was used to compare between the groups. 
It was found the differences in the median values among all the groups were great (H 
= 23.864 with 3 degrees of freedom) enough to reject the null hypothesis (P = 
<0.001) so that there was a highly statistically significant difference between all sites 
(all types of lesion and normal site readings). 
 
      Dunn's Method was applied in All Pairwise Multiple Comparison Procedures to 
compare between the two groups.   
 
Comparison Diff of Ranks Q P<0.05 
Dysplastics vs Normal 51.647 4.738 Yes 
Dysplastics vs Hyperkeratotic 32.299 2.713 Yes 
Dysplastics vs Inflammatory 27.462 2.552 No 
Inflammatory lesion vs Normal 24.185 2.952 Yes 
Inflammatory  vs Hyperkeratotic 4.838 0.510 No 
Hyperkeratotic vs Normal 19.347 2.006 No 
 
Table 5.14. Pairwise comparison between the groups (type of the lesions). 
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Figure 5.23. Fluorescence intensity ratio at (635/500nm) or red/green ratio of the diagnosed 
oral lesions and normal sites. 
 
 
 
      The total sample size of each type of diagnosed oral lesion and normal site 
spectra were averaged to display the shape of the line graphs and show the 
autofluorescence and PpIX peaks. 
 
      A total of  43 normal, 26 benign hyperkeratotic, 47 inflammatory and 18 
dysplasia spectra were averaged in relation the histology classification group and 
displayed into four line graphs as shown in figure  5.24. 
 
  
      The autofluorescence intensity (green spectrum) of the normal site spectra is the 
highest peak followed by benign hyperkeratotic, inflammatory and dysplasia lesions 
respectively. However the PpIX (red) peak was lowest in normal site spectra and 
increases in the lesion sites. There was noticeable overlap between inflammatory and 
dysplasia PpIX peaks as shown in the spectra graphs (figure 5.24 the real time 
averaged spectra and figure 5.25, spectra after normalisation or transformed data).  
The spectra graphs show the variability in the fluorescence intensity peaks at the 
autofluorescence (green or 500nm) and PpIX (red or 635nm) regions. This 
comparison was noticed both in real time spectra measurements and after 
normalization. This finding comes in consistent with the results of the statistical 
analysis presents in table 5.14.  
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Figure 5.24. Averages of the fluorescence spectra obtained from 43 normal, 26 
hyperkeratotic lesion, 47 inflammatory lesion and 18 dysplastic lesion sites.  
 
 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
420 470 520 570 620 670 720
Wavelength (nm)
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
)
No rmal
H yperkerato t ic
Inf lammato ry
Dysplast ics
 
 
Figure 5.25. Normalized of the average fluorescence spectra obtained from 43 normal, 26 
hyperkeratotic lesion, 47 inflammatory lesion and 18 dysplastic lesion sites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   5.3.3 Sensitivity and specificity of the use Fluorescence 
  
             intensity ratio (FIR) measurements in detecting oral 
             premalignant (clinically suspicious) lesions 
 
      The data in appendix 7 table Index 7.7 were used for this part of the result 
section. Fluorescence intensity ratios of the diagnosed lesions and normal sites were 
utilized to detect the sensitivity and specificity of fluorescence in assessing clinically 
suspicious oral lesions. 
 
    5.3.3.1 Sensitivity and specificity of FIR in detecting oral lesions 
 
 
      For optimal data analysis, FIR should be obtained from normal and abnormal 
sites in each patient. Since the technique of data collection was two readings 
obtained from the lesion sites and one from the normal site (more than 5mm away 
from the lesion border), it would be wise to compare the 1st readings only of the 
lesions regardless of the diagnosis with the readings obtained from the normal sites. 
This occurred in 43 biopsy site since the normal readings from four of the biopsied 
patients were not obtained (biopsy 2, 3, 39, and biopsy 42 see table Index 7.6&7).  
Figure 5.26 shows the FIR of the 1st lesion and normal site readings of 47 biopsies. 
Biopsy no. 2,3,39 and 42 showed missing normal reading, hence will not be included 
in the analysis. The data from these sites were not used in analyzing the sensitivity 
and specificity of FIR in detecting oral lesions, therefore the 1st readings of a total of 
42 biopsy site readings were only included, therefore a total of 84 measurements 
were included for the analysis. 
       
       The FIR of the histologically abnormal (lesion) sites were greater than those of  
the normal sites except for the readings from biopsies no. 6, 11 and 41 which were 
readings taken from the tongue and floor of the mouth. Because of considerable 
  
patient –to– patient variation in FIR values, the separation between abnormal and 
normal could be better visualized when the abnormal/normal ratio were calculated to 
obtain the cutoff value.  
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Figure 5.26. Comparison of the FIR values of the lesion and normal site readings. Despite 
patient-to-patient variability, it is clearly observed the disease site readings (blue bars) are 
greater than the normal site readings. Data from biopsy 2, 3, 25, 39 and 42 were missing and 
No. 48 representing the cutoff point (1.05). 
 
 
      The cutoff points were obtained by calculating the standard deviation of all 
groups to discriminate between the upper and lower values. 
One Standard Deviation of the total of normal and lesion readings was 1.05 and 
considered cutoff point as shown in figure 5.26. 
 
      If the FIR value of the clinically identified lesion was greater than the cutoff 
point then the spectroscopic reading was considered true positive. Otherwise it was 
classified as false negative. If the FIR value obtained from the normal site was less 
than the cutoff point, then considered as true negative. Otherwise, if above 1.05 it 
  
was considered as false positive. Using this value (1.05) as a cutoff point to classify 
the FIR readings into true positive and negative results was shown in table 5.15. 
 
 
 
 
 
 
Table 5.15. Sensitivity and specificity of FIR value 
in detecting oral lesions. 
 
      By following this criterion the sensitivity yielded was 59.5% (true positive/true 
positive + false negative, 25/42) and specificity was 73.8% (true negative/true 
negative + false positive 31/42). The positive predictive value (PPV) was 69.4% 
(true positive TP / (TP + FP) total positives, 25/36) and negative predictive value 
(NPV) was 65% (true negative TN / (FN + TN) total negatives, 31/48). 
 
 
    5.3.3.2 Sensitivity and specificity of FIR in detecting potentially  
                 malignant oral lesions 
 
      To determine the sensitivity and specificity of the use of FIR measurements in 
detecting the potentially malignant (clinically suspicious) oral lesions and their 
normal site, three comparisons were conducted;  
 
 
 
     5.3.3.2.1 Comparison between FIR measurements of dysplasia   
                     lesions and the normal sites 
Site Positive FIR Negative FIR Total 
Lesion 25 17 42 
Normal 11 31 42 
Total 36 48  
  
 
      The 1st readings of eight histologically diagnosed dysplasia lesions and normal 
(more than 5mm away from the lesion) i.e. total of 16 measurements were utilized 
for the analysis, since normal site FIR measurement was not obtained from patient 
no. 28* (see appendix 7 table Index 7.7) so the dysplasia reading was not included. 
 
      The same method of analysis was followed by taking one standard deviation of 
the 1st reading of the lesion and normal sites and considered as a cutoff point to 
discriminate between the two groups. If the FIR value of the dysplasia lesion was 
greater than the cutoff point then the spectroscopic reading was considered true 
positive. Otherwise it was classified as false negative. If the FIR value obtained from 
the normal site was less than the cutoff point, then considered as true negative. Using 
this value (1.127) as a cutoff point to classify the FIR readings into true positive and 
negative was shown in table 5.16. 
 
      Figure 5.27 showed the FIR measurements obtained from eight dysplasia and 
normal sites and the cutoff point. It was observed that all the FIR measurements of 
dysplasia were greater than that of the normal sites. Cutoff point was noticed higher 
than all the normal measurements and lower than that of dysplasia as shown in figure 
5.27. 
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Figure 5.27. Comparison of the FIR measurements of the dysplasia and normal sites. 
 
 
 
       By following this criterion the sensitivity yielded was 100 % (true positive/true 
positive + false negative, 8/8) and specificity was 100% (true negative/true negative 
+ false positive, 8/8) as shown in table 5.16. The PPV was 100% (true positive TP / 
(TP + FP) total positive, 8/8) and the NPV was 100% (true negative TN / (FN + TN) 
total negative, 8/8)  
 
 
 
 
 
 
 
 
 
Table 5.16. Sensitivity and specificity of FIR value in 
discriminating between dysplasia and normal sites. 
 
 
 
 
 
 
     5.3.3.2.2 Comparison between FIR measurements of inflammatory 
Site Positive FIR Negative FIR Total 
Dysplasia 8 0 8 
Normal 0 8 8 
Total 8 8  
  
                     lesions and the normal site readings 
 
      The 1st readings of twenty four biopsied inflammatory lesions and their normal 
(more than 5mm away from the lesion border) sites were used for this part of study. 
A total of 44 measurements were utilized for the analysis, since normal site FIR 
measurements were not obtained from patient no. 1 (biopsy 2) and patient no.30 
(biopsy 2) (see appendix 7 table Index 7.7) so the inflammatory readings of these 
readings were not included. 
 
      The same method of analysis was followed by taking the value of one standard 
deviation of all the 1st reading of the lesion and normal sites and considered as a 
cutoff point to discriminate between the two groups. 
If the FIR value of the inflammatory lesion was greater than the cutoff point then the 
spectroscopic reading was considered true positive (statistically). Otherwise it was 
classified as false negative. If the FIR value obtained from the normal site was less 
than the cutoff point, then considered as true negative. Otherwise it was classified as 
false positive.  
Figure 5.28 has shown the FIR measurements obtained from the inflammatory 
lesions, normal sites and the cutoff point. It was observed that the FIR measurements 
of 10 inflammatory lesions were greater than the Cutoff point hence considered true 
positive and seven of the normal sites considered false positive. 
 The values of 15 normal readings were (below the cutoff point) considered true 
negative and 12 inflammatory readings considered false negative.   
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Figure 5.28. Comparison of the FIR measurements obtained from the inflammatory lesions 
and normal sites. 
 
 
      By following this criterion the sensitivity yielded was 45% (true positive/true 
positive + false negative, 10/22) and specificity was 68% (true negative/true negative 
+ false positive, 15/22) as shown in table 5.17. The PPV was 58% (true positive TP / 
(TP + FP) total positive, 10/17) and NPV was 55% (true negative TN / (FN + TN) 
total negative, 15/27)  
 
 
 
 
 
 
 
 
 
Table 5.17. Sensitivity and specificity of FIR value in discriminating  
between inflammatory lesions and normal sites. 
 
 
 
 
 
Site Positive FIR Negative FIR Total 
Inflammatory lesion 10 12 22 
Normal 7 15 22 
Total 17 27  
  
     5.3.3.2.3 Comparison between FIR measurements of lichen planus 
                     and lichenoid lesions with the normal sites 
 
 
      The 1st readings of eighteen histologically diagnosed lichen planus (Lp) and 
lichenoid lesions (LL) and normal (more than 5mm away from the lesion border) i.e. 
total of 36 measurements were utilized for the analysis, since normal site FIR 
measurement was not obtained from patient no. 30* (see appendix 7 table Index 7.7) 
so the lesion reading was not included. 
 
      The same method of analysis was followed by merging the two sets of readings 
(the 1st reading of the Lp&LL and normal) and taking the value of one standard 
deviation of readings and considered as a cutoff point to discriminate between the 
two groups. If the FIR value of the Lp&LL lesion was greater than the cutoff point 
then the spectroscopic reading was considered true positive. Otherwise it was 
classified as false negative. If the FIR value obtained from the normal site was less 
than the cutoff point, then considered as true negative, otherwise was considered 
false negative. 
 
      Figure 5.29 showed the FIR measurements obtained from nineteen Lp&LL, The 
same number (but one missing value i.e. 18 readings) from the normal sites and the 
cutoff point. It was observed that the FIR measurements of ten Lp&LL biopsy sites 
were higher than the cuttoff point and hence considered true positive. While 8 
readings obtained from the normal sites were greater than the cuttoff point and 
considered false positive. Ten of the normal readings were greater than the cuttoff 
point and considered false negative, while 8 of Lp&LL were less than the cuttoff 
point and considered true negative for the analysis. 
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Figure 5.29. Comparison of the FIR measurements of the Lp&LL and normal sites. Biopsy 
No.2 has no normal reading and was not included. 
 
      Using this value (0.751) as a cutoff point to classify the FIR readings into true 
positive and negative was shown in table 5.18. By following this criterion the 
sensitivity yielded was 55 % (true positive/true positive + false negative, 10/18) and 
specificity was 55% (true negative/true negative + false positive, 10/18) as shown in 
table 5.15. The positive predictive value was 55% (true positive TP / (TP + FP) total 
positive, 10/18) and negative predictive value was 55% (true negative TN / (FN + 
TN) total negative, 10/18). 
 
Site Positive Negative Total 
Lp&LL 10 8 18 
Normal 8 10 18 
Total 18 18  
 
Table 5.18. Sensitivity and specificity of FIR value in 
discriminating between Lp&LL and normal sites. 
     
  
5.3.3.3 Comparison between FIR measurements of dysplasia and 
                other oral lesions 
 
 
      To determine the sensitivity and specificity of the use of FIR measurements in 
detecting dysplasia, the following comparisons were conducted; 
 
     5.3.3.3.1 Comparison between FIR measurements of dysplastic and 
                      hyerkeratotic lesions 
 
      The 1st and 2nd measurements of nine histologically diagnosed dysplasia lesions 
and the 1st and 2nd readings from the same sample size selected in sequence of benign 
hyperkeratosis (total of 36 FIR measurements) were included in this analysis 
(appendix 7 table Index 7.7).  
 
      Figure 5.30 showed the FIR measurements of the dysplasia and benign 
hyperkeratosis histologically diagnosed lesions. Six hyperkeratosis measurements 
were noticed higher than the cutoff point (false positive), while fourteen dysplasia 
measurements exceeded the point (true positive). 
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Figure 5.30. Comparison of the FIR measurements of the dysplasia and benign 
hyperkeratosis. 
 
 
      Using the value of one standard deviation (1.323) as a cutoff point to classify the 
FIR readings into true positive and negative results is shown in table 5.19, it was 
noticed that the sensitivity yielded was 77.7% (true positive/true positive + false 
negative, 14/18) and specificity was 66.6% (true negative/true negative + false 
positive, 12/18). The PPV was 70% (true positive TP / (TP + FP) total positive, 
14/20) and the NPV was 75% (true negative TN / (FN + TN) total negative, 12/16). 
 
 
 
 
 
 
Table 5.19. Sensitivity and specificity of FIR value in  
discriminating between dysplasia and benign hyperkeratosis sites. 
 
 
 
 
Site Positive FIR Negative FIR Total 
Dysplasia 14 4 18 
Hyperkeratosis 6 12 18 
Total 20 16  
  
     5.3.3.3.2 Comparison between FIR measurements of dysplasia and 
                     inflammatory (lichen planus and lichenoid) lesions 
 
 
      The 1st readings of nine histologically diagnosed dysplasia lesions and the 1st 
readings from the same sample size of  inflammatory lesions (lichen planus and 
lichenoid lesion) i.e. total of 36 FIR measurements were randomly selected and 
included in this analysis (appendix 7 table Index 7.7). 
 
      Figure 5.31 shows the FIR measurements of the dysplasia and inflammatory 
lesions (lichen planus and lichenoid lesion) and the cutoff point (no.19 equal to 
1.431). Six of the inflammatory lesions representing lichen planus and lichenoid 
lesions were noticed higher than the cutoff point (false positive) and twelve were true 
negative, while thirteen dysplasia lesions were considered true positive and five false 
negative. 
 
1.42
0
1
2
3
4
5
6
7
8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
Site of Reading (No.37 cutoff point)
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 R
a
ti
o
Dysplasia
LP&LL
 
 
   Figure 5.31. Comparison of the FIR measurements of the dysplasia and inflammatory 
lesions (lichen planus and lichenoid lesions). 
 
  
      Using the value of one standard deviation (1.431) as a cutoff point to classify the 
FIR readings into true positive and negative results is shown in table 5.20. Six of the 
inflammatory lesions representing lichen planus and lichenoid lesions were noticed 
higher than the cutoff point (false positive) and twelve were true negative, while 
thirteen dysplasia lesions were considered true positive and five false negative. 
 
      It was noticed that the sensitivity yielded was 72.2% (true positive/true positive + 
false negative, 13/18) and specificity was 66.6% (true negative/true negative + false 
positive, 12/18). The PPV was 68 % (true positive TP / (TP + FP) total positive, 
14/20) and the NPV was 70% (true negative TN / (FN + TN) total negative, 12/17). 
 
 
 
 
 
 
 
 
 Table 5.20. Sensitivity and specificity of FIR value in Discriminating  
between dysplasia and inflammatory (lichen planus and lichenoid lesions) sites. 
 
 
 
     5.3.3.3.3 Comparison between FIR measurements of dysplasia and 
                     inflammatory (Candidal leukoplakia) lesions 
 
      The 1st readings and 2nd readings obtained from five histologically diagnosed 
lesions candidal leukoplakia and the same sample size of dysplasia were included for 
this analysis. 
 
Site Positive FIR Negative FIR Total 
Dysplasia 13 5 18 
Lichen planus  
& Lichenoid Lesion 
6 12 18 
Total 19 17  
  
      A total of 20 FIR measurements were used to compare between the two groups. 
Figure 5.32 showed the FIR measurements of the dysplasia and inflammatory lesions 
and the cutoff point (no. 21 equal to 1.816). 
 
       Seven of the inflammatory lesions classified as candidal leukoplakia lesions 
were noticed higher than the cutoff point and considered statistically false positive 
(non dysplastic lesions and have higher fluorescence than dysplasia) and three were 
lower than the cutoff point and considered true negative, while seven dysplasia 
lesions were considered true positive and three false negative. 
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   Figure 5.32. Comparison of the FIR measurements of the dysplasia and inflammatory 
lesions (candidal leukoplakia). 
 
 
      Using the value of one standard deviation (1.816) as a cutoff point to classify the 
FIR readings into true positive and negative results is shown in table 5.21. Seven of 
the inflammatory lesions representing candidal leukoplakia lesions were noticed 
  
higher than the cutoff point (false positive) and three were true negative, while seven 
dysplasia lesions were considered true positive and three false negative. 
  
      It was noticed that the sensitivity yielded was 70% (true positive/true positive + 
false negative, 7/10) and specificity was 30% (true negative/true negative + false 
positive, 3/10). The PPV was 50% (true positive TP / (TP + FP) total positive, 7/14) 
and the NPV was 50% (true negative TN / (FN + TN) total negative, 3/6). 
 
 
 
 
 
 
 
          
 
Table 5.21. Sensitivity and specificity of FIR value in Discriminating  
between dysplasia and inflammatory (candidal leukoplakia) sites. 
Site Positive FIR Negative FIR Total 
Dysplasia 7 3 10 
Candidal Leukoplakia 7 3 10 
Total 14 6  
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Figure 5.33. Clinically suspicious oral lesions (samples of detected lesions). 
 
 
 
       
    Dysplasia of the cheek (PDD006D)            Candidal leukoplakia (PDD020D)  
 
                                                                    
   Squamous cell carcinoma (PDD022D)         Lichenoid lesion (PDD021D) 
 
                                                                                           
   Frictional keratosis (PDD008D)                     Ulcerative keratotic lesion (PDD017D) 
   
   
    Dysplasia of the tongue (PDD026D)           Erosive (atrophic) lichen planus (PDD007) 
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      The study protocol was designed to incorporate two investigation sites, Dundee 
and Glasgow. Compact fluorescence spectroscopy or OBS, as stated before, was 
developed by Glasgow University and used in the photobiology unit in Ninewells 
hospital for clinical research. The OBS used in this study has proved to be a reliable 
instrument that can be used to give an instant diagnostic reading from soft tissue 
body systems. Nadeau, et al (2002) has used the same instrument for in vivo point 
monitoring of aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) 
fluorescence and autofluorescence intensity measurements, as a non-invasive method 
of differentiating normal and cancerous tissue of the gastrointestinal tract. Their 
results illustrated the potential of the system to be used for fluorescence monitoring 
in a variety of clinical applications. Nadeau and his colleagues have also described 
the implementation of a compact fluorescence spectrometer in monitoring the 
photobleaching of ALA-induced PpIX in vivo on the skin of healthy volunteers 
(Nadeau V, et al, 2004). However, Ibbotson et al, (2006) found marked inter- and 
intra-subject variation in ALA-induced PpIX fluorescence in normal human skin. 
She related this to the body site and differences in the stratum corneum. 
 
In their pilot study, Prof Ogden and his team used the instrument and 5-ALA as a 
non invasive tool in detecting oral cancer. They suggested that this instrument may 
be a valuable tool for detecting early oral cancer; however they recommended further 
studies to support their findings (O'Dwyer, et al, 2005). 
 
After commencing this trial, the investigators observed variations in person-to-
person fluorescence intensity peaks at each oral anatomical site in general. These 
variations were noticeable within a particular site in different persons. Furthermore 
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there were variations among different normal anatomical sites within the same 
person. As a result of this, an additional test (pilot study) was required to assess the 
reproducibility of the system in intra oral measurements at different oral locations.  
 
Unlike most other organ systems suitable for fluorescence detection of 
malignancies, the oral cavity is lined with three mucosal types; masticatory, lining 
and specialised mucosa. The variations in the histological features of the oral mucosa 
might reflect differences in fluorescence spectral shape and intensity. For example, 
the cheeks, inner lip, soft palate, and floor of the mouth are lined with non-
keratinized mucosa, while keratinized mucosa can be found on the hard palate, 
gingiva, and tongue. The presence of lingual papillae and taste buds makes the 
tongue coating mucosa unique in histological and anatomical features. Furthermore, 
the palatal mucosa and gingiva are supported by hard tissue or bone, which might 
increase the reflection of incident and fluorescent light. Therefore, it was considered 
worthwhile investigating the influence of oral anatomical location on fluorescence 
characteristics to see if baseline reading for a specific oral site could be obtained for 
comparison with a lesion under investigation. This study displays a map of the oral 
cavity fluorescence. To conduct such a trial in theory, the measurements should be 
compared with the histopathology, however it would be unethical and impractical to 
take biopsies from normal sites, therefore for this part of the study the measurements 
of normal anatomical sites depended on the clinical inspection of the investigators. 
 
To our knowledge there were no previous studies assessing the measurements at 
oral sites using FIR measurements of the drug (enhanced) fluorescence. However 
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there was one study that measured the autofluorescence of the oral mucosa using the 
absolute fluorescence intensity (de Veld  et al, 2003). 
 
The OBS instrument was designed to measure the wavelength ranges from blue 
to red spectra i.e. for the measurement of the autofluorescence (green fluorescence) 
spectrum as well as the PpIX (red fluorescence spectrum). This could be obtained in 
two forms; a spectral line graph which appears on the screen and in real time as 
shown in figures 4.1 and 4.3 (Patients and Method section) and the ratio of any 
wavelengths required (by fixing the cursers on the X axis scale that exist with the 
line graphs) as shown in a slot on the screen of the computer. As mentioned in the 
review section several techniques have been proposed for the evaluation of 
fluorescence spectra. Principal component analysis (PCA) was the technique 
used in O’Dwyer’s pilot study (O’Dwyer et al, 2008); however redundancy 
and transfer of the author limited the availability and the use of the software 
in the result analysis.   
 
 Fluorescence ratios are an approach used to avoid artefacts in the data. 
This technique has been extensively used for tissue characterization 
following the administration of fluorescent tumour markers (de Veld et al 
2005; Sharwani et al, 2005). Red and green fluorescence peaks, and their ratio 
diagnostic algorithm were used to quantify the fluorescence intensities since the 
finding could be recorded and obtained from the instrument. 
 
In statistics, normalization or transforms are usually applied so that the data 
appear to more closely meet the assumptions of a statistical analysis procedure that is 
                                                               - 209 -                               Chapter 6 Discussion 
 
to be applied, or to improve the interpretability or appearance of graph figures 
(Bland, 1996a and b). In the result analyses in general, the comparison was done by 
including all the readings obtained without exclusion of the extreme values (outlier) 
or transforming the values. However, normalization (transforms) of the data and 
spectra linegraphs (in the result section figures 5.2, 5.4, 5.19, 5.22, and 5.25) were 
applied to give better result analysis interpretation. 
 
The 1st pilot study showed the reproducibility of the instrument as a measurement 
device in intraoral application. In clinical practice variability might have occurred in 
some instances, because of some factors that impinge on the result outcome such as 
experience of the practitioner less so, more likely variation in the thickness of 
epithelium, under diagnosed systemic condition that influence fluorescence. . 
 
The results were interpreted in two ways; the first was the traditional comparison 
between variables, which included statistical analysis of the measurement of the FIR 
at each site in relation with the other sites (and its significance). The second type of 
comparison was done spectrally, to show the average spectra line graphs readings at 
each site in relation to the average readings of the other sites.  
 
      These line graphs was representing the fluorophores after excitation at 405nm i.e. 
emission of light at different wavelengths. Several endogenous fluorophores emit 
light at the autofluorescence wavelengths; however PpIX was the only specific 
fluorophore whose emission was elucidated. Therefore, the shapes of the spectra line 
graphs that are displayed portray differences in cellular fluorescence emission, which 
in turn reflect differences in tissue structure. 
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6.1 Fluorescence Intensity Ratio (FIR) Measurement at the Oral   
      anatomical Sites 
 
It was thought initially that twenty four sites would be measured from each 
patient. This was taken from two patients (PDD004 and 5). However the procedure 
was impractical (time consuming and exhausting to the patients), hence the number 
of measurements taken were reduced. 
 
To study the fluorescence of the oral cavity, ten sites were chosen to map out the 
fluorescence of the oral cavity. These sites were selected based on their location to 
include various oral mucosal types (keratinized, non keratinized and specialized) as 
fixed anatomical sites and easy to be accessed in the dark room in which the 
measurements would be taken. Thus the procedure of spectroscope probe application 
could be standardized.  
 
The incisive papilla was a clear anatomical site at the anterior palatal mucosa and 
represents the most vascular in consistency and rarely involved by any oral lesions. 
Mid palatal mucosa right side and close to the mid palatine suture represented 
smooth keratinized mucosa and was easy accessed by the probe. 
 
The tongue measurements were taken from the tip of the tongue 2mm and 3cm 
away from the border which represented the specialised mucosal coatings. The 
ventral tongue (5mm away from the border) was non keratinised mucosa and close to 
the floor of the mouth environment.  
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Floor of the mouth at mid Wharton’s duct was fixed and an accessible site where 
bacteria and saliva are collected for a long period of time. 
 
Two points were taken from the cheek representing the measurement of the fixed 
contralateral sites of the oral mucosa, in addition to detect internal consistency of the 
fluorescence measurement outcome. 
 
The gingival site chosen was taken from the lower anterior region of the gingival 
mucosa at the top of the lower labial fraenal attachment. This site was easily 
accessed and representing attached gingival mucosa, regardless of whether the 
participant was dentate or edentulous. 
 
The lower lip mucosal site was taken from the lower lip mucosa above the lower 
labial fraenal attachment. It was a lining mucosa which could easily be accessed by 
the probe. 
 
Although our intention was to keep the fluorescence probe in the same position 
for all measurements, variations in positioning might have accounted for some of the 
variation in the fluorescence intensities. In addition the investigator was very 
conscious of not taking measurements from anatomical site involved by the lesion.  
 
de Veld and her colleagues studied the autofluorescence intensity of the normal 
oral sites and discussed their results thoroughly. They anticipated that ratio-
techniques and statistical methods applied to normalized spectra would be more 
accurate than techniques that rely on the absolute intensity for the diagnostics. These 
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techniques will reduce inter patient variability as well as irreproducibility, since 
Fluorescence Intensity Ratio seems more consistent than spectral shape or mere 
fluorescence intensity (de Veld et al, 2003). For this reason we have interpreted the 
result graphs in both normalised and none normalised forms (transformed data). 
Logarithm or natural transform method was applied to improve the data 
interpretation in box plot graphs as shown in figure 5.2. 
 
Multicomparison classification for the ten anatomical sites has shown that 
fluorescence spectra obtained from the palate and the tongue were significantly 
different from those obtained from other anatomical locations at p<0.001 in 
particular when compared with the buccal mucosa. It is thought that the increase in 
cell layer thickness attenuated the tissue fluorescence emission and the green light in 
particular (Harries et al 1995; Stringer et al, 2008). This finding was in agreement 
with McGee (2008) who found that sites that are normally keratinized were distinct 
from nonkeratinized sites for a number of parameters and the data frequently 
clustered together. Schwarz et al, (2009) referred in their results to the variability 
between the keratinised and none keratinised mucosa and shallow verses deeper 
stroma in oral tissue sites. 
 
Fluorescence of the palate and the tongue at the IP, MP, TT (2mm away from the 
tip) and DT (3cm away from the tip) sites were closely related statistically and 
spectrally. This may be due to the similar nature of the keratinised tissue coating or 
reflects on the microbial presence at these sites (Brazier, 1990; Konig et al, 2000). 
The FIR of the remaining locations (VT, FM, RC, LC, GN and LP) seems to be 
distributed similarly with no statistically significant difference.  
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 In the result tables, the relation of the fluorescence intensity ratio (FIR) 
measurements and the normal oral sites was compared at two levels (0.05 and 0.001) 
of significance to explore in depth the comparisons between the ten oral sites 
measurements selected in this study.  
 
The spectral distribution of DT and MP line graphs were lower in 
autofluorescence and drug fluorescence intensity peaks but the red/green ratio were 
similar which made the statistical analysis non significant. These findings suggest 
that the clinician should evaluate the peaks at two wavelengths (e.g. 500 and 635nm) 
and the ratio of the fluorescence peaks for each site in the comparison between the 
anatomical site and the normal and lesion site. This is in agreement with de Veld et 
al, (2003) who stated that total fluorescence intensities are highly inconsistent, both 
intra- and inter-individually and suggested the use of ratios of emission peaks at a 
single wavelength. Furthermore, in the same article, they anticipated that ratio-
techniques and statistical methods applied to normalized spectra will be more 
accurate than techniques that rely on the absolute intensity for their diagnostic 
ability. It was thought this would reduce inter patient variability. 
 
RC and LC were consistent in spectra line graph distribution i.e. there was no 
significant difference between left and right buccal mucosa. They had the highest 
autofluorescence and lowest drug (PpIX) fluorescence peaks which make them 
identical to the normal tissue (anticipated spectral linegraph shape in theory). There 
was variation in the fluorescence peaks in FOM as well as VT sites which could be 
due to the saliva and microbial flora accumulated that causes PpIX fluorescence 
emission. 
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The data analysis and the spectral line graphs of the anatomical sites could 
broadly be separated into two groups, the dorsal tongue & hard palate and the rest of 
the oral sites (mainly non keratinised). They could be used as a base line data for 
comparison with diseased tissue. A separate data base should therefore be considered 
for the palate and tongue. This finding was consistent with McGee and colleague 
who concluded that accurate spectroscopic detection of oral disease must account for 
spectral variations among anatomic sites in developing algorithm for the result 
analysis, and the nature regarding the keratinised and non keratinised mucosa 
(McGee et al, 2008, 2009). 
 
Although the various oral sites showed certain similarities in FIR, that they vary 
with epithelial type (and hence were not identical) perhaps argues for a site specific 
table of normal values for comparison with lesions from the same oral site. 
 
Based on these readings, it is suggested that the clinician should evaluate the 
lesions and compare them with the normal (contra-lateral) site in the same patient. 
 
 
6.2 Fluorescence Intensity Ratio (FIR) Measurements in Relation 
      to the Individual Characteristics 
 
This study noted a statistically significant spectral difference between clinically 
normal oral mucosa at different anatomical sites. This suggests that compact 
fluorescence spectroscopy might be sensitive to individual characteristics since 
variation in FIR measurements between patients was noticed. No previous study has 
reported the effect of individual characteristics on the oral mucosa using drug 
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fluorescence; however de Veld and colleague reported their study on variation in 
autofluorescence intensity (de veld et al, 2004)  
 
FIR measurements encompass both tissue autofluorescence and drug fluorescence 
peaks. Fluorescence spectroscopy is a non-invasive tool for the detection of 
alterations in the structural and chemical composition of cells ((Profio et al, 1984; 
Upile et al, 2007). Autofluorescence of tissues is produced by several endogenous 
fluorophores. These include fluorophores from tissue matrix molecules and 
intracellular molecules like collagen, elastin, keratin and NADH (Stringer et al, 
2008). The presence of disease changes the concentration of these fluorophores as 
well as the light absorption and emission properties of the tissue. This takes place 
due to changes in blood concentration, epithelial thickness, nuclear size distribution, 
collagen and elastin content. It is therefore expected that the presence of disease will 
be reflected in fluorescence spectral shape and intensity. 
 
Our hypothesis was that the non-pathological tissue alterations that cause these 
differences in FIR characteristics correspond to characteristics of the individual, such 
as age, gender, tobacco use, alcohol consumption, metabolic diseases and wearing of 
dental prosthesis.  
 
Unfortunately the Glasgow team was not ble to collect all the patients 
information in spite of the limited number they recruited for the trial so the author 
included only the age and gender that were obtained from the case report forms 
(CRF) for the statistical analysis. 
 
                                                               - 216 -                               Chapter 6 Discussion 
 
   6.2.1 Comparison between Age Groups 
 
Age groups were classified as over 50 years and under 50 years, since we have 
limited number of young participants age.  
 
Previous studies on animal oral tissue samples taken from the palate, cheek and 
ventral surface of the tongue found no single age-associated change in epithelial 
structure or renewal common to all epithelia (Hill, 1988) In humans, it was 
concluded that the characteristic structural and functional changes that occur in skin 
and mucosa with age are not well defined (Hill, 2006).  
Our results showed no significant difference in the FIR between the two age groups. 
However, in spectral analysis there was a slight elevation in the average drug 
fluorescence compared to autofluorescence in the young (less than 50 years) group. 
This could be attributed to the oral flora of young dentate patients participated in the 
trial compared to the older group many of whom were edentulous.  
 
   6.2.2 Comparison between Genders  
 
The numbers of male and female participants were equal in distribution whilst the 
number of spectra is slightly different due to the missing values. In our results 
analysis for FIR, it was found that there was no statistically significant difference of 
the FIR between the gender groups. This finding shows there was no effect of the 
gender on the autofluorescence and drug fluorescence intensity ratio; however de 
Veld et al, (2004) reported that gender did have a significant influence on 
autofluorescence spectra.  They explained that males’ autofluorescence spectra 
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showed more blood absorption than females’, while, the average autofluorescence 
spectra for men and women show equal peak intensities, indicating that the higher 
blood absorption is not a normalization artefact. Despite there being no substantial 
evidence for this in the literatures they explained this by differences in 
vascularisation between men and women or difference in epithelial thickness. We 
would consider the hormonal changes might have an impact on the oral mucosa of 
the females at certain conditions (due to physiological or medical management) 
(Friedlander, 2002) which later influence the autofluorescence peak; however such 
effect is limited on the FIR measurements. 
 
Measuring the ratio of two wavelengths should be more reliable in detecting 
tissue changes (Sinaasappel and Sterenbor, 1993; Sterenborg, 1994). This 
measurement has been extensively used for tissue characterization 
following the administration of fluorescent tumour markers (Zheng et al, 
2002, 2004). 
 
Spectral linegraph shapes show the autofluorescence and drug fluorescence peaks 
of the male were higher than the female, however the ratios of the peaks seem similar 
in the values as shown in the figures (result section). The FIR measurement value 
distributions look consistent when comparing the inter-quartile range box plots of the 
two groups. 
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   6.2.3 Comparison between Dental Prosthesis and None Prosthesis 
        Wearers 
 
A dental prosthesis is considered a factor that has influence on the oral flora. The 
microbiology of denture plaque and poor denture hygiene is associated with 
stomatitis (Candida infection). Photofrin demonstrated the susceptibility of C. 
albicans to its photodynamic effects (Chabrier-Roselló et al, 2005). These organisms 
may influence the mucosal tissue fluorescence. Our intention was to study the 
influence of the oral microbial flora of the participant wearing dental prosthesis on 
the FIR. We didn’t find any significant difference between the FIR measurements 
dental prosthesis wearer and none prosthesis wearers. 
 
The averaged spectral line graphs of the two groups showed a similar 
autofluorescence intensity level; however there was slight elevation in the non 
prosthesis wearer. This finding was unexpected since prostheses are known to cause 
alteration of the oral flora which would increase the red spectrum fluorescence. 
 
   6.2.4 Effect of Systemic Diseases 
Metabolic diseases such as diabetes and hyperthyroidism can interfere with tissue 
activities which occur due to structural and/or biochemical alteration of the cells. The 
oral mucosa is commonly affected due to alteration of the tissue structure and 
function of saliva (Negrato and Tarzia, 2010; Venturi and Venturi, 2009). Diabetes is 
a metabolic disease associated with oral manifestations related to immune alteration, 
reduction in saliva flow rate and microbial infection. Cellular fluorescence of the 
diabetic skin has been studied. Ediger  and his colleagues suggested that non-
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invasive measurement of dermal fluorescence may be an effective tool to identify 
individuals at risk for diabetes and its complications (Ediger et al, 2009). We 
anticipated that oral mucosa fluorescence of diabetic patients would have an impact 
on the normal site readings which could influence the results analyses.    
The number of participant recruited with systemic disease was low in comparison 
with none disease. Condition included diabetes and thyroid disease and the spectra 
obtained were utilised for the comparison.  
The results showed there was no significant difference in the FIR measurements 
between the systemically diseased and none systemically diseased group. This means 
the autofluorescence and drug fluorescence (which reflect the cellular changes and 
presumably the bacterial flora) of the oral cavity were not affected by the systemic 
disease. This could be due to the fact that the patients were well controlled for their 
medical condition. Further studies are required involving those with uncontrolled 
diabetes (with different blood sugar levels) correlated with the FIR measurement to 
detect the effect of diabetes on mucosal fluorescence. 
The spectral line graphs showed elevation of both autofluorescence and drug 
fluorescence in the systemic diseased group which compared with those lacking 
systemic disease. This difference could be due to variation in catabolic and anabolic 
cellular changes. 
    6.2.5 Effect of Smoking 
 
The inflammatory effects of nicotine on the oral mucosa have been demonstrated 
(Dussor et al, 2003). The effect of cigarette smoking on the oral mucosa has been 
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assessed through the application of quantitative cytomorphometric analysis to smears 
obtained from clinically normal buccal mucosa. Ogden and co workers (1990) in 
their result analyses suggested that for normal buccal mucosa smoking does appear 
to influence cytomorphology. Smoking habit is considered as a commonality linking 
oral health with an increased risk for malignant disease (Seymour, 2010).  However, 
oral epithelial dysplasia may exist in patients who do not smoke tobacco or drink 
alcohol (Jaber, 2010).  
 
Our results for FIR showed no significant difference between smokers and none 
smokers FIR. However de Veld et al, (2004) found significant difference in the 
autofluorescence intensity peaks between smokers and non smokers while none 
significant difference between smokers and ex smokers. The controversy we have 
noticed in their results is the relatively no correlation between absolute smoking 
behaviour and fluorescence intensity and hardly any differences were observed 
between non-smokers and ex-smokers. They concluded that the effect of smoking on 
autofluorescence characteristics was of a temporary nature. In this study, we have 
included all smokers regardless of the number of cigarettes. There was no difference 
when compare smoker with non-smokers. The variation between our findings and 
theirs might be due to difference in study design and inclusion criteria. However, the 
spectral line graph of the smokers showed slight elevation in the red spectrum peak 
in comparison with none smokers. Hence the fluorescence intensity peaks indicated a 
slight effect of smoking on the oral tissue fluorescence (spectrally but not 
statistically).  
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Further studies should attempt to correlate the number of cigarettes consumed 
with the FIR measurements at a specific oral mucosal site since many people who 
develop oral malignant disease smoke and hence these influence need to be known 
and taken into account when assessing such conditions. 
 
   6.2.6 Effect of Alcohol Consumption 
 
Alcohol has been recognized as an important risk factor for mouth cancer for 
almost 50 years. Ogden (2005) reviewed the effect of alcohol on cellular structure 
and function in reference to histologic and exfoliative cytologic studies of the oral 
epithelia. Alcohol may affect cell function of stem cells by both intracellular and 
intercellular pathways. In this thesis, alcohol consumption is based on the use or 
none use of alcohol regardless of the number of units drunk, because alcohol intake 
may vary and not be accurately reported.  
 
Our results showed no significant difference in the FIR between the alcohol user 
and none alcohol user groups. In addition, the spectra line graphs showed closely 
related line distribution regarding the autofluorescence and drug fluorescence 
intensity peaks. This may be due the inclusion criteria that were applied in this study 
i.e. the amount of alcohol consumption were not graded to correlate the effect of the 
amount of alcohol with the FIR since this is considered as an oral malignant 
predisposing factor. 
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6.3 Fluorescence Intensity Ratio (FIR) Measurements in Detecting 
      the Oral Lesions 
 
   6.3.1 Comparing the lesion and normal sites 
 
The initial study protocol required multiple readings to be obtained from five 
sites (upper, anterior, lower, posterior and centre of the lesion) to cover the lesion 
size spectroscopically, however the punch biopsy of 5mm size would not include all 
the areas from which readings were obtained. In addition, in theory the biopsy 
reports would not interpret (necessarily) the cellular changes at the site the 
fluorescence reading is taken from. This is the limitation of this system (point 
monitoring system, unlike image monitoring system which could cover broader 
areas). Therefore, it would be more precise to take two readings (1st and 2nd readings) 
from 5mm size lesion (from the area which are clinically most suspected) to insure 
that the biopsied lesion area was measured “spectrally”, for this reason the initial 
study design was modified.  
 
    1- Comparison between the 1st readings, 2nd readings and normal readings. The 
statistical analysis was done between the 1st, 2nd and the normal site readings. The 
Kruskal-Wallis procedure was chosen to compare between the three readings 
because of its reduced sensitivity to outliers and unbalanced data (=data with unequal 
sample sizes for the different groups). This reduced sensitivity occurs because the 
procedure performs an analysis of variance (ANOVA) on the ranks of the PC scores, 
rather than on their numeric values, like in standard ANOVA. A Multi comparison 
was performed on the Kruskal-Wallis results to test for any significant differences 
between different pairs of readings. It was found there was no statistically significant 
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difference between the 1st and 2nd readings which indicate the reliability of the 
readings (fluorescence intensity ratio measurements) in obtaining the readings from 
the lesion sites. In addition, there was  a highly significant difference between the 1st 
reading from the lesion and normal site on one hand and 2nd reading from the lesion 
and normal sites on the other hand, which indicate the reliability of each reading in 
identifying difference between the lesion and the normal sites. It was presumed that 
using either set of lesion reading (FIR measurements) in the comparison would have 
similar result. 
 
Spectrally, there was slight variation between the line graphs for autofluorescence 
level between the two lesion readings however they were overlapped on the PpIX 
peak which indicated little variation in the fluorophore and/or keratin fluorescence 
emission due to changes in the location measurement as shown in figure 4.18. 
 
    2- The other method of comparison was conducted between lesion sites and 
normal sites using the same sets of readings. This was done by merging the two 
lesion readings and compared with the normal site readings in order to assess the 
reliability of the OBS (spectroscopic measurements) in detecting any alterations in 
structure and composition of the tissue. The results showed that the FIR 
measurements were able to distinguish between the lesion and normal sites. This 
comparison was observed statistically and spectrally as well. This finding was in 
agreement with previous studies that used autofluorescence intensity (Gillenwater et 
al, 1998; de Veld et al, 2004) and photodynamic method in detecting the oral lesions 
(Swinson et al, 2006) and could conclude that the instrument was able to distinguish 
lesions in general from clinically normal tissue.  
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It has been noticed that porphyrin-like peaks “using autofluorescence 
spectroscopy” can appear in benign lesions (32%), dysplastic lesions (19%), 
malignant lesions (73%) and even occasionally in healthy oral mucosa (de Veld et al, 
2003).  
 
Selection of the cutoff point for the Statistical methods, in this study, was based 
on the concept which stated that the point may be used in addition to the clinical 
experience, analytical and empirical evidence for finding more reliable and valid 
cutoff point for classifying cases as positive or negative (Singh, 2007). Therefore the 
value of one SD of the merged groups’ data was used to discriminate between the 
negative and positive readings. 
 
      The researchers often concentrate on the sensitivity and specificity of the test. 
However, the predictive values of the screening test are equally important as they 
measure the accuracy of the prediction made on a subject whose true condition is 
unknown i.e. the sensitivity and specificity was measured as a screening tool to test 
the percentage, while the predictive values test the proportions of the outcome 
(Severino, 2010), therefore, the two analyses were conducted in the result section. 
 
The sensitivity of the fluorescence in distinguishing lesions from normal oral 
mucosa using compact fluorescence spectroscopy and 5-ALA was 59.5% with a 
specificity of 73.8%. This level of sensitivity and specificity was attributed to the 
method of including all types of oral lesions in the analysis, which involve benign 
hyperkeratosis that showed fluorescence emission behaviour (autofluorescence and 
PpIX peaks) similar to that of the normal tissue. Further studies classifying by type 
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of lesions to assess the sensitivity and specificity for each group should be 
undertaken. 
 
   6.3.2 Detecting Clinically Suspicious (Potentially Malignant) Oral 
            Lesions 
 
The method of collecting data was considered blindly, as neither the investigator 
who took the fluorescence measurements nor the pathologist who diagnosed the 
lesions were aware of each others outcome. The lesions classified as hyperkeratosis 
showed increased thickness of the keratin layer only, with no evidence of any 
inflammatory superimposition as described in the histopathological report. It was 
found that these lesions showed mild changes in the FIR measurements in real time 
spectrally, however the second group of lesion classified as inflammatory (includes 
lichen planus, lichenoid lesions and candidal leukoplakia) when the histology report 
mentioned inflammatory cell infiltrate and/or candidal infection without dysplastic 
changes. In clinical practice “spectrally” it was noticed that there was elevation in the 
FIR measurements, so that these lesions would have been classified differently from 
benign hyperkeratosis if blinded to the histopathological diagnosis. Dysplasia and 
neoplasia was classified into one group since staging of the disease was not included 
in the analysis and in addition the sample size was limited.   
 
 There was a statistically significant difference between the lesion and normal 
sites. This difference was explored spectrally "in real time " and normalized forms, as 
shown on the line graphs figures in the result section. The autofluorescence peak 
spectral line graphs were higher in normal sites and lower in benign hyperkeratosis, 
inflammatory lesion with dysplasia the least respectively. However the PpIX 
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fluorescence peaks were the lowest for the normal site and slightly increased in 
benign hyperkeratosis with highest peaks seen in inflammatory and dysplasia which 
overlapped one another. This was in agreement with the fluorescence spectral line 
graphs plotted to study the dysplastic changes of the tissue in the oral cavity 
(Gillenwater et al, 1998; de Veld et al, 2004) and in other organs (Stringer et al, 
2008). 
 
The specific alterations in tissue structure or biochemical composition causing the 
variation in fluorescence intensities of neoplastic and dysplastic tissue have not been 
fully elucidated. Endogenous fluorophores such as flavins, nicotinamide adenine 
dinucleotide (NADH), and collagen may undergo changes in quantity or form during 
neoplastic progression (Richards-Kortum and Sevick-Muraca, 1996). Gillenwater’s 
group also found decreased peak intensities in pathologically abnormal vs normal 
tissues and increased intensity in the red region when comparing abnormal to normal 
tissues (Gillenwater et al, 1998). 
 
A paper reviewing in vivo autofluorescence spectroscopy as a non invasive 
method in detecting oral cancer was published in 2005 (de Veld et al, 2005). They 
studied the autofluorescence and imaging for the early detection and classification of 
(pre) malignancies of the oral mucosa. They stated that sensitivity and specificity of 
the result analysis were varied in relation to the type of instrument used, method of 
detection, excitation wavelengths and classification algorithm. In discussing their 
results they thought that there was a problem in discriminating between benign 
lesions on the one hand and dysplastic and malignant lesions on the other hand. They 
have given explanation that tumours as well as benign and dysplastic lesions can be 
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of various degrees of keratinisation, hyperplasia and blood content and therefore, 
they will influence the shape and intensity of autofluorescence spectra (de Veld et al, 
2005). 
 
Our results showed that there was a significant difference in the FIR between 
dysplastic lesions and normal sites. The difference was clearly noticed in the data 
distribution as shown in box-plot and spectra linegraphs figures as well. 
 
Detection of the classified lesions was further evaluated by analysing the 
sensitivity and specificity of the result. The 1st and 2nd lesion readings were utilized 
for this part of the study based on the fact that there was no significant difference 
between the two readings.  
  
The sensitivity of the compact fluorescence spectroscopy and 5-ALA was 100% 
and specificity 100% in distinguishing dysplasia from normal sites due to specific 
cellular accumulation of PpIX. 
  
The sensitivity and specificity values reduced when comparing between all 
inflammatory lesions (Lp, LL and candidal leukoplakia) with their normal sites. The 
low specificity values (55%) was noticed when the Lp&LL group was compared 
with the normal side which indicates that these lesions emitted light relatively similar 
to the normal tissues.  
 
The results also showed there was statistically significant difference between 
dysplastic lesions and benign hyperkeratotic lesions with sensitivity was 77.7% and 
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specificity was 66.6%. This is due to relatively high cellular activity of the dysplastic 
or neoplastic lesions when compared with cellular activity of the benign lesions 
regarding the FIR measurements. 
 
When assessing inflammatory lesions in comparison with dysplasia lesion, the 
statistical analysis including the various inflammatory lesions (lichen planus, 
lichenoid lesions and candidal leukoplakia) showed no statistically significant 
difference between this group and dysplasia, this could be explained by the heavy 
lymphocytic infiltration in the subepithelial connective tissue which can impact on 
tissue fluorescence (Krammer and Plaetzer, 2008) and the candidal hyphae 
superimposed on the lesion (as diagnosed by the histopathology reports). In isolating 
the classified inflammatory lesions (Lp&LL and candidiasis) the sensitivity and 
specificity varies in favour of dysplasia when compared with Lp&LL only. 
 
As a matter of scientific curiosity for future studies, further group of lesion based 
on the presence of candida albican in the histopathology reports of the lesions has 
been classified and the sensitivity and specificity were calculated. The specificity of 
using fluorescence in detecting dysplasia from candidal leukoplakia was low (30%) 
in comparison with other inflammatory lesions (Lichen planus and Lichenoid 
lesions) (66.6%). Since fungal hyphae embedded in or on the surface of the oral 
lesions can induce synthesis of protoporphyrin IX from 5-aminolevulinic acid 
(Strakhovskaya et al, 1998), it could be anticipated that this might have an effect on 
the results.        
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      The technique is highly sensitive to detect accumulation of PpIX inside the 
metabolically and structurally altered cells (dysplastic changes), however microbial 
presence in the oral cavity and to some extent the inflammatory infiltrates 
superimposing the lesion may have an affect on the statistical significance between 
the dysplasia and inflammatory groups. Therefore it could be concluded that  
Photodynamic Detection (PDD) method using compact fluorescence spectroscopy 
and 5-ALA was able to detect oral lesions from normal sites (but so is the naked 
eye!),  however there was variation in the sensitivity and specificity in detecting a 
different pathological lesions. The technique was highly sensitive in detecting 
dysplasia from normal sites and the sensitivity varied in detecting classified lesions 
but unfortunately the technique is not able to discriminate reliably between dysplasia 
and inflammatory lesions whose clinical appearance can be very similar. 
 
One point would be worth mentioning and supports the findings "practically "
during conducting the trial. The author had written reports for a couple of lesions to 
the maxillofacial surgeon in Ninewells hospital describing the behaviour of some 
suspicious oral lesions “photodynamically” to assist in detecting the extent of the 
lesion and the highly suspicious areas for surgical removal. The reports were in 
details which encouraged the surgeon to refer more cases for investigation, but 
unfortunately the investigators had to comply with the MHRA recommendation to 
terminate the trial. 
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7.1 CONCLUSION 
 
      This dissertation has investigated the use of the compact fluorescence 
spectroscopy together with the photosensitizer 5-aminolevulinic acid in assessing 
clinically suspicious oral lesions (photodynamic detection method) and the following 
conclusions can be drawn; 
 
7.1.1 Pilot study 
 
      The pilot study confirmed the reliability and reproducibility of the use of the 
instrument for oral application with the photosensitizer 5-ALA. 
 
      No conclusion could be drawn as regards the reason for PpIX peaks from normal 
dorsal tongue. Some evidence for the influence of bacteria was obtained. 
 
7.1.2 Main study 
 
    7.1.2.1 Fluorescence intensity ratio (FIR) measurement at the oral 
                anatomical sites 
 
      The main aim of the study was to map the normal oral mucosa fluorescence 
intensity ratios (FIR) at ten different sites. The result showed that the oral sites could 
be classified into two main groups to be used as a baseline for comparison with 
lesionsat these sites; the dorsal tongue and palate as one group and ventral tongue, 
floor of mouth, cheeks, gingiva and lip as the other. 
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    7.1.2.2 Fluorescence intensity ratio (FIR) measurements in relation to 
                the participants individual characteristics 
 
 
      The aim of this aspect of the study was to determine the effect of individual 
characteristics which included age, gender, presence of dental prosthesis, systemic 
diseases, smoking habits and alcohol consumption on the (FIR) measurements. The 
results showed no effects of these factors on the readings obtained for the study, 
however there was slight variation spectrally but statistically the difference was not 
significant.  
 
    7.1.2.3 Fluorescence intensity ratio (FIR) measurements in detecting 
                the oral lesions 
 
      In this study the aim was to determine whether the technique could detect 
potential malignant change in a range of oral mucosal lesions with particular      
reference to oral lichen planus. 
 
     7.1.2.3.1 Comparing the lesion and normal sites.  
 
      Comparison between 2 readings taken from the lesion and the normal 
corresponding site readings showed there was no difference between the 2 lesion 
readings i.e. intralesional consistency; however there was a difference when the 
lesion measurements were compared with the normal site readings 
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         7.1.2.3.2 Detecting clinically suspicious (potentially malignant) oral 
                        lesions 
 
      The lesions were classified into three histological groups;  
a- Hyperkeratosis showed increased thickness of the keratin layer only.  
b- Inflammatory (includes lichen planus, lichenoid lesions and candidal 
    leukoplakia). 
c- Dysplasia (and neoplasia).   
 
      It was noticed that  
 
• There was a difference in the FIR between the:  
      Dysplastic lesions and normal sites. 
      Dysplastic lesions and benign hyperkeratosis.  
      Inflammatory lesions and normal sites. 
 
• However there was no difference between the:  
      Dysplastic and inflammatory lesions. 
      Inflammatory lesions and benign hyperkeratotic lesion. 
      Benign hyperkeratotic lesions and the normal sites. 
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     7.1.2.3.3 Sensitivity and specificity of the use of Fluorescence 
                    Intensity Ratio (FIR) measurements in detecting oral 
                    premalignant (clinically suspicious) lesions 
 
The sensitivity and specificity were calculated using the cutoff point (the value of one 
standard deviation of the compared groups) to discriminate the FIR measurements 
(Negative and Posative values) between the compared groups. It could be concluded 
that the technique was highly sensitive in detecting dysplasia from normal sites and 
the sensitivity is relatively varied in detecting different pathological lesions but 
unfortunately the technique is not able to discriminate reliably between dysplasia and 
inflammatory lesions whose clinical appearance can be very similar.  
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7.2 LIMITATION OF THE STUDY 
 
The proposed recruitment (following statistical advice from Prof. Peter Donnan, 
University of Dundee) was a total of 50 patients, 25 at each of the two centres. 
Unfortunately, this target couldn’t be achieved due to a number of factors;  Numerous 
administrative and technical constraints that emerged after commencing the clinical 
work, such as management problem from the NHS who tried to impose limitations on 
when and where the compact fluorescence spectroscopy (OBS) measurements and 
biopsies could be taken, low referral of suitable patients due to competing pressure 
from other studies in the department, restricted availability of the OBS instrument due 
to its use in other trials, loss of staff having expertise in the use of the OBS system (Dr 
Martin O’Dwyer physicist at the University of Glasgow was made redundant and not 
replaced). Furthermore the preparations and consequences of the MHRA trial 
inspection meant that for some considerable time we couldn’t recruit additional 
patients and the targeted number of patients could not be achieved due to the trial 
being prematurely closed on what was considered a technicality. The study had no QP 
release (Qualified Person) to confirm that the generic drug had not be tampered with 
during it’s passage from it’s site of production in a German factory to Ninewells 
hospital, Tayside. 
 
Dundee (the centre where the author and the principal investigator resided) was 
able to achieve the target number and additional patients were recruited but only after 
having to wait to get permission from the REC, the MHRA and local R&D office 
following what is termed a substantial amendment to compensate for the shortfall 
from the Glasgow centre. 
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MHRA visit to Dundee  
 
The University of Dundee, NHS Tayside, the Clinical Research Centre and 
Tayside Clinical Trials Unit (TCTU) officials were notified that they would be visited 
by the MHRA for inspection in May 2009. The PI, author and other investigators 
were informed that their trial had been chosen for particular attention and thus to 
prepare for the entire documentation to be checked by the inspectors. Ten trials were 
chosen for inspection with ours being one of six trials to be checked in detail. The 
MHRA have the authority to close down clinical trials. Tayside Clinical Trials Unit 
presented a series of seminars and workshops to train the investigators on how to 
conduct a CTIMP to the best standard and how to comply with the regulations of ICH 
GCP. The author had attended all these meetings, seminars and workshops. 
 
The raw product of 5-ALA used in this trial was produced, signed and licensed in 
Germany. In subsequent meetings with the authorities in Dundee (prior to the MHRA 
visit) regarding the inspection, the trial pharmacist reassured the PI and the author of 
this thesis that although the drug was a raw material and prepared in Germany it 
should be acceptable.  
 
On the day of the MHRA inspection of this study the papers were checked 
thoroughly and the inspectors asked for the QP signature in Dundee. Since there was 
no qualified person authorised to sign the drug release, the MHRA recommended 
terminating the trial unless QP release could be obtained. 
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Since Ninewells Hospital did not have a QP (and wouldn’t fund this) the trial was 
withdrawn and no further patients could be recruited. This was due in part to the 
worry to contend this decision might lead to problem with Tayside going approved to 
be a recognized centre for such studies. A few days after the MHRA visit, a message 
was received informing Dundee that it had received provisional approval as a clinical 
trials centre, which subsequently received full approval. It established the Tayside 
Medical Science Centre (TASC) in 1st January 2010. 
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7.2 SUGGESTIONS FOR FURTHER STUDIES 
 
During the study a number of issues arose, prompting consideration of the following 
studies, to improve our understanding of the system and its utility in diagnosing oral 
cancer at an early stage. 
 
• Recruiting more malignant lesions as well as dysplastic lesions. 
• Correlation of the stage of dysplasia with the FIR measurement, (mild, 
moderate and severe dysplasia, carcinoma in situ, early oral cancer and 
advanced oral cancer). 
• Investigation of the effect of fungal (or bacterial) superimposition on FIR 
measurements. 
• To recruit volunteers who do not have oral lesions in order to map the normal 
anatomical sites to improve the mapping of FIR measurements. 
• To investigate why there is a high FIR measurement from the normal dorsal 
tongue mucosa.  
• Expand the number of participants to include a wider age range, gender and 
race for comparison of the FIR measurements between groups. 
• To study whether dental prostheses can effect the FIR measurements.   
• To investigate whether systemic or metabolic diseases can interfere with the 
FIR measurements from normal oral mucosa. 
• To investigate the correlation (if any) between the number of cigarettes 
consumed and FIR measurements from normal oral mucosa. 
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• To investigate the correlation (if any) between the amount of alcohol 
consumed and FIR measurements from normal oral mucosa. 
• To investigate whether DNA ploidy analysis in conjunction with FIR 
measurements can improve the sensitivity and specificity of the technique 
particularly in respect of discriminating inflammatory from dysplastic lesions.
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